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IV. Abstract  
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As the ultimate mediator of fetal growth and well-being, the placenta is 
inundated with a number of molecular cues from both the maternal and fetal systems. 
Successful integration of these signals is critical to the ongoing health of the 
pregnancy, and may have important implications for the future health of both mother 
and child. Maternal adipose tissue releases a variety of adipokines, whose primary 
aim is to regulate energy metabolism. Given this, and the importance of this process 
in the placenta, it follows that adipokines may have profound effects on the 
trophoblast cells of the placenta. However, the influence of most of these adipokines 
on the placenta remains poorly understood. We examined the role the adipokine, 
adiponectin, has on the human placenta using isolated trophoblasts collected from 
healthy term pregnancies. Treatment of these cells with adiponectin in culture 
inhibited the production of human chorionic gonadotropin (hCG), placental lactogen 
and progesterone, all hormones produced by the placenta that play a key role in the 
continued health and viability of the pregnancy. In addition, adiponectin induced a 
pro-inflammatory environment in trophoblast cells, with increases in production of 
both interleukin (IL)-1β and IL-8. We have gone on to show that adiponectin can 
mediate its actions on trophoblast cells through the adaptor protein APPL1, the 
signaling molecules mitogen-activated protein kinases (MAPKs), and the epidermal 
growth factor (EGF) receptor. Finally, we examined the effects of adiponectin on 
gene expression by term trophoblasts. These data have highlighted a number of 
additional processes influenced by adiponectin, including insulin-like growth factor 
bioavailability and cortisol metabolism. The implications for these effects at the 
maternal-fetal interface are great. From these data, we hypothesize that adiponectin 
13 
 
works to maintain the balance between the energy demands of the fetus and the needs 
of the mother, with specific functions at the placenta that appear to favor the mother. 
Such a role is increasingly critical as gestation progresses and fetal demands continue 
to increase. With the continued prevalence of metabolic health diseases, such as 
obesity, it is especially important to understand the influences hormones such as 




















1. The Human Placenta 
Classification 
There are many different characteristics that have been used to classify 
placentas of different species. Based on the shape and region of maternal-fetal 
exchange, the human placenta is classified as a discoid placenta, meaning it contains 
a single zone in which intimate maternal-fetal contact is possible (Boyd and 
Hamilton, 1970). The human shares this type of placenta with other primates and 
rodents.  
Based on the Grosser classification (reviewed in (Boyd and Hamilton, 1970)), 
the human placenta is of the hemochorial type, meaning it is composed of three 
layers, with trophoblast cells of fetal origin in direct contact with maternal blood. 
Such classification has been criticized and further refined such that during the first 
trimester of gestation, the human placenta can be further classified as hemodichorial, 
meaning there are two distinct layers, one of mononuclear cytotrophoblasts and a 
single layer of multi-nucleated syncytiotrophoblast cells (Enders, 1965a). By the end 
of gestation however, the human placenta has become hemomonochorial, with 
significant fusion of the cytotrophoblast layer into the syncytiotrophoblast layer. 
Pre-lacunar Stage of Development 
The first distinct cell lineage to differentiate during the blastocyst stage of 
embryonic development are mononuclear trophoblast cells. These cells surround the 
inner cell mass (ICM) and the blastocoel, and will eventually differentiate into a fully 
functional placenta. Placental development is considered to begin at the initiation of 
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blastocyst implantation into the uterine epithelium (6-7dpc) (Huppertz, 2008). At this 
point the trophoblast cells apposed to the inner cell mass (i.e. the polar trophoblast 
cells) gain contact with the uterine lining (Boyd and Hamilton, 1970). After 
attachment of the blastocyst, the polar trophoblast cells proliferate to form two layers. 
The layer most distal to the ICM then differentiates to a multi-nucleated 
syncytiotrophoblast. During this period the syncytiotrophoblast is invasive, allowing 
the blastocyst to penetrate into the uterine epithelium.  
Lacunar Stage  
On day 8 following conception (8 dpc) fluid-filled spaces begin to form within 
the syncytiotrophoblast and merge to create lacunae (Boyd and Hamilton, 1970). The 
lacunae as well as the syncytiotrophoblast layers that separate them, known as the 
trabeculae, will eventually form the villous tree structures of the mature placenta. By 
12 dpc the blastocyst has invaded so deeply that the uterine epithelium closes over the 
site of implantation, allowing differentiation of a multinucleated syncytium 
completely surrounding the blastocyst (Benirschke and Kaufmann, 1990). Although 
this syncytium and the underlying cytotrophoblast cells are proliferative, they will 
subsequently regress, creating the smooth membranes of the fetal compartment. The 
three “zones” of the placenta can now be observed: the chorionic plate, a region of 
mononuclear cytotrophoblasts facing the embryo; the primitive villous region 
containing lacunae and trabeculae; and the trophoblastic shell, the attachment site of 
the developing placenta in contact with the maternal endometrium.  
Beginning on 12 dpc, cytotrophoblast cells invade the syncytiotrophoblast 
trabeculae, reaching maternal tissue by 15 dpc (Huppertz, 2008). From this point 
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onward, the cytotrophoblasts, now termed extravillous trophoblasts, are responsible 
for all of the invasive characteristics of the placenta. Furthermore, a subset of these 
invasive cells, the endovascular trophoblasts, will reach maternal blood vessels and 
replace the endothelial cells of these vessels to transform the uterine spiral arteries. 
Villous Stage 
 Beginning around 13 dpc, the trabeculae begin to branch out, forming primary 
villi that reach into the lacunae, henceforth referred to as intervillous space. 
Extraembryonic mesodermal cells then begin to invade as well, following the path of 
the cytotrophoblast cells through the trabeculae. The mesodermal cells do not invade 
all the way into the maternal space as the cytotrophoblasts do, and therefore fill the 
trabeculae and primary villi, leaving cytotrophoblast cells alone to form columns in 
the area of the trabeculae closest to the maternal endometrium. Invasion of 
mesodermal cells into the primary villi establishes a mesodermal core. Once a 
mesodermal core is established in a villous it is classified as a secondary villous. 
Mesodermal cells of the secondary villi begin to develop a vascular system that is 
independent from the vascular system of the embryo proper. With the development of 
vasculature, the villi are then classified as tertiary villi. Those villi that maintain their 
contact with the trophoblastic shell are referred to as anchoring villi, with the 




 The body of the placenta is made up of the villous trees. A mature placenta 
contains an average of 60-70 villous trees (Huppertz, 2008). The villi are widely 
classified into one of five categories (Kaufmann et al., 1979): 
1. The stem villi contain a highly fibrous stroma and large arteries and veins. 
They have the largest diameter of all of the villi types, and provide the 
mechanical strength of the placenta.  
2. The mature intermediate villi are derived from the stem villi. They are 
long and slender and are characterized by a loose stromal compartment 
with small blood vessels. 
3. The terminal villi are the last of the villous types to develop, and are 
commonly thought of as the most physiologically important class of villi 
within the placenta. They are the final branches on the villous tree and 
contain a large amount of capillaries. These capillaries often dilate to the 
point of being in direct juxtaposition with a thin layer of 
syncytiotrophoblast, making the distance between maternal and fetal blood 
spaces the smallest of all villi. 
4. The immature intermediate villi arise from the developing mesenchymal 
villi early on in gestation. They are large and bulbous with a large amount 
of stroma and relatively few arterioles and venules. The stem villi will 
arise from these villi, with only a few immature intermediate villi 
remaining at term.  
5. The mesenchymal villi are the earliest villi to form in the developing 
placenta, and are therefore most prominent during the early stages of 
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gestation. They contain a weakly organized stromal compartment with 
rudimentary vessels. 
Trophoblast types 
 The villous cytotrophoblast cells (also known as Langhan’s cells; (Boyd and 
Hamilton, 1970)) are in direct contact with the basement membrane next to the fetal 
compartment, with their apical membrane in contact with the syncytiotrophoblast 
layer (Figure V-1). During the first trimester of pregnancy, the villous 
cytotrophoblasts form a complete layer directly below the syncytiotrophoblast. By 
term however, this continuity is lost, with cytotrophoblasts sporadically located below 
the syncytiotrophoblast. Nonetheless, the absolute number of the proliferative 
cytotrophoblasts is greater at term compared to the first trimester. By term, the 
amount of syncytium has grown to the extent that the cytotrophoblasts no longer 
make a complete monolayer beneath it. Cytotrophoblasts serve as progenitor cells for 
all other trophoblast subtypes within the placenta, and allow for regeneration of the 
various subtypes throughout gestation. 
 The syncytiotrophoblast is the multinucleated continuous layer that covers the 
surface of the villi, and is the layer responsible for nutrient and gas exchange between 
the fetal and maternal compartments (Figure V-1). The apical surface of the 
syncytiotrophoblast is also covered in microvilli, increasing the surface area exposed 
to the intervillous space by about 7-fold (Huppertz, 2008). The syncytiotrophoblast 
layer does not proliferate, and thus relies entirely on the underlying cytotrophoblasts 
for regeneration throughout gestation (Enders, 1965b). The syncytium is regenerated 
through an apoptotic mechanism (Huppertz et al., 1999). Late-stage apoptotic nuclei 
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in the syncytium are condensed into syncytial knots, which are then extruded into the 
intervillous space (Gauster et al., 2009).  
 Extravillous trophoblasts arise from villous cytotrophoblasts as soon as the 
cytotrophoblast loses contact with the basement membrane (Huppertz, 2008). Once 
the initial invasion process has occurred during implantation, the extravillous 
trophoblast cells are the only cells that display invasive characteristics. These cells 
are responsible for the remodeling of spiral arteries and cross-talk with maternal 
immune cells.     
Placental Anatomy 
 At term, the mature placenta is composed of the basal plate, the villous lobes, 
and the chorionic plate. The basal plate is the section of decidua that is delivered 
along with the placenta. This region contains a variety of different cell types, 
including extravillous trophoblast cells, maternal immune cells, and stroma. Along 
the edge of the placenta the basal plate becomes continuous with the chorionic plate 
from the fetal side of the placenta to form the smooth membranes that surround the 
fetus during gestation (Huppertz, 2008). These are composed of the amnion, the 
chorion, and the decidua capularis (Benirschke and Kaufmann, 1990). The amnion 
contains a single layer of amniotic epithelial cells and the amniotic mesenchyme, 





Figure V-1. Schematic representation of the first trimester human placenta.
 The human placenta is composed of villous cytotrophoblast cells (CTB), from 
which both syncytiotrophoblast and extravillous, invasive cytotrophoblast cells arise. 
Villous cytotrophoblasts lie directly under the syncytial layer, and thereby regenerate 
it by fusing with its basal membrane. Other villous cytotrophoblasts stream down the 
anchoring villi, becoming invasive cytotrophoblasts. These cells will subsequently 























 Human chorionic gonadotropin (hCG) is one of the predominant hormones 
produced by the syncytiotrophoblast, and allows for the maternal recognition of 
pregnancy in the human. It is widely used as a marker of pregnancy, as it can be 
detected in the urine of pregnant women very early on in gestation. The hormone is a 
member of the glycoprotein family of hormones, and is composed of the common α-
subunit and a β-subunit unique to hCG. It is very similar in sequence and function to 
luteinizing hormone (LH), and the two hormones share the same receptor. Its primary 
function during pregnancy is to prevent lysis of the corpus luteum. Production of hCG 
peaks around 8-10 weeks of pregnancy, after which the placenta is producing large 
amounts of progesterone, and thus the corpus luteum is no longer needed. The 
production of hCG declines to a relative low level for the rest of gestation.  
 Progesterone production by the placenta begins almost immediately after 
implantation, however until about the 10th week of gestation progesterone production 
by the corpus luteum of the ovary is the primary source of the hormone. Progesterone 
levels produced by the placenta continue to rise throughout gestation. Progesterone 
serves a number of functions throughout gestation, including priming the uterus for 
implantation and decidualization of the endometrium (Ramathal et al., 2010). 
Progesterone secretion also maintains uterine quiescence throughout gestation by 
inhibiting myometrial contractions. In addition, the high levels of progesterone 
produced by the placenta causes the production of gelatinous secretions from the 
cervix, which may help deter pathogens from entering the uterus (Hedge et al., 1987). 
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Progesterone of placental origin is also important in priming the mammary glands for 
lactation following parturition.  
 Similar to progesterone, estrogens are produced in very high amounts during 
gestation, and continue to rise as gestation progresses. Unlike during the menstrual 
cycle, the primary estrogen produced by the syncytiotrophoblast is estriol. Estriol is a 
relatively weak estrogen, but nevertheless is instrumental in mammary gland 
development throughout gestation (Hedge et al., 1987). The placenta lacks the 
steroidogenic enzyme 17α-hydroxylase/C17-20 lyase, making it incapable of producing 
DHEA from pregnenolone, a crucial step in estrogen biosynthesis (Villee, 1969). The 
fetal adrenal is thus responsible for conversion of pregnenolone to DHEA, which is 
sulfated and hydroxylated by the fetal liver (Villee, 1969). The resulting 16α-OH-
DHEA is then transported to the placenta, which can convert it to estriol through the 
actions of 3β-hydroxysteroid dehydrogenase (3βHSD), 17βHSD, and aromatase. In 
this manner the production of estrogens by the placenta is intimately associated with 
the development of the fetus as well. 
 The placenta also produces the protein hormone placental lactogen (hPL), 
which is similar in structure to growth hormone. Placental lactogen production 
increases steadily throughout gestation, until reaching a plateau around the 35th week 
(Hedge et al., 1987). In a manner similar to growth hormone, hPL has growth 
promoting and lactogenic activities, although its potency is significantly less than that 
of growth hormone. It is thought that hPL may play an important role in mediating 
glucose utilization by the mother, as the placenta and fetus continue to place 
increasing demands for energy on the mother as gestation progresses. Indeed, it has 
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been suggested that hPL is the primary hormone responsible for mediating the insulin 
resistance that occurs during normal late gestation, in order to meet the high demands 
of the fetus (Handwerger and Freemark, 2000).  
Immune Evasion 
 The placenta serves two very important, if somewhat discordant, functions 
with regards to immunological protection of the fetus; 1) protection of the allogeneic 
fetus from the immune system of the mother, and 2) passive immunity through the 
transfer of select maternal immunoglobulins.  The avoidance of maternal immune 
activation during implantation is achieved in part through expression of specific 
human leukocyte antigens (HLAs) on the part of the trophoblast cells.  
 Extravillous trophoblasts only express HLA-C, -G, and -E, thus avoiding the 
highly polymorphic (and consequently highly prone to immune activation) HLA-A 
and -B. In addition, the first trimester decidua contains relatively few cytotoxic T 
cells. Instead, the predominant immune cell type in the early decidua is uterine 
natural killer (uNK) cells. These specific uNK cells express killer inhibitory receptors 
(KIRs), which can recognize the specific HLAs expressed by the trophoblast 
(Moffett-King, 2002). Binding of HLA-C to a specific haplotype of KIR on uNK 
cells will activate the uNK cell to increase cytokine production, rather than behave as 
a killer cell (Moffett-King, 2002). Studies have also shown that HLA-G is expressed 
by extravillous trophoblast cells, and can also act as a pro-gestation signal by 
activating uNK cells to increase cytokine production. 
 In contrast to extravillous trophoblasts, the syncytiotrophoblast do not express 
HLA-C, in order to avoid maternal immune recognition (Clark et al., 2010). In this 
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manner, it is thought that the initial invasion by syncytiotrophoblasts early in 
implantation may allow for a certain level of protection of the embryo.  
 The placenta also allows for the selective transport of maternal IgG, equipping 
the fetus with a low level of passive immunity. The placenta forms a barrier to 
transfer of all other immunoglobulins however. The human placenta transfers IgG1, 3, 
and 4 subclasses to such an extent that the levels of these in fetal circulation can reach 
or surpass levels in maternal serum (Lanman, 1975). All of these are weakly 
cytotoxic, allowing for low levels of immunity. Although the mother will also pass 
immunoglobulins to the infant through the delivery of colostrum in the early stages of 
lactation, the placenta aids in this passive immunity through the transfer of IgG across 
its surface and into the fetal compartment. 
Nutritional Support 
 The placenta serves as the sole pipeline for nutritional support and gas 
exchange of the developing fetus. As such it is critically important to the maintenance 
of a healthy pregnancy. This process can be complicated by suboptimal nutritional 
conditions of the mother. Indeed, there is increasing interest in the effect of maternal 
energy irregularities (e.g. maternal obesity) on long-term fetal health, extending past 
gestation and affecting the offspring’s health throughout its lifetime. Regulation of 
the placenta’s response to such stresses may have a profound effect on the subsequent 
programming of the fetus. The placenta is responsible for moving a large number of 
different molecules across its surface, and consequently has developed a variety of 
different mechanisms and specific transporters to deal with each of these. Discussed 
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below are some of the major molecules that need to be made available to the fetus as 
it continues to grow and develop.  
 With respect to transfer of nutrients across the placenta, the human appears to 
be relatively efficient in that the terminal villi, where most of the nutrient transfer 
occurs, is composed of only a thin layer of syncytiotrophoblast separating the 
maternal and fetal blood flows (Kaufmann et al., 1979). As such, the exchange rate of 
electrolytes such as sodium, which largely utilize the principle of diffusion based on 
concentration gradients, increases steadily as gestation progresses and the 
syncytiotrophoblast surface area increases (Dancis and Schneider, 1975).  
In the case of iron, the placenta must utilize an active transport mechanism to 
direct the fetus’ high requirements for iron against a concentration gradient. By the 
final trimester of gestation, the fetus requires a large amount of iron, such that over 
90% of the iron in maternal circulation will be transferred through the placenta to the 
fetus, with no transfer in the opposite direction (Dancis and Schneider, 1975).  
 Glucose is the primary energy source for the developing fetus. Transfer of 
glucose across the syncytiotrophoblast occurs through the actions of a specific 
isoform of the glucose transporters, GLUT1. GLUT1 is expressed on both the apical 
microvilli and on the basal surface of the syncytiotrophoblast, with a higher level of 
expression on the microvilli side (Jansson et al., 1993, Takata et al., 1992), suggesting 
this isoform may play a predominant role in uptake of glucose from the maternal 
circulation. In addition, the fetal arteriole endothelium expresses the GLUT3 isoform, 
suggesting that it functions to transfer glucose to the fetal circulation, and thus further 
increase the fetal:maternal glucose ratio (Hauguel-de Mouzon et al., 1997). There has 
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been one report of expression of the insulin-sensitive isoform, GLUT4, in the cytosol 
of the first trimester syncytiotrophoblast (Ericsson et al., 2005), although the 
physiological relevance of this is debated (Jansson et al., 1993). The increased density 
of GLUT1 on the microvillous side of the syncytiotrophoblast serves to move a large 
amount of glucose into the syncytium in order to serve the placenta as well as the 
fetus. Neither GLUT1 nor GLUT3 are responsive to insulin, which promotes a 
steadier influx of glucose into the placenta (Illsley, 2000). As such, glucose levels in 
the fetus at any given time can be directly correlated with the levels of glucose in 
maternal circulation (Illsley, 2000). 
 Amino acids are transported across the placenta through active transport 
mechanisms. Although some of the transporters utilize ATP or sodium, many of them 
exchange one amino acid for another across the membrane. It is thought that both the 
transporters that accumulate and those that exchange amino acids work together to 
attain the appropriate amount and specificity of amino acids (Cleal and Lewis, 2008). 
Although amino acid transport across the microvilli and into the syncytiotrophoblast 
is understood to occur largely through the work of amino acid accumulator and 
exchange transporters, the mechanism(s) by which amino acids leave the 
syncytiotrophoblast through the basal membrane are poorly understood. There is 
evidence to suggest that another family of amino acid transporters that function as 
facilitated transporters are at work on the basal membrane, to push the amino acids to 
the fetal compartment against a steep concentration gradient (Cleal and Lewis, 2008).  
In contrast to the more complex, regulated mechanisms employed in the 
transport of glucose and amino acids, the placenta is thought to exchange gas through 
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simple diffusion. Although the gases, primarily oxygen and carbon dioxide, will favor 
diffusion to the compartment with the lowest concentration, there are some 
complicating factors that favor the movement of oxygen to the fetal compartment. 
Fetal hemoglobin has a higher affinity for oxygen than does adult hemoglobin, and 
therefore the levels of dissolved oxygen in the maternal blood may be higher than in 
fetal blood. In addition, movement of oxygen to the fetal compartment is favored by 
the simultaneous transfer of carbon dioxide from the fetal to the maternal 
compartment, through the Bohr Effect phenomenon, which will decrease maternal 
hemoglobin’s affinity for oxygen as more carbon dioxide enters the maternal 
circulation (Dancis and Schneider, 1975). The remodeling of the spiral arteries also 
allows for low resistance blood flow in the placental compartment, further enhancing 
the ability of the syncytiotrophoblast to efficiently exchange the necessary nutrients, 
gases, etc.   
 
2. Diseases of Pregnancy 
Due to the intimate association between a mother and her developing fetus, 
damage to her health can also be detrimental to the fetus. Therefore, a discussion of 
the diseases that affect pregnancy could by quite extensive. In this section however, I 
have chosen to focus on three major diseases that are uniquely related to pregnancy, 
i.e. they do not manifest until pregnancy is attained.  
Gestational Diabetes 
The incredible energy demands placed on the mother as gestation advances 
usually result in some degree of maternal insulin resistance (reviewed in (Lain and 
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Catalano, 2007)). In approximately 7% of pregnant women however the degree of 
insulin resistance is exacerbated, resulting in gestational diabetes (Reece, 2008). 
Gestational diabetes mellitus (GDM) is largely a disease of late gestation, as the 
mother’s metabolism early in gestation is primarily anabolic, that is she stores energy 
to accommodate the forthcoming demands of the fetus. This switches to a metabolism 
that is profoundly catabolic during the latter part of gestation, as the fetus grows 
dramatically and places increasing energy demands on the mother (Lain and 
Catalano, 2007).  
The normal amount of insulin resistance that occurs in a late-gestation 
pregnant woman is exacerbated in women with GDM, not only by down-regulation of 
the insulin signaling protein, insulin receptor substrate (IRS)-1, but also a decreased 
ability of the β component of the insulin receptor to undergo tyrosine phosphorylation 
and perpetuate the insulin signal intracellularly (Lain and Catalano, 2007). Women 
with GDM are also thought to have decreased pancreatic β-cell function relative to 
women that maintain normal glucose tolerance throughout pregnancy, and thus, while 
able to respond to the increased need for insulin, are unable to do so to an adequate 
extent (Lain and Catalano, 2007).  Development of GDM also puts the mother at a 
significantly higher risk of becoming diabetic later in life, and her risk of developing 
a number of complications including heart disease, stroke, and hypertension increases 
substantially (Metzger, 2007). 
A number of maternal hormones and cytokines are known to be altered in 
GDM, including the metabolic hormone adiponectin (Altinova et al., 2007, Ranheim 
et al., 2004, Retnakaran et al., 2007, Tsai et al., 2005, Williams et al., 2004, Cseh et 
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al., 2004, Georgiou et al., 2008, Gao et al., 2008, Lain et al., 2008, Cortelazzi et al., 
2007). Other hormones and cytokines such as leptin, tumor necrosis factor-α (TNF-α) 
and adipocyte fatty acid binding protein (AFABP) have been shown to be increased 
in GDM, even before the levels of maternal glucose are significantly higher than 
normal controls (Gao et al., 2008, Kralisch et al., 2009). The hormone placental 
lactogen has been suggested to be involved in mediating insulin resistance during 
pregnancy due to it similarities to growth hormone, and has also been found to be 
elevated in the serum of women with GDM (Ursell et al., 1973). Additionally, human 
placental growth hormone, a hormone in the same family as hPL, has been shown to 
induce insulin resistance in non-pregnant mice (Barbour et al., 2002). 
The occurrence of GDM has been associated with induced placental 
expression of a number of genes, predominantly ones involved in stress and 
inflammatory responses, although other genes involved in metabolism and endothelial 
differentiation are also altered in GDM placentas (Radaelli et al., 2003). These data 
point to the induction of an inflammatory response and remodeling of the placental 
vasculature during GDM, both of which could have profound effects on the 
development of the fetus. 
Gestational diabetes can have deleterious effects on both the mother and fetus, 
frequently resulting in a macrosomic fetus and delivery complications (Gilbert, 1949, 
The Hapo Study Cooperative Research Group, 2008). Pregnancies complicated by 
GDM frequently result in a fetus that is hyperinsulinemic (Desoye and Hauguel-de 
Mouzon, 2007). This is thought to be a result of high levels of glucose in maternal 
circulation, and not a response to increases in placental transporter expression. 
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Although the syncytiotrophoblast expresses high levels of insulin receptor, this is 
predominantly early in gestation, and the receptor density pattern shifts from the 
microvillous membrane of the syncytiotrophoblast during the first trimester, to the 
villous endothelial cells by term (Desoye et al., 1997). Thus, insulin’s control over the 
placenta appears to be primarily during the first trimester (Hiden et al., 2006).  
The transition of insulin receptor expression to the endothelium toward the 
end of pregnancy may have profound implications in gestational diabetes in 
particular, allowing the abnormally high levels of insulin being produced by the fetus 
to modify placental behavior as well. Increasing amounts of fetal insulin will also 
increase fetal demand for oxygen, as aerobic glucose metabolism is stimulated 
(Desoye and Hauguel-de Mouzon, 2007). This in turn will stimulate growth of the 
placental endothelium and the syncytiotrophoblast surface area (Desoye and Hauguel-
de Mouzon, 2007). Indeed, an enlarged placental weight is a characteristic of GDM, 
and this may be one mechanism by which a GDM fetus becomes macrosomic. 
Although GLUT1 expression on the microvillous membrane of the 
syncytiotrophoblast does not change dramatically during GDM, GLUT1 expression 
on the basal membrane of the syncytiotrophoblast increases during cases of GDM, 
possibly serving as another mechanism by which the fetus receives increased levels of 
glucose during GDM (Gaither et al., 1999). In addition, increases in the insulin-like 
growth factors (IGF)-1 and -2 are also observed in cases of GDM (Hiden et al., 2009). 
Increased IGF-1 and -2 can lead to increases in expression of amino acid transporters 
on the placenta, which in turn may explain the increased levels of amino acids in 
fetus’ from GDM pregnancies (Cetin et al., 2005). 
33 
 
The obesity epidemic in the developed world serves to further increase the 
number of women who develop this serious and relatively common disorder during 
pregnancy. Indeed, the risk of gestational diabetes mellitus (GDM) rises 5.2 fold in 
obese women versus women of normal body mass index (BMI; (Baeten et al., 2001)).  
A growing body of evidence suggests that GDM may put the fetus at an 
increased risk of metabolic disorders such as diabetes and obesity later in life (Reece, 
2008). Although GDM poses a grave threat to both mother and fetus, we have only a 
rudimentary understanding of the molecular events that are altered during GDM. It is 
especially important that the effect of GDM on the placenta be evaluated in more 
depth, as the placenta is the sole mediator of interaction between mother and fetus.  
Intrauterine Growth Restriction 
 A fetus that is pathologically small, i.e. not simply small for gestational age 
(SGA), but is malformed or malnourished, will often be diagnosed with intrauterine 
growth restriction (IUGR). IUGR is second only to prematurity as the leading cause 
for perinatal mortality (Baschat et al., 2007). The most widely used definition for 
IUGR is a fetus with an estimated weight below the 10th percentile for its gestational 
age with an abdominal circumference below the 2.5th percentile. IUGR can be 
classified as either symmetric or asymmetric based off of the pattern of growth. 
Asymmetric growth is diagnosed when the fetus directs most of its available nutrients 
to the growth of vital organs, and thus may have a normal size head, but small 
abdominal girth and small limbs. Asymmetric growth may be a consequence of 
insufficient transfer of nutrients by the placenta.  
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Although many times IUGR can be attributed to environmental and/or genetic 
factors, there are a significant number of IUGR cases that remain idiopathic. Of those 
incidences when IUGR can be related to a specific cause, it is often a maternal 
vascular disease, such as hypertension or thrombophilia (a congenital condition of 
overactive coagulation), that decreases placental blood flow (Baschat et al., 2007). A 
diagnosis of IUGR has been associated with increased levels of interleukin-6 (IL-6) in 
placental lysates taken at term, as well as a decrease in umbilical cord serum levels of 
adiponectin (Street et al., 2009). While such factors may play a role in the etiology of 
IUGR, they may also be a manifestation of an underlying cause for a maternal-
placental environment that is suboptimal for fetal growth. Inadequate maternal 
nutrition, and especially limited protein intake, is widely recognized as a risk factor 
for IUGR (Baschat et al., 2007). In addition, maternal factors such as drug use, 
including smoking and alcohol use, have been implicated in the onset of IUGR. This 
is thought to occur not only through an associated inadequate intake of nutrients, but 
also as an independent factor (Baschat et al., 2007).  
The mother however is not always the sole culprit responsible for IUGR. 
Chromosomal abnormalities, intrauterine infections, and congenital malformations 
also account for a fraction of IUGR cases (Baschat et al., 2007). Increased demands 
on the placenta, such as in twin pregnancies, may also result in IUGR. The majority 
of IUGR cases arise from placental insufficiency resulting from a malformed 
placenta. Placental insufficiency can be due to a large number of placental 
malformations including premature placental abruption (detachment of the placenta 
from the uterine wall), persistent villous immaturity, development of only one 
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umbilical artery, placenta accreta (overly deep invasion of the placenta and 
attachment to the uterine myometrium), or complicating diseases, such as 
preeclampsia (Benirschke and Kaufmann, 1990). 
A diagnosis of IUGR has been suggested to be associated with a number of 
alterations at the level of the placenta affecting the movement of nutrients to the fetal 
compartment. Two members of the triglyceride lipase gene (TLG) family, endothelial 
lipase (EL) and lipoprotein lipase (LPL), have recently been shown to be altered in 
cases of IUGR (Gauster et al., 2007). The TLG family is involved in the release of 
fatty acids from lipoproteins after they have been transported across the cell 
membrane. The authors of this study identified a decrease in EL, the predominant 
TLG expressed on trophoblasts and placental endothelial cells, and an increase in 
LPL expression. These data suggest altered efficiency of fatty acid transport may play 
a role in the etiology of IUGR. In addition, a decrease in the expression of Na+/K+ 
ATPase on the microvillous membrane of syncytiotrophoblast is reported to be 
associated with IUGR (Johansson et al., 2003). This could lead to a decrease in a 
major mechanism of nutrient transfer in the syncytiotrophoblast that relies on a 
sodium gradient for transport across the membrane. 
In addition to reduced and abnormal weight gain by the fetus affected by 
IUGR, the condition may represent a number of underlying problems affecting 
normal development of the fetus. These include cardiovascular, metabolic, endocrine 
and hematologic abnormalities (Baschat et al., 2007). Insufficient oxygen and glucose 
uptake through the placenta will mobilize the fetal liver to release glycogen stores. If 
this is continued, it will eventually lead to a reduction in amino acid transport across 
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the placenta, which will stimulate the breakdown of muscle in the fetus. A decrease in 
glucose and amino acids will also down-regulate fetal production of insulin and IGF-
1 and -2, while the hormone associated with stress, cortisol, increases (Baschat et al., 
2007). Persistence of these metabolic and endocrine changes may program the fetus 
toward a propensity for altered metabolic responses later in life.  
As is the case for many diseases of pregnancy, IUGR has also been associated 
with the manifestation of diseases later in the life of the offspring. These include an 
increased risk of type 2 diabetes mellitus, hypertension, and cardiovascular disease 
(Valsamakis et al., 2006). Using a sheep model, Duffield and colleagues have 
demonstrated that IUGR can alter adipocyte growth and gene expression after birth 
(Duffield et al., 2009). These data may have important implications relating to obesity 
and the associated negative health outcomes in children diagnosed with IUGR during 
gestation.  
Preeclampsia 
 Preeclampsia is a disease of pregnancy characterized by maternal 
hypertension and proteinuria, thought to be due to shallow placentation. It affects up 
to 3% of women, and, left untreated, can result in serious complications for mother 
and child, including, in rare instances, death (Redman and Sargent, 2005). Risk 
factors for the condition include preexisting insulin resistance, previous diagnosis of 
preeclampsia, a high BMI, high blood pressure, nulliparity, a twin pregnancy, a 
family history of preeclampsia, advanced maternal age, and large amounts of physical 
activity (Østerdal et al., 2009, Solomon and Seely, 2001, Duckitt and Harrington, 
2005). In addition, a women’s risk of developing preeclampsia decreases with 
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previous exposure to the paternal antigens, either through a previous pregnancy or a 
long period of co-habitation (Lie et al., 1998, Trupin et al., 1996). Long-term 
consequences for mother and child have been suggested as well, and multiple studies 
have demonstrated an increased risk of cardiovascular disease and death in mothers 
that had a preeclamptic pregnancy, although this may be attributable to an increased 
prevalence of metabolic and/or hypertensive diseases in the study populations as well 
(Irgens et al., 2001, Manten et al., 2007). The only known cure for the disease is 
delivery of the placenta, although treatments such as antioxidant vitamins, 
hypertension medications, and magnesium sulfate (to treat maternal seizures in cases 
of severe preeclampsia) have been suggested as possible mechanisms to treat the 
condition without the requirement of delivery of the child (Sibai, 2003, Redman and 
Sargent, 2005). Like gestational diabetes mellitus, preeclampsia is typically a disease 
of the later stages of pregnancy. However, it can be diagnosed anytime after the 20th 
week of gestation, and the disease tends to be more severe the earlier in gestation it is 
diagnosed. 
 Preeclampsia arises following the onset of endothelial dysfunction, whether of 
maternal or placental in origin (Redman and Sargent, 2005). It is thought to be the 
result of a hypoxic placental environment and oxidative stress caused by insufficient 
invasion and spiral artery remodeling by extravillous trophoblast cells (Jauniaux et 
al., 2003). As a result, supplementation of preeclamptic women with high levels of 
the potent antioxidants vitamins C and E has been studied. Initial trials suggested a 
positive outcome, with significantly less at risk women developing preeclampsia 
when given vitamin C and E supplements for the last half of pregnancy (Chappell et 
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al., 1999). However, a subsequent larger clinical trial found that women given 
supraphysiological doses of vitamins C and E during pregnancy do not have a lower 
risk of preeclampsia, and the rate of low birthweight babies in this cohort actually 
increased with vitamin supplementation (Poston et al., 2006). In addition, subsequent 
in vitro analysis of the effects of high levels of vitamins C and E on trophoblast cells 
show a diminished production of hCG coupled with increases in TNF-α production 
(Aris et al., 2008).  
Preeclampsia is thought to be a by-product of insufficient trophoblast invasion 
of the maternal endometrium, leading to poor remodeling of the spiral arteries and a 
subsequent inability of the maternal blood supply to keep up with the increasing 
demands for oxygen as the placenta grows (Redman and Sargent, 2005). Increases in 
the amounts of soluble fms-like tyrosine kinase receptor-1 (sFlt-1) and soluble 
endoglin in serum and amniotic fluid from preeclamptic patients has been described 
(Levine et al., 2006, Levine et al., 2004, Jeyabalan et al., 2008, Masuyama et al., 
2007, Wang et al., 2010). In addition, culture of trophoblast cells from normal and 
preeclamptic women show increased amounts of sFlt-1 and sEndoglin secretion from 
preeclamptic trophoblasts compared to healthy control cells (Gu et al., 2008). Both 
sFlt-1 and sEndoglin are antiangiogenic, and thus are hypothesized to block the 
angiogenic effects of vascular endothelial growth factor (VEGF), placental growth 
factor (PlGF) and transforming growth factor (TGF)-β, consequently leading to the 
characteristic maternal hypertension of preeclampsia. It has been suggested that 
signaling involving calcineurin and angiotensin II receptor from activated T cells can 
lead to the overproduction of sFlt-1 as well (Zhou et al., 2008).  
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Due to the inflammatory environment often associated with preeclampsia, 
many researchers have investigated a variety of pro-inflammatory stimulators within 
the context of preeclampsia (Visser et al., 2007). Treatment of pregnant rats with 
polyinosinic:polycytidylic acid (poly I:C), an activator of toll-like receptor 3 (TLR3), 
results in elevated systolic blood pressure in these rats compared to controls, 
suggesting TLR3 activation may play a role in the preeclamptic phenotype (Tinsley et 
al., 2009). Other suggestions include an excessive turnover of the 
syncytiotrophoblast, leading to a large number of synctial knots being released into 
the intervillous space and a subsequent inflammatory response (Gauster et al., 2009). 
In contrast, impaired cellular fusion, leading to increased apoptosis rates in 
cytotrophoblasts has also been suggested to lead to the inflammatory response in 
preeclampsia (Langbein et al., 2008). Increased decidual production of IL-6, perhaps 
as part of the pro-inflammatory response commonly associated with preeclampsia, 
has also been described (Lockwood et al., 2008). 
Insulin-like growth factors (IGFs) are known to have profound effects on 
glucose mobilization and metabolism by the fetoplacental unit during gestation. 
Studies suggest that the syncytiotrophoblast and maternal decidua can increase 
expression of the protease that cleaves IGF-binding proteins (PAPPA2) during 
preeclampsia, thus increasing availability of IGFs for signaling at the placenta in an 
effort to increase glucose and amino acid transfer and metabolism (Nishizawa et al., 
2008, Winn et al., 2009). 
Despite these findings, the etiology of preeclampsia remains unclear, and a 
variety of potential instigators of the condition have been proposed. Some of the most 
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compelling evidence regarding the development of preeclampsia however involves 
the recognition of HLA-C, expressed by extravillous trophoblasts by specific KIR 
haplotypes on uNK cells. These data suggest that women with low to no expression 
of the “AA” type carrying a fetus expressing trophoblastic HLA-C2 are at a 
significantly higher risk of developing preeclampsia (Hiby et al., 2004).  
The maternal role in the manifestation of preeclampsia is most commonly 
attributed to vascular disorders or longstanding diseases such as hypertension (Ness 
and Roberts, 1996). As a result, the importance of careful monitoring of women who 
present with diseases such as hypertension or metabolic syndrome is paramount to 
catching the onset of preeclampsia early (Davis et al., 2007). Aberrant production of a 
number of adipokines, most notably leptin and adiponectin, have been associated with 
preeclampsia (Herse et al., 2009, Masuyama et al., 2007), although these data remain 
controversial (Bienertová-Va et al., 2008). Interestingly, Siglec-6, a transmembrane 
protein that has been shown to bind leptin, has also been shown to be increased in 
trophoblasts from preeclamptic patients (Winn et al., 2009).  
It has been suggested that the driving force behind poor placentation outcomes 
resulting in IUGR and/or preeclampsia is an underlying maternal condition of 
metabolic syndrome (Ness and Sibai, 2006). This may certainly be one component in 
the manifestation of preeclampsia, however other data suggests IUGR and 
preeclampsia can arise from two different mechanisms. Trophoblasts taken at term 
from normal, IUGR, preeclamptic, or preeclamptic with IUGR placentas placed in 
long-term culture have been reported to have significantly different degrees of 
syncytialization and hCG production (Newhouse et al., 2007), with trophoblasts 
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affected by preeclampsia having low levels of hCG production. These data would 
certainly suggest that IUGR and preeclampsia arise from different mechanisms, as the 
trophoblast cells display behaviors distinct from one another even in an isolated in 
vitro environment. 
 The lack of a solid understanding regarding the origins of preeclampsia, 
coupled with the fact that there remains no known cure, has led many researchers to 
attempt to find markers for the onset of preeclampsia that physicians may use to 
screen at-risk mothers (Farina et al., 2009, Founds et al., 2009, Okazaki et al., 2007, 
Sasaki et al., 2002). To date, although a number of genes, mostly involved in invasion 
and inflammation have been suggested, there remains no established method for 
predicting the onset of preeclampsia in pregnant women.  
 
3. The Impact of Other Physiological Systems on the Placenta 
The fact that pregnancy does not occur in a vacuum, mediated solely by the 
fetus and the placenta, makes it one of the most interesting, albeit complicating, 
systems to study. All physiological systems of the mother can profoundly influence 
the health of the pregnancy, just as the fetoplacental unit can exert a powerful 
influence over physiological systems of the mother. In this section I will focus on two 
such systems as they relate to human pregnancy, as our data implicates the hormone 
adiponectin to mediate the actions of both of these systems on sycytialized 




 As the uterine endometrium transforms to decidua, a large number of 
leukocytes invade the tissue (King, 2000). These are predominantly uterine NK cells, 
along with macrophages and a small number of T cells, with a notable absence of B 
cells which are characteristic of an adaptive immune response (Moffett-King, 2002, 
King et al., 1998). As gestation progresses however, uNK cells become fewer in 
number, and by term they are absent from the decidua. This pattern suggests uNK 
cells are crucial mediators of the invasion process. The CD56highCD16- uNK cells are 
distinct from the CD56+CD16+ NK cells found in circulation, and thus play a specific 
and unique role during implantation and invasion of the human blastocyst. The uNK 
cells express specific killer inhibitory receptor (KIR) haplotypes that will specifically 
recognize HLA-C expressed by extravillous trophoblasts and the inhibitory receptor 
for HLA-E (also expressed by extravillous trophoblasts). In addition, their production 
of the cytokines colony stimulating factor 1 (CSF1), granulocyte-macrophage colony 
stimulating factor (GM-CSF), interferon γ (IFNγ) and tumor-necrosis factor (TNF) 
also may influence the behavior of extravillous trophoblast cells (Moffett-King, 
2002).  
The developing placenta also influences uNK cells, as hCG has been shown to 
increase proliferation of these cells through binding to the mannose receptor 
(CD206), expressed on the surface of uNK cells (Kane et al., 2009). In addition, 
placental growth factor (PlGF), a growth factor produced by a variety of cell types at 
the maternal-fetal interface, promotes uNK cell proliferation. Expression of PlGF is 
reduced during cases of preeclampsia, and loss of PlGF results in an increase in uNK 
cell maturation (Tayade et al., 2007). uNK cells themselves also produce angiogenic 
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molecules including PlGF as well as vascular endothelial growth factor (VEGF) and 
angiopoietin 2 (Moffett-King, 2002). As a consequence, uNK cells may play an 
important role in vascular remodeling of the placental bed, and their misregulation 
and/or production of these growth factors may have important implications in 
preeclampsia.  
Another cell type that promotes immune tolerance of the fetus is the unique 
subset of T cells known as T regulatory cells (Tregs). These cells are found in higher 
abundance in the decidua during pregnancy than in peripheral blood, and have been 
shown to be reduced in cases of spontaneous abortion (Yang et al., 2009, Tilburgs et 
al., 2006, Sasaki et al., 2004). They were initially identified through their role in 
promoting maternal tolerance during pregnancy in studies using mouse models 
deficient in Tregs. When mated in an allogeneic breeding scheme, these mice aborted 
the fetuses, however syngeneic pregnancies progressed normally (Aluvihare et al., 
2004).  
The expansion of T regulatory cells during the early stages of pregnancy has 
been suggested to occur through a variety of methods. Although controversial, Tai 
and colleagues have provided evidence for Treg expansion by treatment with 
physiologically relevant doses of estrogen (Tai et al., 2008). However, these data 
have not been corroborated by others (Zhao et al., 2007). The subset of regulatory T 
cells recruited to the maternal-fetal interface is suggested to be specific for paternal 
alloantigens (Mjösberg et al., 2007, Tilburgs et al., 2008). Other groups therefore 
have suggested that the proliferation of paternally specific Tregs occurs soon after 
semen exposure (Leber et al., 2010). The migration of these cells to the decidua 
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appears to largely be mediated via production of an assortment of chemokines 
produced by cells at the maternal-fetal interface including macrophages, dendritic 
cells and T cells (Leber et al., 2010). In addition, hCG has been shown to attract 
Tregs, which express the LH/CG receptor (Schumacher et al., 2009). 
T regulatory cells seem to be unique to pregnancy, as their transfer from a 
pregnant mouse to a CBA/J x DBA/2J abortive mouse model rescued the pregnancy 
if transferred during the very early stages of pregnancy, however pregnancy failed 
when T regulatory cells from a non-pregnant animal were transferred (Zenclussen et 
al., 2005). Once T regulatory cells have been activated through antigen presentation 
by macrophages or dendritic cells, they gain regulatory properties (Saito et al., 2007). 
The Treg population can then promote tolerance either through contact with other 
cells or by producing specific cytokines such as transforming growth factor β (TGFβ) 
and interleukin-10 (IL-10), which have been shown to be beneficial to the 
maintenance of pregnancy (Saito et al., 2007, Thaxton and Sharma, 2010, Leber et al., 
2010).  
In addition, T regulatory cells in the placenta express cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), which in turn may enhance the production of IFNγ by 
decidual leukocytes. The production of IFNγ may increase production of the 
tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) by dendritic 
cells or macrophages, a phenomenon which promotes fetal tolerance by metabolizing 
tryptophan and preventing T cell activation (Saito et al., 2007). This complex 
mechanism is supported by the observation that IDO is decreased in cases of 
miscarriage (Miwa et al., 2005). In addition, recent evidence suggests galactin-1, 
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expressed by Tregs, promotes apoptosis of activated T cells, the expansion of Tregs, 
and is important in mediating IL-10 induced immune tolerance (Leber et al., 2010). 
Despite the abundance of reports showing the importance of Treg cells in promoting 
healthy immune tolerance during pregnancy, many obstacles remain before this 
knowledge can be of practical importance in preventing spontaneous miscarriage in a 
human population (Leber et al., 2010). In addition, the amount of redundancy in the 
physiological tolerance of pregnancy makes the system much more complicated than 
can be explained by one specific cell type. 
In addition to the presence of unique cell types such as uNK and Treg cells, 
the maternal-fetal interface utilizes a variety of different cell surface markers on 
trophoblast and resident immune cells in the decidua in order to promote 
immunological tolerance. The interaction between these immunomodulatory proteins 
elicits specific tolerogenic events. 
Members of the B7 family have been shown to mediate cell-cell interactions, 
and include B7-1 and B7-2, as well as B7-H1, B7-H2, B7-H3, B7-H4, B7-H6 and 
B7-DC (Petroff and Perchellet, 2010). Of these, B7-DC is expressed by the 
syncytiotrophoblast, but only during the early stages of pregnancy, while B7-H2 and 
B7-H3 are expressed by extravillous trophoblasts throughout gestation (Petroff et al., 
2005). The B7-H1 molecule is expressed by both syncytiotrophoblast and extravillous 
trophoblasts cells, with a more robust presence as pregnancy continues (Petroff et al., 
2003). In contrast, B7-2 appears to be present only in fetal macrophages, and is 
absent from trophoblast cells (Petroff et al., 2003). B7-1, B7-H4, and B7-H6 appear 
to be absent from the maternal-fetal interface all together (Petroff et al., 2003, Petroff 
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and Perchellet, 2010). The varied expression pattern of this family of molecules 
makes it probable that they play a multitude of functions at the maternal-fetal 
interface. Although evidence exists for B7-H1 inhibition of production of the pro-
inflammatory molecules, IFNγ and TNFα by T cells (Taglauer et al., 2008), the role 
of the various members of the B7 family of molecules in maternal immune tolerance 
largely remains to be eludiated. 
In addition to specific expression of cell surface proteins, the trophoblasts 
produce a number of unique soluble factors, such as HLA-G and members of the 
TNFα superfamily that serve immunomodulatory roles at the maternal-fetal interface. 
The HLA-G gene consists of seven different isoforms, which arise from alternative 
splicing (Hunt, 2006). Expression of the different isoforms have been shown to be 
regulated by factors important for dictating trophoblast fate, including oxygen 
concentration (differentiation to extravillous trophoblast, HLA-G1, -G2, -G5, and -G6 
expression) and epidermal growth factor (differentiation to syncytiotrophoblast, 
HLA-G5) (Hunt, 2006). Of these, both HLA-G5 and HLA-G6 are soluble isoforms 
that circulate in the mother’s blood throughout pregnancy (Hunt, 2006). The effects 
of HLA-G on the immune system generally promote immune tolerance, and include 
regulation of cytokine production, regulation of NK actions including migration and 
killing, suppression of T cell killing, and changes in dendritic cell stimulation (Hunt, 
2006). An abundance of data allows HLA-G to be widely regarded as an important 
mechanism in the suppression of the maternal immune system.  
 Trophoblast cells of the human placenta also produce a number of members 
of the TNF superfamily, including eight members that have been shown to induce 
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death of activated immune cells; TNFα, lymphotoxin (LT)α, LTβ, Fas ligand (FasL), 
TNF-related apoptosis-inducing ligand (TRAIL), TNF-like weak inducer of apoptosis 
(TWEAK), tumor necrosis factor superfamily member 14 (TNFSF14/LIGHT), and 
tumor necrosis factor superfamily member 9 (TNFSF9/4-1BBL) (Phillips et al., 
2001). At least one of these, TRAIL, has been shown to induce apoptosis in cells 
found at the maternal-fetal interface, such as macrophages, but not trophoblast cells 
(Phillips et al., 1999). This may be due to the nuclear localization of its receptor in 
trophoblast cells (Bai et al., 2009). All told, the mechanisms utilized at the maternal-
fetal interface to avoid the mother’s immune system are varied and highly redundant. 
Many other mechanisms, and likely some not yet discovered, also play a part in this 
complex interplay between mother and offspring. 
Adipose Tissue 
With the rise in the obesity rate in the developed world, the important 
functions adipose tissue plays on whole-body physiology have garnered increased 
attention. Obesity is one of the primary risk factors for a host of diseases including 
atherosclerosis, type 2 diabetes mellitus, hypertension, cardiovascular disease, stroke, 
and osteoarthritis. Indeed, obesity-related diseases are among the leading causes of 
death in the United States (Heron et al., 2009). Additionally, maternal obesity prior to 
pregnancy has been identified as a risk factor for a host of birth defects including 
spina bifida, heart defects, diaphragmatic hernia, and limb reductions (Waller et al., 
2007). Interestingly, approximately 10-25% of obese individuals do not develop 
metabolic diseases related to obesity, and are essentially healthy (Bluher, 2010). This 
phenomenon may be to due to a propensity in individuals to accumulate fat stores 
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either subcutaneously or viscerally, and underscores the important role adipose tissue 
plays in mediating the physiological effects associated with over-consumption of 
calories.  
Adipose tissue is a heterogeneous tissue, comprised of adipocytes, 
preadipocytes, macrophages, and vasculature. A host of hormones and cytokines, 
collectively known as adipokines, are secreted by adipocytes and the surrounding 
stroma. The behavior of adipose tissue (i.e. adipose tissue dysfunction), as well as the 
site of adipose deposition (visceral vs. subcutaneous), appear to influence the overall 
health of obese men and women. Those individuals with high visceral fat mass, 
regardless of BMI or total fat mass, have been shown to be much more likely to 
develop insulin resistance (Bluher, 2010). This is thought to be largely due to the 
enhanced ability of subcutaneous fat to expand, whereas visceral fat will reach its full 
potential for expansion relatively quickly, leading to ectopic lipid deposition in the 
skeletal muscle, liver, and β cells of the pancreas (Bluher, 2010). Additional evidence 
exists for fundamental differences between subcutaneous and visceral fat. Many of 
the pro-inflammatory cytokines associated with adipocyte dysfunction are 
predominantly made by visceral fat, whereas subcutaneous fat has a different 
production profile of adipokines (Bluher, 2009, Chudek and Wiecek, 2006). Visceral 
fat area is also positively correlated with the amount of triglycerides, free fatty acids, 
and insulin in the plasma, and negatively correlated with insulin sensitivity 
parameters such as rate of glucose uptake and serum levels of testosterone and sex 
hormone binding globulin (SHBG) (Bluher, 2009).  
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As reviewed by Guilherme and colleagues (Guilherme et al., 2008), adipose 
tissue plays a key role in modulating skeletal muscle and hepatic sensitivity to insulin. 
Adipose tissue helps to maintain insulin sensitivity through the storage and regulated 
release of lipids for energy metabolism during periods of low glucose, as well as 
maintenance of a specific adipokine milieu in circulation. In the case of obesity, 
adipose tissue initiates an inflammatory response, causing the release of fatty acids 
and triglycerides into circulation, with subsequent storage in skeletal muscle, 
resulting in impaired response to insulin (reviewed in (Guilherme et al., 2008)). High 
levels of circulating free fatty acids have also been linked with the development of 
insulin resistance (Guilherme et al., 2008). As the skeletal muscle is exposed to more 
fatty acids, either by direct uptake from the circulation or intracellular release of 
ectopic stores, the myocyte will begin to utilize them as its energy source, resulting in 
decreased glucose uptake into the cell and insulin resistance (Guilherme et al., 2008).  
The problem is compounded by the recruitment of macrophages to the adipose 
tissue, resulting in the induction of a pro-inflammatory state and production of 
cytokines such as TNFα. These cytokines will impair the adipocyte’s ability to store 
triglycerides, promoting the release of more fatty acids into circulation, ultimately 
resulting in adipocyte dysfunction (Guilherme et al., 2008). In addition, the 
circulating adipokine balance is disrupted, exacerbating the inability of skeletal 
muscle and hepatocytes to respond to insulin.  
The number of adipocytes in an individual is set early on in life, and the rate 
of turnover is not altered by BMI status (Spalding et al., 2008). Therefore, as an adult 
individual puts on weight, the size of the adipocyte increases, as opposed to the 
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number of individual adipocytes. As these cells become increasingly swollen with 
lipids their production of monocyte chemoattractant protein-1 (MCP-1) is increased, 
leading to an infiltration of macrophages and initiation of a pro-inflammatory state 
(Guilherme et al., 2008). Moreover, the size of the adipocyte can be an important 
determinant in adipokine production by that cell (Bluher, 2009), a phenomenon which 
will exacerbate the metabolic abnormalities initiated by adipocyte dysfunction.  
Furthermore, it is currently thought that as adipocytes swell and adipose tissue 
enlarges, pockets of adipocytes that are relatively distant from the vascular supply 
experience a certain degree of hypoxia (Trayhurn et al., 2008). This in turn leads to 
alterations not only in the adipocyte production of angiogenic factors, but also pro-
inflammatory mediators, specific adipokines, as well as changes in metabolic 
responses to hypoxia, such as the glucose transporter, GLUT1 (Trayhurn et al., 2008). 
Adipocyte dysfunction and inflammation not only contributes to the release of fatty 
acids from the cell, it alters the expression of key genes, such as peroxisome 
proliferator-activated receptor γ (PPARγ), a transcription factor known for its role in 
adipogenesis and normal adipocyte function (Guilherme et al., 2008). 
Adipose tissue is not simply a storage facility for lipids, but is also now 
appreciated for its potent endocrine role. The variety of systems and molecular 
pathways influenced by adipokines is continually amended as identification and 
examination of each adipokine increases. Broadly, the adipokines appear to be 
involved in regulating energy homeostasis, and thus have predominately been studied 
for their effects on glucose metabolism and insulin responsiveness.  
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The ever-expanding list of adipokines includes traditional metabolic hormones 
such as leptin and adiponectin, as well as more traditional cytokines such as TNFα 
and interleukin-6 (IL-6). In addition, a large number of novel factors are now known 
to be produced by adipose tissue, including retinol binding protein 4 (RBP4), resistin, 
apelin, fasting induced adipose factor (FIAF) and visfatin. While many of these 
factors support the adipose tissue itself, such a large variety of secretory proteins 
emphasize the importance adipose tissue plays in whole-body physiology. Adipose 
tissue is known to communicate with a number of different organs in the body such as 
the brain (e.g. via leptin and adiponectin), the immune system (e.g. IL-6, TNFα, 
transforming growth factor β (TGFβ), IL-8, IL-1β, IL-10, MCP-1, resistin), and the 
vasculature (e.g. vascular endothelial transforming growth factor (VEGF) and 
plasminogen activator inhibitor-1 (PAI-1) (Trayhurn et al., 2006).  
The influence of adipokines extends to the reproductive system and 
pregnancy. Not only does adipose tissue have profound effects on pregnancy through 
its key role in maintaining energy homeostasis and reserves in order to support the 
developing child, many adipokines have also been shown to be altered during 
pregnancy and disease states of pregnancy.  
Due to the frequency in which obesity is correlated with polycystic ovary 
syndrome (PCOS), many have investigated a possible role for various adipokines in 
the development of this condition. Resistin is one adipokine that has been implicated 
in the development of PCOS, with the insulin sensitizer, rosiglitazone (a PPARγ 
agonist), being shown to decrease resistin levels in PCOS patients (Majuri et al., 
2007). In normal menstrual cycles, both leptin and resistin levels are higher during 
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the luteal phase, although the physiological significance of this is not yet clear 
(Asimakopoulos et al., 2009). Other adipokines, such as RBP4, have been shown to 
be associated with gonadotropin levels (Makimura et al., 2009). 
With regards to pregnancy, the adipokines have only recently begun to be 
evaluated. Circulating levels of leptin rise as gestation continues, and then drop to 
pre-pregnancy levels around parturition (Briana and Malamitsi-Puchner, 2009). In 
addition, leptin has been reported to be elevated in cases of preeclampsia (Haugen et 
al., 2006). These levels and expression pattern cannot however be attributed solely to 
adipose tissue, as the human placenta also produces a substantial amount of leptin 
(Senaris et al., 1997), presumably as a means for the placenta to regulate maternal 
energy metabolism. Indeed, placental production of leptin has been shown to drop in 
cases of gestational diabetes mellitus (Lappas et al., 2005b). Leptin is known to 
regulate trophoblast invasion, proliferation, and nutrient transfer (Magarinos et al., 
2007, Briana and Malamitsi-Puchner, 2009, Schulz and Widmaier, 2004). The 
hormone has also been reported to induce pro-inflammatory cytokine production by 
the placenta and maternal adipose tissue (Lappas et al., 2005a). Leptin has also been 
shown to increase production of hCG in human cytotrophoblasts collected at term, 
while progesterone production was decreased in cultures (Cameo et al., 2003). 
With the exception of leptin, very little is known about the role of other 
adipokines during pregnancy. Expression of resistin has been noted in both term 
human placental explants, and BeWo choriocarcinoma cells (Yura et al., 2003). 
Systemic resistin levels are known to increase throughout gestation in a normal 
pregnancy, and resistin has been positively correlated with birth weight (Cortelazzi et 
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al., 2007, Jansson et al., 2008, Chen et al., 2005). There is discrepancy in the 
literature regarding whether circulating resistin levels drop or are elevated in cases of 
preeclampsia (Cortelazzi et al., 2007, Haugen et al., 2006), probably due to 
differences in study design and disease definitions. Interestingly, treatment of BeWo 
cells with recombinant human resistin induced expression of matrix metalloproteinase 
(MMP)-2 and resulted in a concomitant decrease in tissue inhibitor of 
metalloproteinases (TIMP)-1 and -2 (Di Simone et al., 2006). These changes were 
associated with an increase in invasive behavior of BeWo cells (Di Simone et al., 
2006).  
Retinol binding protein 4 (RBP4) is produced by both the liver and adipose 
tissue. Aside from transporting retinol in the blood, it has also been recently classified 
as an adipokine, and associated with insulin resistance. The levels of RBP4 in women 
suffering from GDM have been reported to be elevated compared to healthy pregnant 
women (Maghbooli et al., 2010, Mazaki-Tovi et al., 2010), although these results 
remain controversial (Tepper et al., 2010, Ueland et al., 2008). Hypertensive pregnant 
women have also been reported to have elevated levels of RBP4 in circulation (Seiji 
et al., 2009). Similarly, the paucity of data and conflicting reports regarding levels of 
RBP4 during preeclampsia make it difficult to determine the influence this adipokine 
may have on diseases of pregnancy (Vaisbuch et al., 2009, Stepan et al., 2009). 
Despite these incongruities, those studies that have been done regarding adipokines 
and their potential influence on the placenta substantiate the hypothesis that they are 






Adiponectin, first identified by five independent groups (Hu et al., 1996, 
Maeda et al., 1996, Nakano et al., 1996, Scherer et al., 1995, Arita et al., 1999), is 
composed of an N-terminal collagen-like domain and a C-terminal globular domain 
(for a review on adiponectin see (Kadowaki and Yamauchi, 2005)). The protein is 
highly similar to that of complement factor C1q and collagens VIII and X (Arita et 
al., 1999). In serum, adiponectin forms multimers through disulfide bond formation. 
High molecular weight (HMW) adiponectin, composed of up to 18 molecules of 
adiponectin bound together, is the most abundant form found in serum. However, low 
and medium molecular weight adiponectin, composed of trimers or hexamers, can 
also be found in circulation (Kadowaki and Yamauchi, 2005). In addition, full-length 
adiponectin can be cleaved to form a truncated globular form which appears to be 
more biologically active than the full-length molecule (Yamauchi et al., 2001). 
Adiponectin circulates at very high levels, making up approximately 0.01% of total 
protein in human serum (Zhu et al., 2008). Circulating levels are higher in females 
than males (Pajvani et al., 2003, Zoccali et al., 2002), perhaps because of the 
divergence in adipocity between the sexes.  
The primary metabolic function ascribed to adiponectin is to maintain 
peripheral insulin sensitivity. This is accomplished by decreasing hepatic glucose 
production (Berg et al., 2001, Combs et al., 2001), increasing fatty acid oxidation in 
the liver (Yamauchi et al., 2001), and decreasing the amount of triglyceride 
accumulation in skeletal muscle (Yamauchi et al., 2001, Fruebis et al., 2001). 
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Although incompletely enumerated, it is thought that adiponectin elicits these broad 
biological effects primarily through activation of the adaptor protein APPL1 (adapter 
protein containing plekstrin homology domain, phosphotyrosine domain, and leucine 
zipper motif), which can in turn interact with a number of intracellular signaling 
cascades, including insulin signaling, glucose transport and fatty acid metabolism 
(Mao et al., 2006, Yamauchi et al., 2001). 
Modulation of insulin responsiveness by adiponectin has been examined by a 
number of groups through both over-expression systems and genetic depletion 
(Yamauchi et al., 2003b, Maeda et al., 2002, Ma et al., 2002, Kubota et al., 2002, 
Satoh et al., 2005, Shklyaev et al., 2003, Combs et al., 2004), with the predominant 
outcome being a role for adiponectin in improving insulin sensitivity. Interestingly, 
the influence of adiponectin appears to be more profound in the liver, as one group 
has recently reported hepatic, but not muscular, insulin resistance in adiponectin null 
mice (Yano et al., 2008). In keeping with these findings, serum adiponectin is 
decreased in cases of obesity, a physiological state in which insulin resistance is 
common. A very intriguing study has recently shown that over-expression of 
adiponectin in the leptin null mouse (Ob/Ob) is sufficient to normalize glucose and 
insulin levels and rescue the diabetic phenotype, despite these mice remaining obese 
(Kim et al., 2007). These data underscore 1) the importance of adiponectin in 
maintaining insulin sensitivity, 2) that adipocyte dysfunction and consequent 
alterations in adipokine profiles are key in producing an insulin resistant phenotype, 
and 3) the yin/yang relationship between leptin and adiponectin.  
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In keeping with the pro-inflammatory state of obesity, IL-6 has been shown to 
inhibit the production of adiponectin in an adipocyte cell line (Fasshauer et al., 2003), 
as has the transcription factor, PPARγ (Maeda et al., 2001). Adiponectin has also 
been postulated to play a protective role in the development of diabetes (Lindsay et 
al., 2002), creating interest in its potential as a therapeutic device in treating type 2 
diabetes. In addition to its insulin sensitizing role, the molecule has recently been 
shown to influence cellular differentiation (Oshima et al., 2005, Yamaguchi et al., 
2008, Yamaguchi et al., 2007, Fiaschi et al., 2009), proliferation (Lee et al., 2008), 
and hormone production (Lu et al., 2008, Coope et al., 2008, Wen et al., 2008, 
Ledoux et al., 2006, Lagaly et al., 2008) in other tissues. Although adiponectin has 
understandably been investigated primarily with regards to obesity and diabetes (both 
instances in which its expression is decreased), it has been reported to be increased in 
cases of anorexia nervosa (Delporte et al., 2003), a physiological state in many ways 
opposite that of obesity. 
Adiponectin is reported to elicit both pro-inflammatory and anti-inflammatory 
responses, dependent on the biological system and molecular weight form of 
adiponectin under study. Its initial beneficial effects on atherosclerosis and 
endothelial dysfunction suggested adiponectin was anti-inflammatory. In keeping 
with this hypothesis, a mouse model for collagen-induced arthritis has shown 
adiponectin to alleviate many of the markers of inflammation, including the 
production of pro-inflammatory cytokines (Ebina et al., 2009). Adiponectin has also 
been implicated in inducing anti-inflammatory pathways in cases of liver disease 
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(Mandal et al., 2010), and increase production of the anti-inflammatory cytokine, IL-
10 (Wolf et al., 2004, Wulster-Radcliffe et al., 2004).  
In contrast, adiponectin can stimulate production of interleukin-8 (IL-8) by 
rheumatoid fibroblasts in culture (Kitahara et al., 2009), and thus act as a pro-
inflammatory mediator. Although the full-length form of adiponectin is commonly 
used as the anti-inflammatory form of adiponectin, whether adiponectin elicits a pro- 
or anti-inflammatory cascade has been proposed to be a result of which molecular 
weight form of adiponectin is under question. The high molecular weight (HMW) 
form of adiponectin has been implicated in mediating pro-inflammatory responses in 
peripheral blood mononuclear cells (PBMCs) (Song et al., 2009). Additionally, the 
globular form of adiponectin activates the pro-inflammatory signaling molecule, 
NFκB to an even greater extent than HMW adiponectin (Tomizawa et al., 2008). 
Adiponectin Receptors 
Two receptors for adiponectin have been identified, adiponectin receptor 1 
(adipoR1) and adiponectin receptor 2 (adipoR2) (Yamauchi et al., 2003a). Both are 
composed of seven transmembrane domains, although they are structurally and 
functionally distinct from G-protein coupled receptors (Yamauchi et al., 2003a). They 
are members of a distinct family of receptors, known as the PAQR family, which in 
addition to the adiponectin receptors includes the seven transmembrane receptors 
through which nongenomic actions of progestins have been suggested to be mediated 
(Tang et al., 2005). The PAQR family of receptors, of which 11 family members have 
been identified as conserved in multicellular eukaryotes, show structural similarity 
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primarily in the membrane spanning and intracellular loop motifs, similar to what is 
seen in some families of GPCRs (Tang et al., 2005).  
In the mouse, adipoR1 is expressed ubiquitously, but is most abundant in 
skeletal muscle while adipoR2 is more highly expressed in the liver (Yamauchi et al., 
2003a). In contrast, both receptors appear to be expressed in relatively equal 
abundance in human skeletal muscle compared to liver, a pattern that is also seen in 
the rat (Yamauchi et al., 2003a, Satoh et al., 2005).  
AdipoR1 is a high-affinity receptor for the globular form of adiponectin, while 
adipoR2 possesses intermediate affinity for both globular and full-length adiponectin 
(Yamauchi et al., 2003a). In addition, there is evidence suggesting adiponectin can 
bind to the cell surface molecule T-cadherin, although the functional role of this 
phenomenon needs to be elucidated (Hug et al., 2004). Although the hormone can 
bind to either receptor, and both receptors are expressed in many of the same tissues, 
they appear to mediate very different physiological actions. Mice devoid of adipoR1 
displayed an increased propensity for adipose accumulation as well as reduced 
glucose tolerance, energy expenditure, and heightened leptin  and plasma cholesterol 
levels (Bjursell et al., 2007). In contrast, when AdipoR2-/- mice where challenged with 
a high fat diet, they appeared resistant to glucose intolerance and displayed lower 
levels of cholesterol than their wildtype counterparts (Bjursell et al., 2007). Many of 
the classical actions of adiponectin are thought to be mediated through adipoR1, 





Not only do the two adiponectin receptors have somewhat divergent 
expression patterns and ligand affinities, they also appear to utilize unique 
intracellular signaling cascades. Disruption of adipoR1 expression results in a 
decrease in adiponectin stimulated adenosine 5’-monophosphate-activated kinase 
(AMPK) activity, while knockdown of adipoR2 causes a loss of signaling through 
peroxisome proliferator-activated receptor (PPAR)α (Yamauchi et al., 2007). 
Interestingly, AMPK has recently been identified to be important in regulating 
differentiation in skeletal myocytes, as part of the cell’s ability to respond to changes 
in nutrient availability (Fulco et al., 2008). Furthermore, the AMPK activator 5-
aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) is known to inhibit 
adipocyte differentiation in vitro (Giri et al., 2006, Habinowski and Witters, 2001, 
Hwang et al., 2005), although whether the effects of AICAR are mediated entirely 
through AMPK remains to be conclusively shown. In support of the suggestion that 
AMPK can regulate cellular differentiation, the phytochemicals genistein, EGCG and 
capsaicin have all been shown to activate AMPK and inhibit adipocyte differentiation 
(Hwang et al., 2005). Additionally, there are other reports that implicate adiponectin 
directly in inhibition of osteoclast formation (Yamaguchi et al., 2008, Yamaguchi et 
al., 2007, Oshima et al., 2005), and mediated through adipoR1 and AMPK 
(Yamaguchi et al., 2008).  
Although the AMPK signaling pathway is widely thought of as the primary 
mechanism of adiponectin signal amplification, cases exist in which the AMPK 
pathway does not appear to be responding to adiponectin stimulation. In these 
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instances the mitogen-activated protein kinase, ERK1/2, pathway appears to be 
dominant (Maillard et al., 2010, Chabrolle et al., 2009, Lee et al., 2008). 
Adiponectin also appears to initiate intracellular events through a variety of 
other signaling mechanisms including the insulin signaling cascade, p38 mitogen-
activated protein kinase, c-Jun-N-terminal kinase (JNK), phosphatidylinositol 3-
kinase (PI3K), Janus kinase/Signal Transducers and Activators of Transcription 
(JAK/STAT) and NFκB pathways (Coope et al., 2008, Haugen and Drevon, 2007, 
Yamauchi et al., 2003a, Chabrolle et al., 2009, Tang and Lu, 2009, Tomizawa et al., 
2009). Although many of the details regarding signaling initiated by adiponectin are 
yet to be elucidated, there is a growing body of evidence linking the adaptor protein 
APPL1 to adiponectin signal transduction. In cultured myocytes adiponectin-
mediated activation of both AMPK and p38 MAPK appears to be mediated at least in 
part by APPL1 (Mao et al., 2006). Lee and colleagues have shown that APPL1 can 
mediate the downstream actions of the adiponectin receptor even when the receptors 
do not directly activate AMPK. Down-regulation of APPL1 using siRNA impaired 
the ability of adiponectin to activate ERK1/2 in HEK293 cells (Lee et al., 2008). In 
addition, APPL1 may provide the means by which adiponectin interacts with insulin 
signaling and glucose uptake in skeletal muscle (Mao et al., 2006).  
Interaction with the GTPase Rab5 allows APPL1 to influence glucose 
transport in skeletal myocytes, and APPL1 has been linked to modulation of insulin-
mediated Akt signaling (reviewed in (Hosch et al., 2006)). Perhaps most telling, over-
expression of the APPL1 isoform, APPL2, in muscle cells interrupts adiponectin 
signaling (Wang et al., 2009). These authors showed that, under basal conditions, 
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APPL2 is associated with the adiponectin receptor at the plasma membrane, while 
APPL1 resides largely in the cytosol. Upon adiponectin binding to its receptor, the 
location of these two proteins switches, such that APPL1 is associated with the 
receptor and can potentiate the signal initiated by adiponectin.  The same group also 
showed that over-expression of APPL2 in their system can lead to a down-regulation 
of adiponectin signaling (Wang et al., 2009). Thus, APPL2 is a negative regulator of 
adiponectin signaling.  
Alternatively, both serine/threonine kinase 11 (STK11 or LKB1) and 
calcium/calmodulin-dependent protein kinase kinase (CaMKK) are postulated to 
mediate adiponectin’s effects upstream of AMPK (Fujii et al., 2006). With regard to 
the placenta, adiponectin effects have been reported to be mediated through AMPK, 
ERK1/2, PPARγ and NFκB (Lappas et al., 2005a, Benaitreau et al., 2009). The 
mechanisms employed by adiponectin at the maternal-fetal interface have received 
scant attention however, thereby leaving a number of possible means by which 
adiponectin may function within the placenta. 
Adiponectin in Reproduction 
 The role of adiponectin has also been investigated in various tissues of the 
reproductive system. For the most part however, the focus has been on adiponectin’s 
ability to increase insulin sensitivity during cases of obesity-induced polycystic ovary 
syndrome (PCOS) (Majuri et al., 2007, Mitchell et al., 2005). Transcripts for 
adiponectin as well as its receptors have been reported in a variety of bovine ovarian-
derived cell types, including granulosa cells, follicles of different stages, the corpus 
luteum, cumulus cells and oocytes (Maillard et al., 2010). However, it is important to 
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note that regarding the human, adiponectin production has not been identified in 
granulosa cells, although they were positive for both adipoR1 and adipoR2 (Chabrolle 
et al., 2009), and adiponectin has been found in follicular fluid of women undergoing 
in vitro fertilization (Gutman et al., 2008).  
Adiponectin appears to complement the ovarian actions of a variety of 
hormones/growth factors without necessarily exerting the same actions 
independently. For instance, insulin-like growth factor (IGF)-induced granulosa cell 
proliferation is significantly enhanced by addition of adiponectin to the culture media, 
but not following adiponectin treatment in the absence of IGF (Maillard et al., 2010). 
Similarly, in bovine theca cells, adiponectin treatment results in a drop in luteinizing 
hormone (LH)-induced progesterone and androstenedione production, as well as 
steroidogenic enzyme gene expression (Lagaly et al., 2008). In bovine granulosa 
cells, the insulin-stimulated progesterone and estradiol production was significantly 
reduced by addition of adiponectin (Maillard et al., 2010). This phenomenon is 
mirrored in the pig ovary, where a drop in aromatase expression following 
adiponectin treatment has been reported (Ledoux et al., 2006). In contrast, in primary 
human granulosa cell cultures, adiponectin was reported to increase IGF-I stimulated 
progesterone and estradiol production (Chabrolle et al., 2009). The discrepancies in 
these data highlight the need for more extensive investigation as well as potential 
divergence between humans and potential model species.  
Extremely little data has been reported regarding the effect, if any, of 
adiponectin on male reproduction. Adiponectin has been reported to be produced by 
Leydig cells of the rat testis (Caminos et al., 2008), although the data is scant. The 
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same group has reported adiponectin’s inhibition of testosterone production in rat 
testicular cell cultures, both basally and in response to hCG stimulation (Caminos et 
al., 2008). One study examining the specific effects of the adiponectin receptors 
reported that AdipoR2-/- mice had smaller testes weight, atrophy of the seminiferous 
tubules, and aspermia when compared to their wildtype counterparts (Bjursell et al., 
2007). These same animals had no change in testosterone levels (Bjursell et al., 
2007). 
Studies examining the effect of adiponectin on hypothalamic neurons and 
gonadotrope cells report adiponectin exposure causes a decrease in gonadotropin 
releasing hormone (GnRH; (Wen et al., 2008)) and LH secretion (Lu et al., 2008, 
Rodriguez-Pacheco et al., 2007). Interestingly, female infertility and an increase in 
systemic prolactin levels has been reported in a transgenic mouse model 
overexpressing adiponectin (Combs et al., 2004). Furthermore, the levels of 
adiponectin in follicular fluid were higher in response to treatment with luteinizing 
hormone (LH) (Gutman et al., 2008), suggesting a possible feedback loop between 
the pituitary and adipose. Such data set precedence for a role of adiponectin in 
various aspects of reproduction.  
Adiponectin in Pregnancy  
Placental expression of adiponectin remains controversial. Positive 
adiponectin immunoreactivity has been identified in rabbit day 6 blastocysts, 
although the staining pattern is much stronger in the inner cell mass (ICM) compared 
to the differentiating trophoblasts (Schmidt et al., 2008). Caminos and coworkers 
have reported adiponectin expression in both the rat and human placenta as well as 
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both adipoR1 and adipoR2 receptors (Caminos et al., 2005). These data have been 
corroborated by others, demonstrating adiponectin mRNA and protein expression in 
the syncytiotrophoblast of term placentas, as well as adiponectin secretion from 
placental explants (Lappas et al., 2005b, Chen et al., 2006). However there remain 
concerns as to whether the tissues and methodologies used in these studies 
conclusively demonstrate adiponectin expression specifically in trophoblast cells. 
Indeed, more recent investigations have failed to detect adiponectin gene expression 
in the placenta (Haugen et al., 2006, Ichida et al., 2007, McDonald and Wolfe, 2009). 
By one report, placental lysates that have been extensively washed to remove all 
intervillous blood lose their previous positive banding pattern for adiponectin by 
western blot (Desoye and Hauguel-de Mouzon, 2007). The controversy regarding 
adiponectin expression by the placenta underscores the need for focused attention on 
the role of adiponectin at the maternal-fetal interface.  
To date, few published studies have examined the role of adiponectin at the 
maternal-fetal interface. These studies primarily utilized placental explant cultures 
collected at term.  Treatment of placental explants with adiponectin resulted in an 
increase in secretion of the cytokines interleukin (IL)-1β, IL-6 and tumor necrosis 
factor (TNF)-α, as well as the prostaglandins PGE2 and PGF2α (Lappas et al., 
2005a). Adiponectin administration in vivo caused a decrease in placental mRNA 
expression of the glucose transporter GLUT-3, lipoprotein lipase (LPL), adipoR2 and 
transforming growth factor (TGF)-β in the rat (Caminos et al., 2005). The authors 
postulate that adiponectin may be influencing nutrient transport and trophoblast 
proliferation/invasion, although these results need to be corroborated. One study 
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using the Jeg-3 and BeWo choriocarcinoma cell lines, reported that adiponectin 
inhibited proliferation of these cells (Benaitreau et al., 2009). These same authors 
were also unable to amplify adiponectin mRNA from choriocarcinoma cells (in 
agreement with our data as well as that of others). As a result, the proliferative effect 
of adiponectin may only be relevant to the cytotrophoblast layer of the mature 
placenta. A recent report using primary term trophoblast cells from healthy placentas 
has shown full-length adiponectin to inhibit the insulin-stimulated increase in amino 
acid transport (Jones et al., 2010), data which are intriguing given the dogma that 
adiponectin acts to sensitize tissues to insulin. Interestingly, treatment with the 
globular form of adiponectin in these cells failed to elicit the inhibition of insulin-
mediated events (Jones et al., 2010). The discrepancy between different forms of 
adiponectin and their physiological actions is an area that requires more careful 
examination. 
The remaining reports regarding adiponectin and the placenta to date have 
examined effectors of adiponectin release from placental explants (Lappas et al., 
2005b, Chen et al., 2006), and are therefore somewhat controversial. These studies 
are largely not in accord with one another, and given the model system, make it 
difficult to determine the significance of the results. Despite this ambiguity, 
adiponectin circulates in µg/ml quantities and as a consequence the placenta is 
exposed to adiponectin via maternal blood once the mature hemochorial placenta has 
been established. In addition, although data regarding placental production of 
adiponectin is inconsistent, the literature is in agreement regarding placental 
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expression of both adipoR1 and adipoR2. Therefore the effects of adiponectin on the 
placenta remain a potentially important aspect of placental biology.  
A number of studies have examined the expression of adiponectin throughout 
the normal progression of pregnancy, as well as in disease states such as gestational 
diabetes and preeclampsia. During normal gestation, maternal serum levels of 
adiponectin drop slightly as gestation advances (Suwaki et al., 2006, Cortelazzi et al., 
2007, Catalano et al., 2006, Fuglsang et al., 2006, O'Sullivan et al., 2006, Mazaki-
Tovi et al., 2007, Ramsay et al., 2003, Cseh et al., 2004). During cases of GDM 
however, a significant decline in circulating adiponectin levels has been observed 
(Cortelazzi et al., 2007, Altinova et al., 2007, Ranheim et al., 2004, Retnakaran et al., 
2007, Tsai et al., 2005, Williams et al., 2004, Cseh et al., 2004, Georgiou et al., 2008, 
Mazaki-Tovi et al., 2009b). This decrease in serum adiponectin during GDM in many 
cases persists after correcting for BMI, suggesting adiponectin expression may be 
altered during GDM even in cases when the mother is within a normal weight range. 
Furthermore, examination of adiponectin levels during the first trimester of 
pregnancy suggest a reduction in serum levels of adiponectin may be predictive of 
later development of GDM (Georgiou et al., 2008, Williams et al., 2004). These data 
illustrate adiponectin’s intimate association with insulin levels, and suggest the 
adipokine may play a role in the manifestation of GDM. An exacerbated reduction in 
adiponectin during GDM could result in the loss of its protective effects, both 
systemically for the mother, as well as at the maternal-fetal interface. Although the 
data is intriguing, all evaluations of adiponectin and GDM are correlative studies 
evaluating maternal serum levels of adiponectin and pregnancy outcomes. Therefore, 
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the bulk of the literature serves to illustrate and justify the need for mechanistic 
examination of the role of adiponectin at the maternal-fetal interface. 
With regards to preeclampsia, correlative studies of adiponectin levels in 
maternal serum and disease status comprise all of the data thus far reported. Studies 
have shown that in women suffering from preeclampsia adiponectin is elevated (Avci 
et al., 2010, D'Anna et al., 2006, Fasshauer et al., 2008, Nien et al., 2007), although 
not all studies  are in agreement (Mazaki-Tovi et al., 2009c). Adiponectin is also 
higher in women diagnosed with abnormal uterine perfusion, with frequent 
development into IUGR or preeclampsia (Fasshauer et al., 2007). In addition, 
adipoR1 and adipoR2 are increased at term in women with preeclampsia (Jarvenpaa 
et al., 2009, Tie et al., 2009). That being said, adiponectin levels may actually be 
lower during the first trimester in women destined to be diagnosed with preeclampsia 
(D'Anna et al., 2005, D'Anna et al., 2006). The difference in adiponectin levels seem 
to diverge based on whether the patient is diagnosed with early- or late-onset 
preeclampsia, thus potentially highlighting the different pathogenesis between these 
two diagnoses.  
There is increasing interest in the potential role adiponectin may directly have 
on the fetus. Thus, studies examining the level of adiponectin in amniotic fluid and 
umbilical cord blood are being reported with increased frequency. The levels of 
adiponectin in cord blood are lower in offspring from diabetic pregnancies, compared 
to those children from insulin sensitive pregnancies (Lindsay et al., 2003). This is also 
the case in the small child from a set of twins with divergent growth (Mazaki-Tovi et 
al., 2009a). Interestingly, the levels of amniotic adiponectin do not seem to be 
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correlated with those in maternal blood, suggesting the fetus is capable of making 
adiponectin, at least as early as mid-term (Baviera et al., 2007). These data raise the 
possibility that, in a scenario much like that of fetal insulin, adiponectin of fetal as 
well as that of maternal origin may be able to influence the behavior of the placenta. 
It is important to remember however, these data are in their infancy and the exposure 
levels of placental trophoblasts are likely to be much higher with regard to maternal 
adiponectin. 
 
5. Study Significance  
Pregnancy is a time of metabolic stress for the mother, exacerbated in disease 
states and cases of obesity. The role of adipokines in mediating physiological 
responses to this stress has only recently gained appreciation. Adiponectin is one such 
molecule known to be important in mediating insulin sensitivity, with recent evidence 
of a role for adiponectin outside the classical tissues associated with insulin action 
(i.e. liver and skeletal muscle). A multitude of studies have examined serum levels of 
adiponectin during various gestational complications, however few have evaluated 
the influence of adiponectin on the placenta. Disorders such as GDM, IUGR, and 
preeclampsia result in an aberrant hormonal milieu in maternal serum. This 
phenomenon can have profound effects on the developing fetus, as the placenta is 
bathed in maternal blood and thus exposed to all circulating hormones, and is the sole 
mediator of how the maternal environment is translated to the fetus. As one of the key 
hormones affected during GDM, it is vital that the effects of adiponectin on the 
placenta be examined thoroughly. 
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The goal of this study was to identify the effects, if any, of adiponectin on the 
human placenta. A number of clinical studies have identified a correlation between 
adiponectin levels in maternal circulation and GDM, preeclampsia, and/or IUGR. At 
initiation of this study, the only reports regarding adiponectin at the maternal-fetal 
interface were done in placental explants, a model system composed of many 
different cell types. We have utilized primary cultures of human trophoblasts 
collected at term in order to identify the effects of adiponectin on the trophoblast.  
In the first study, “Adiponectin Attenuation of Endocrine Function within 
Human Term Trophoblast Cells,” we began by identifying that adiponectin is not 
produced by the placenta at term, although both the adipoR1 and adipoR2 receptors 
are present. Therefore, we establish that the placenta is able to respond to adiponectin 
in maternal circulation. Based on these findings, we establish our long-term culture 
conditions in order to allow the cytotrophoblast cells to syncytialize in vitro, as 
syncytialized cells will be the most likely to be exposed to adiponectin circulating in 
the mother’s blood. Due to evidence in the literature that adiponectin can affect cell 
differentiation, we exposed syncytialized trophoblast cells to adiponectin throughout 
the culture period. We identified that adiponectin decreased gene expression for a 
number of hormones, one of the key functions of the syncytiotrophoblast. Chorionic 
gonadotropin, progesterone, and placental lactogen all dropped after 5d adiponectin 
exposure. We also found that these effects are not due to an inhibition of 
differentiation by adiponectin, indeed the cells syncytialized at least as well with 
adiponectin as the no treatment control cells.  
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In the second study, “The Pro-Inflammatory Role of Adiponectin at the 
Maternal-Fetal Interface,” we continued with identification of the effects of 
adiponectin on human term trophoblasts syncytialized in culture. Long-term (5d) 
adiponectin exposure increased production of the pro-inflammatory cytokines, IL-1β 
and IL-8. In addition, we recognized that the protein Siglec10 is up-regulated 
following adiponectin exposure. Siglec10 has been recently implicated in dampening 
the immune response to danger-associated molecular patterns (DAMPs). We have 
also shown that both Siglec10 and its partner, CD24, are expressed by trophoblasts. In 
non-treated cells, Siglec10 is expressed at low levels, and seems to be localized to the 
syncytiotrophoblast. These data suggest Siglec10 may be a mechanism used by the 
trophoblast to dampen immune responses. 
In the third study, “Signaling Cascades Initiated by Adiponectin in 
Trophoblast Cells,” we investigated the mechanisms by which adiponectin elicits 
the effects we have previously identified. We report that adiponectin activates the 
ERK1/2 and JNK pathways in term trophoblasts. In addition, we observed activation 
of the EGF receptor within 5 minutes of adiponectin treatment. The signaling 
mechanisms of adiponectin are mediated through the adaptor protein APPL1, as over-
expression of its inhibitory binding isoform, APPL2, abolished adiponectin signaling. 
Interestingly, we also showed that leptin and adiponectin are intimately linked at the 
maternal-fetal interface, as over-expression of leptin in term trophoblasts also 
abolished adiponectin signaling. These data identify possible mechanisms by which 
the trophoblast cell may regulate its response to adiponectin.  
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In the final study, “Microarray Analysis of Adiponectin on Trophoblast 
Cells,” a number of genes, including some outlined in previous chapters, are altered 
following 5d exposure to adiponectin in term trophoblast cells. Included in this list 
are numerous genes involved in the mediation of IGF bioavailability, such as IGF 
binding proteins and proteases. The pattern of up- and down-regulation in this set of 
genes seems to suggest that adiponectin decreases the amounts of available IGF at the 
maternal-fetal interface. In this manner, adiponectin may alter one of the fundamental 
mechanisms in nutrient transfer and growth at the placenta. Other sets of genes, such 
as 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) and type 2 (HSD11B2) are 
also altered according to the microarray data. These data suggest that cortisol 
metabolism is changed following adiponectin treatment such that higher levels of 
active cortisol are likely to be present in the trophoblast. The microarray has provided 
important data by which we may identify many of the mechanisms altered by 
adiponectin in the human, syncytialized trophoblast. 
Taken together, these studies significantly advance the field by providing the 
first data regarding the effects of adiponectin on human trophoblast cells. Since 
initiation of this study a report has come out examining adiponectin treatment on 
choriocarcinoma cell lines. These data are valuable, however we have been unable to 
recapitulate many effects we see using primary cultures, including those delineated in 
this report, in choriocarcinoma cell lines. On the whole, our studies suggest 
adiponectin may be thought of as a “pro-maternal” hormone, meaning that it works 
through multiple mechanisms to interfere with functions of the syncytiotrophoblast. 
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In this manner, adiponectin may be one hormone working to maintain the balance 















VI: Chapter Two: 
 
Adiponectin Attenuation of Endocrine Function within Human Term 





The hormone adiponectin has been shown to be important in maintaining 
insulin sensitivity throughout the body, while potential effects on the placenta have 
not been assessed. Pregnancy constitutes a unique physiological environment in 
which metabolism has a profound effect on the health of both the mother as well as 
the developing fetus. It is imperative that a delicate balance in glucose delivery be 
maintained between maternal tissues and the fetal/placental unit. Adiponectin’s role 
in regulating peripheral insulin responsiveness suggests it may be a factor in 
maintaining this balance during gestation as well. Examination of human 
cytotrophoblast cells revealed that mRNA for both adiponectin receptors, adipoR1 
and adipoR2, are abundantly expressed at term. We were however, unable to reliably 
detect mRNA for adiponectin in primary cytotrophoblasts. Expression of both 
receptors was maintained following induction of syncytium formation by exogenous 
EGF treatment. Treatment of cytotrophoblasts with adiponectin resulted in a 
significant drop, as assessed by quantitative RT-PCR, in expression for a number of 
genes involved in the endocrine function of the placenta, including the chorionic 
gonadotropin subunits, placental lactogen, and some steroidogenic enzymes. 
Immunofluorescent staining for connexin 43 and desmoplakin in primary trophoblasts 
revealed that adiponectin does not inhibit syncytialization of trophoblast cells in 
culture. Taken together, these data describe a novel role for maternal adiponectin in 
regulating the placental environment. Determination of the effects of such adipokines 
on the maternal-fetal interface is increasingly important, as the incidence of 
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pregnancies complicated by gestational diabetes remains a significant health problem 





Pregnancy represents a unique stage in an organism’s lifespan in which the 
female must be able to cope with the large energy demands placed on her by the 
developing fetus, while continuing to meet her own metabolic needs. Hormones such 
as insulin and leptin have long been known to mediate this balance, with diseases 
such as gestational diabetes resulting in cases when this balance is not maintained.  
The relatively recent acknowledgement of adipose tissue as an endocrine 
organ has occurred by the discovery of adipose secretion of a number of hormones 
and cytokines, collectively known as adipokines. Among this diverse and growing 
family of molecules is the hormone adiponectin, first discovered as a factor secreted 
by adipocytes by four independent groups (Hu et al., 1996, Maeda et al., 1996, 
Nakano et al., 1996, Scherer et al., 1995). Adiponectin has subsequently been shown 
to act as a potent insulin sensitizer, and has thus been primarily investigated for its 
role in decreasing both hepatic glucose production in the liver (Berg et al., 2001, 
Combs et al., 2001) and triglyceride accumulation in skeletal muscle (Yamauchi et 
al., 2001, Fruebis et al., 2001), while simultaneously increasing fatty acid oxidation in 
the liver (Yamauchi et al., 2001). 
Pregnancy represents a period during which a woman’s metabolic 
homeostasis is under significant stress. In addition, a physiological inability to 
maintain this delicate balance can result in impaired fetal development and maternal 
health. It follows that the hormone adiponectin, with its important role in maintaining 
peripheral insulin sensitivity during basal conditions, may be of increased 
significance during gestation. Indeed, there is a growing body of literature citing 
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lower maternal serum concentrations of adiponectin in cases of gestational diabetes 
(Cortelazzi et al., 2007, Altinova et al., 2007, D'Anna et al., 2005, Ranheim et al., 
2004, Tsai et al., 2005, Williams et al., 2004, Cseh et al., 2004, Georgiou et al., 
2008). Investigation of adiponectin at the maternal-fetal interface has generated some 
conflicting results. Initially, adiponectin was reported to be produced by the placenta 
(Chen et al., 2006, Lappas et al., 2005b, Caminos et al., 2005), suggestive of an 
autocrine and/or paracrine mechanism employed by adiponectin within the placenta. 
These data however, have remained controversial (Haugen et al., 2006, Ichida et al., 
2007). In addition, there has been little investigation regarding the effects of 
adiponectin on the placenta. Treatment of placental explants with adiponectin has 
been reported to result in increased secretion of proinflammatory cytokines and 
prostaglandins by placental explants (Lappas et al., 2005a). A specific effect of 
adiponectin on one of the functional units of the placenta, the trophoblast cells, has 
not been elucidated. We hypothesized that adiponectin has a direct effect on the 
trophoblast cells of the placenta, serving as an important mediator in maintaining the 
energy balance between mother and fetus that is vital for a successful pregnancy.  
Our data suggest adiponectin can exert potent effects on trophoblast cells of 
the term placenta. We show significant reductions in endocrine gene expression as a 
result of adiponectin treatment of term trophoblast cells in vitro. This apparent 
decrease in endocrine function does not however appear to be the result of a 
significant impairment of syncytialization. Indeed, those cells administered 
adiponectin appear to undergo robust syncytialization, as evidenced by desmoplakin 
staining. These results provide the first evidence of a specific role for adiponectin at 
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the maternal-fetal interface, and provide evidence of a potential regulatory 
mechanism by which maternal insulin sensitivity during pregnancy is tightly 




3. Materials and Methods 
Cell isolation and culture 
Human placentas were obtained under protocols approved by the institutional 
review board at the University of Kansas Medical Center. Cytotrophoblasts were 
isolated from healthy placentas delivered via cesarean at term as previously described 
(23). Villous tissue was dissected away from the basal plate of the placenta and 
subjected to treatment with deoxyribonuclease I (type IV; Sigma Chemical, St. Louis, 
MO) and trypsin (Invitrogen Corp., Carlsbad, CA). The resulting single-cell 
suspension was size fractionated by application to a Percoll (Sigma) density gradient. 
To ensure a homogeneous population of cytotrophoblasts, the cells underwent 
negative selection using an antibody recognizing human leukocyte antigen-A, -B, and 
-C (W6/32; Bio-Express, West Lebanon, NH) with a magnetically labeled secondary 
antibody (Miltenyi Biotec GmBH, Bergisch Gladbach, Germany). Cytospins of 
trophoblasts from each preparation were stained for cytokeratin 7 expression (N-TL 
12/30; Dako, Glostrup, Denmark) to assess purity. Purified cells were placed in 
culture medium (Iscove’s modified Dulbecco’s medium with 10% fetal bovine serum, 
1% L-glutamine, 1% penicillin/streptomycin/ amphotericin B) and allowed to adhere 
to the culture dish by incubation in a humidified chamber for 4 h before receiving 
treatment. All cells underwent regular medium changes, with refreshment of 
treatment conditions every 48 h. After addition of recombinant globular adiponectin 
(2 µg/ml; Phoenix Pharmaceuticals, Burlingame, CA) to the culture medium, cells 
were allowed to differentiate spontaneously before being harvested on d 5 of culture. 
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For adiponectin and adiponectin receptor expression analysis, the 
choriocarcinoma cell lines Jeg-3, Jar, and BeWo (American Type Culture Collection, 
Manassas, VA) were maintained in growth medium (1x DMEM with 10% fetal 
bovine serum, 1% penicillin/streptomycin). Induction of syncytialization of term 
cytotrophoblast cells was achieved by treatment with epidermal growth factor (EGF) 
for 72 h (10 ng/ml; Invitrogen), with syncytialization assessed by desmoplakin 
staining and RT-PCR for chorionic gonadotropin-β gene expression. 
RT-PCR and quantitative real-time PCR (qPCR) 
RNA from trophoblasts in culture was isolated using Trizol (Invitrogen) 
according to the manufacturer’s instructions. Adipose tissue total RNA (Ambion; 
Applied Biosystems, Foster City, CA) was used as a positive control. Total RNA was 
reverse transcribed using Superscript II reverse transcriptase (Invitrogen) and random 
primers. The resultant cDNA was used in traditional PCR with Taq polymerase 
(Invitrogen) and visualized through gel electrophoresis.  
qPCR was performed using SYBRgreen technology (Applied Biosystems). 
All gene expression data were normalized to 18S levels within the respective sample. 
Primers for genes of interest (Table VI-1) were designed using Primer Express 3.0 
software (Applied Biosystems), with the exception of the syncytin primer (24), and 
synthesized by IntegratedDNATechnology (Coralville, IA). Resulting data were 
analyzed using the ΔΔCt method [mean Cts (cycle thresholds) for each gene were 
determined then subtracted from each sample’s Ct for 18S RNA (ΔCt), and deviation 
from the no treatment control Ct for each gene was calculated (ΔΔCt)], after assuring 
amplification efficiency for both target and normalizing gene were equivalent. 
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Table VI-1. Primer Sequences for Quantitative RT-PCR. 
Gene Forward Primer Reverse Primer 
18S 5'-cgccgctagaggtgaaattct-3' 5'-cgaacctccgactttcgttct-3' 
3βHSD 5'-tcagcgagatctggcgtataag-3' 5'-acccactccaccgttttctg-3' 
AdipoR1 5'-acaagagcaggcgtgttcct-3' 5'-ctcagcgatagtaaagtgcatggt-3' 
AdipoR2 5'-tttccctggcaaatgtgaca-3' 5'-aaaagctccagcaaccacaaa-3' 
Aromatase (Cyp19) 5'-catatgatctgtctgtggcaaaagt-3' 5'-aagtggctgaggcataaatcga-3' 
Chorionic gonadotropin 
α-subunit 5'-gaatgcacgctacaggaaaacc-3' 5'-cagcccatgcactgaagtattg-3' 
Chorionic gonadotropin 
β-subunit 5'-acaaccccgaggtataaagcc-3' 5'-ccttggatgcccatgtcc-3' 
Connexin43 5'-catcctccaaggagttcaatcac-3' 5'-gggcaccactcttttgcttaaa-3' 
MMP9 5'-cccggaccaaggatacagttt-3' 5'-gtgccggatgccattca-3' 
p450scc (Cyp11A1) 5'-caccttcaccatgtccagaattt-3' 5'-ctccacgttgccgagctt-3' 






Proteins (15 µg) were fractionated by 8% SDS-PAGE and transferred to 
nitrocellulose membranes (Whatman Inc., Florham Park, NJ). Membranes were then 
subjected to Western blot analysis for chorionic gonadotropin-α (ME.109; Abcam, 
Cambridge, MA), chorionic gonadotropin-β (ab53087; Abcam), human placental 
lactogen (ab15554; Abcam), p450 side-chain cleavage (p450scc) (25), or aromatase 
(A7981; Sigma). Levels of actin (AC-15; Sigma) were monitored to assess protein 
loading. Primary antibodies were detected using secondary antibodies conjugated to 
near-infrared fluorophores (LiCor Biosciences, Lincoln, NE). Western blots were 
then imaged with the use of the Odyssey Infrared Imaging System (LiCor). 
Immunoprecipitation 
To detect chorionic gonadotropin α-subunit levels after adiponectin treatment, 
we immunoprecipitated the heterodimeric chorionic gonadotropin hormone from 
media collected from primary trophoblast cells in culture. Cell treatments were done 
as described above. The immunoprecipitation was performed with protein G magnetic 
beads (New England Biolabs, Ipswich, MA) according to the manufacturer’s 
instructions. Briefly, precleared medium from treated and nontreated cells was 
incubated with antibody against the β-subunit of chorionic gonadotropin (ab53087; 
Abcam). Protein G magnetic beads were then added. The samples were washed, 




Progesterone levels were detected in media collected from adiponectin-treated 
and control cells using the Coat-A-Count kit (Siemens Medical Solutions 
Diagnostics, Los Angeles, CA) according to the manufacturer’s instructions. Briefly, 
progesterone calibrators and unknown medium samples were added to tubes coated 
with progesterone antibody. All samples were incubated with [125I]progesterone for 3 
h before being counted on a γ-counter. Unknown sample concentrations were 
determined by fitting to the standard curve generated by the progesterone calibrator 
samples (intraassay coefficient of variation of 2.4%). 
Immunohistochemistry 
To assess the spontaneous differentiation of these cells, term cytotrophoblast 
cells were cultured on chamber slides (Thermo Fisher Scientific, Rochester, NY) and 
treated with adiponectin as described above. Treated and untreated control cells were 
then fixed with paraformaldehyde (1%; Sigma) before being immunostained with 
antibodies directed against desmoplakin 1 and 2 (DP2.15; Millipore Corp., Billerica, 
MA) or connexin 43 (sc-9059; Santa Cruz Biotechnology, Santa Cruz, CA) and 
identified using a fluorescently tagged secondary antibody (Invitrogen) before being 
nuclear counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (Invitrogen). 
Cells were also cultured and stained in parallel with nonspecific IgG as a negative 
control. 
Gelatin zymography 
Protease activity was assessed by application of conditioned medium to 8% 
acrylamide gels containing porcine gelatin. After electrophoresis, gels were washed 
for a total of 1.5 h in Tris-Cl with Triton X-100. Gels were then cut into strips, with 
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replicate samples on each strip, and incubated overnight in Tris-Cl with either EDTA 
[matrix metalloproteinase (MMP) inhibitor; Sigma], phenylmethylsulfonyl fluoride 
(serine protease inhibitor; Sigma), leupeptin (cysteine protease inhibitor; Sigma), 
pepstatin A (aspartate protease inhibitor; Sigma), or buffer alone. The next day, gels 
were stained to an appropriate contrast with Coomassie blue dye. 
Data analysis 
All experiments were performed with a minimum of four different cell 
preparations collected from distinct placentas. Statistical analysis was done using 
SigmaStat 3.1 software (Systat Software, Inc., San Jose, CA). Means for untreated 
control cells vs. adiponectin-treated cells were compared using the unpaired t test. For 





Adiponectin of a distant source can act on trophoblast cells of the placenta 
To investigate the role of adiponectin at the maternal-fetal interface, we began 
by identifying potential sources of adiponectin during pregnancy. Despite initial 
reports suggesting adiponectin is produced by the placenta (Caminos et al., 2005, 
Lappas et al., 2005b, Chen et al., 2006), we were unable to detect a transcript for 
adiponectin using either RT-PCR or qPCR (Fig. VI-1a). In contrast, adiponectin was 
readily detected in mRNA from human adipose tissue (Fig. VI-1a). Our inability to 
amplify adiponectin cDNA from any of the choriocarcinoma cell lines (Jeg-3, JAR or 
BeWo) led us to conclude that adiponectin is not a product of trophoblast cells. To 
ensure adiponectin production was not restricted to a specific lineage of differentiated 
trophoblast, such as the syncytium, we performed RT-PCR for adiponectin using 
cDNA obtained from total placenta tissue as well as cytotrophoblasts induced to 
syncytialize via EGF treatment. Similar to our previous data, we failed to detect an 
adiponectin transcript, lending further evidence to the idea that the placenta is not a 
source of adiponectin. 
 In agreement with previous reports (Caminos et al., 2005), we were able to 
detect mRNA expression for both adiponectin receptors, adipoR1 and adipoR2, using 
purified cytotrophoblasts as well as cytotrophoblasts cultured with EGF (Fig. VI-1b). 
In addition, expression of these receptors was not significantly altered as the cells 
syncytialized (Fig. VI-1c). Thus, we conclude that while the placenta may not be a 
source of adiponectin, the trophoblast cells of the placenta are presumably able to 
respond to the hormone through both the adipoR1 and adipoR2 receptors.   
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Figure VI-1. Expression of adiponectin and its receptors in the placenta. (a) RT-
PCR for adiponectin using RNA collected from human trophoblasts, placenta and 
adipose tissue. (b) RT-PCR for adipoR1 and adipoR2 using trophoblasts isolated at 
term. (c) Relative gene expression for adipoR1 and adipoR2 using quantitative RT-
PCR on trophoblasts collected at term and cultured for 24 or 120 hours, mean ± SEM. 
Jeg-3, JAR, and BeWo, human choriocarcinoma cell lines; Placenta, term placental 
explants; STB, term trophoblast cells syncytialized in culture; Adipose, human 



















































































Adiponectin treatment decreases endocrine gene expression in trophoblasts 
As cytotrophoblasts remain in culture they spontaneously differentiate to form 
a multinucleated syncytium (Kliman et al., 1986). We examined the effect of 
adiponectin on this process by treating cytotrophoblasts isolated from term placentas 
in culture with recombinant globular adiponectin. In order to allow adequate time for 
spontaneous differentiation, the culture treatment was maintained for five days. 
Initially we treated with 0.5 or 2 µg/ml of recombinant globular adiponectin. 
Although we observed trends with the 0.5 µg/ml treatment, this sub-physiological 
dose of adiponectin failed to show significant alterations in mRNA expression (data 
not shown). Quantitative RT-PCR using RNA isolated from cells treated with 2 µg/ml 
adiponectin showed a significant drop in gene expression for numerous endocrine 
transcripts, including both the chorionic gonadotropin α (77.8±5.6% reduction) and β 
(84.5±2.0% reduction) subunits and human placental lactogen (PL-A and PL-B; 
91.3±2.3% reduction; Fig. VI-2a-c).  
These results were substantiated by western blot for the α and β subunits of 
CG, as well as PL (Fig. VI-2d). For CGβ and PL, media samples from adiponectin 
treated cells (5d; 2 µg/ml) were compared to media from nontreated control cells via 
western blot. The expression of CGα was evaluated by first performing 
immunoprecipitation with an antibody directed against CGβ. Western blots for CGα 
revealed an immunoreactive band corresponding to the heterodimeric protein, and 
migrated at the same position as protein detected with the CGβ antibody. Shown in 
Figure 2d are representative blots from one placenta. The experiment was repeated 
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with six different placentas, with 4/6 of these placentas displaying a similar drop in 
protein expression following adiponectin treatment.  
Examination of the expression of specific enzymes involved in placental 
steroid hormone production, i.e. cholesterol side-chain cleavage enzyme (p450scc) 
and cytochrome p450 aromatase, also revealed a suppression in transcript levels 
(55.0±9.2% and 62.1±19.8% reduction respectively; Fig. VI-3a and VI-3b). 
Interestingly, mRNA expression of the enzyme 3β hydroxysteroid dehydrogenase 
(3βHSD) was unaltered by adiponectin treatment (Fig. VI-3c), suggesting divergent 
regulatory pathways controlling distinct steps in the steroidogenic pathway. In 
addition, examination of the protein levels showed a drop in both p450scc and 
aromatase expression following exposure to 2 µg/ml adiponectin for five days in vitro 
(Fig. VI-3d). These data are further corroborated by a drop in progesterone 
production, as determined by radioimmunoassay, in 4/6 placentas examined (Fig. VI-
4). Hormone production is one of the key functions of the syncytium. Our data 
suggest adiponectin may impair this functionality, a phenomenon that could be 
achieved by inhibiting the differentiation process or specifically targeting the genes 




Figure VI-2. Adiponectin inhibits endocrine gene expression. Quantitative RT-
PCR using RNA from term trophoblasts cultured for five days in the absence (nt) or 
presence of adiponectin (2 µg/ml). Relative quantity of (a) chorionic gonadotropin α 
subunit, (b) chorionic gonadotropin β subunit, and (c) placental lactogen mRNA. (d) 
Protein expression of chorionic gonadotropin α and β subunits, placental lactogen.  





































































































Figure VI-3. Adiponectin regulates gene expression of steroidogenic enzymes in 
an enzyme-specific manner. Exposure of term trophoblast cells to adiponectin for 
five days in vitro resulted in an inhibition of gene expression for both p450 side chain 
cleavage and aromatase enzymes, while failing to result in a significant drop in 
expression of 3βHSD. Relative quantity of p450 side chain cleavage (a), aromatase 
(b), and 3βHSD (c) mRNA in cells cultured in the absence (nt) or presence of 
adiponectin (2 µg/ml). (d) Primary trophoblasts treated with adiponectin for 5 days in 






































































































Figure VI-4. Adiponectin decreases progesterone production by trophoblast 
cells in vitro. Radioimmunoassay for progesterone was performed on media from 
cells treated with 2 µg/ml adiponectin for five days, as well as non-treated control 
cells. There was a significant drop in progesterone secretion following adiponectin 
treatment in four of six placentas examined. Interestingly, those two placentas that 
failed to show a decrease in progesterone production, also failed to show a drop in 





































Adiponectin does not inhibit spontaneous differentiation of trophoblasts in vitro 
 In order to examine the effect of adiponectin on the spontaneous 
differentiation of trophoblast cells, we cultured cytotrophoblasts from term placenta 
on chamber slides in the presence of recombinant adiponectin (2 µg/ml) for five days. 
Cells were then stained for either desmoplakin or connexin 43 in order to observe any 
morphological changes as a result of adiponectin treatment. The gap junction 
component, connexin 43, has been shown to be present between cytotrophoblasts and 
cytotrophoblasts in contact with syncytiotrophoblasts (Cronier et al., 2002). Both 
desmoplakin as well as the connexin 43 staining failed to reveal any inhibition in the 
spontaneous aggregation/differentiation process undergone by cytotrophoblasts (Fig. 
VI-5). Indeed, those cells exposed to adiponectin may even display a higher degree of 
differentiation than the control untreated cells, as evidenced by increased plasma 
membrane localization of desmoplakin (Fig. VI-5a and VI-5b) and a lower degree of 
connexin 43 staining (Fig. VI-5d and VI-5e). Quantitative RT-PCR for connexin 43 
and the retroviral gene syncytin failed to show a significant difference in gene 
expression between the control cells and those treated with adiponectin for either 
transcript (Fig. VI-5c and VI-5f). Taken together, these data show a lack of inhibition 
of morphological differentiation of trophoblast cells after they have been exposed to 
adiponectin in long-term culture.  
 We also evaluated MMP expression and activity through qPCR and gelatin 
zymography. In contrast to the endocrine genes, we observed no significant 
difference in the gene expression of MMP9 (data not shown). The trophoblasts were 
also secreting abundant amounts of active MMP. We were however unable to detect a 
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significant difference in the level of MMP activity in adiponectin treated cells 




Figure VI-5. Adiponectin does not inhibit differentiation of trophoblasts in 
vitro. Immunocytochemistry for desmoplakin and connexin 43 was performed on 
cells exposed to adiponectin (2 µg/ml) for five days in vitro in order to examine 
spontaneous differentiation of the trophoblast cells. Similar staining was observed 
between the untreated cells (a, d) and those exposed to adiponectin (b, e). (a) Control 
cells stained with desmoplakin and DAPI. (b) Cells treated with adiponectin and 
stained for desmoplakin and DAPI. (d) Control cells stained for connexin 43 and 
DAPI. (e) Adiponectin treated cells stained for connexin 43 and DAPI. Scale bar = 
100 µm. (c) Relative quantity of syncytin mRNA using quantitative RT-PCR on 
control and adiponectin treated cells. (f) Relative quantity of connexin 43 mRNA in 
cells receiving either no treatment or adiponectin for five days in culture; mean ± 
































































 Despite its relative recent characterization, adiponectin is widely regarded as 
an important means by which an organism regulates it metabolic status. The placenta 
represents an organ unique in its pivotal role in mediating the nutritive state of the 
developing fetus. In addition, the placenta is highly secretory, producing a number of 
hormones and growth factors, such as members of the growth hormone family, which 
have been implicated in influencing maternal energy homeostasis (Barbour et al., 
2002).  Both placental lactogen and placental growth hormone, produced in large 
amounts by the mature placenta, can act on distant targets to increase insulin 
resistance and thus allow for increased glucose availability to the fetal-placental unit 
(Barbour et al., 2002, Handwerger and Freemark, 2000). In addition, clinical evidence 
exists for higher placental lactogen levels in cases of gestational diabetes, particularly 
in instances of gestational diabetes without placental dysfunction (Ursell et al., 1973).  
While a certain amount of maternal insulin resistance is necessary during 
pregnancy in order to ensure adequate glucose transfer to the fetus (Lain and 
Catalano, 2007, Reece, 2008), this system must remain under tight control. One such 
mechanism by which the mother may be able to control the influence of the placenta 
on her own insulin sensitivity is through maternal adiponectin secretion. Our data 
suggest a novel role for adiponectin at the level of the maternal-fetal interface 
whereby adiponectin may regulate hormone production by the placenta, thus reducing 
the amount of peripheral insulin resistance induced by many of these hormones. Such 
a hypothesis is supported by the abundance of evidence in the literature citing a 
decrease in serum adiponectin levels during cases of extreme maternal insulin 
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resistance (i.e. gestational diabetes mellitus) (Cortelazzi et al., 2007, Altinova et al., 
2007, D'Anna et al., 2005, Ranheim et al., 2004, Tsai et al., 2005, Williams et al., 
2004, Cseh et al., 2004, Georgiou et al., 2008). In addition, studies in bovine and 
porcine ovaries, as well as a murine hypothalamic and pituitary model, have set 
precedence for adiponectin having a negative impact on hormone production (Lu et 
al., 2008, Wen et al., 2008, Ledoux et al., 2006, Lagaly et al., 2008). The data 
presented herein suggests for the first time a direct effect of adiponectin on hormone 
production by the placenta.  
Hormone production by the human placenta is a unique function of the 
syncytiotrophoblast cells. This subpopulation of trophoblast cells make up the outer 
lining of the villi, and are derived from the underlying cytotrophoblast layer. 
Differentiation of cytotrophoblasts to syncytiotrophoblasts in culture is commonly 
measured by the up regulation of endocrine genes and hormone production. Due to 
the significant decrease in endocrine gene expression seen following adiponectin 
administration to trophoblasts in vitro, we hypothesized that adiponectin may be 
inhibiting this differentiation process. Morphological analysis of cells treated with 
adiponectin, however, did not reveal an obvious inhibition of cellular aggregation and 
syncytialization when compared to the untreated controls.  This suggests divergent 
mechanisms may exist for morphological syncytialization as compared to formation 
of a functioning syncytium, at least with regard to endocrine function. The cellular 




 Although we have chosen to focus on adiponectin production by the mother, it 
remains important to point out that the fetus is also producing adiponectin by late 
gestation (Lindsay et al., 2003). Our data do not preclude the possibility of significant 
fetal contributions to local adiponectin levels at the placenta. Nonetheless, we feel 
this should not distract from the overall hypothesized effect of adiponectin in helping 
to regulate maternal insulin sensitivity via placental hormone synthesis. 
There remains a significant lack of understanding regarding the influence of 
adiponectin at the maternal-fetal interface. Given the proven importance of this 
hormone in maintaining energy homeostasis in other biological systems, there is a 
real need for a better understanding of the influence adiponectin may play on various 
functions of the placenta. Our data provide the first evidence for a significant role of 
adiponectin on the syncytium of the mature placenta. These studies provide a 
springboard from which subsequent studies may elucidate precise mechanisms by 
which adiponectin exerts its influence over the trophoblast cells of the placenta. 
Understanding this regulatory mechanism will enhance our knowledge of the 
physiological processes that may be affected during cases of gestational diabetes 
mellitus, thus allowing for more comprehensive care of both the mother and child 
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VII: Chapter Three: 
 





A successful pregnancy is contingent on maternal tolerance of the 
immunologically foreign fetus. Prevalent diseases such as preeclampsia are thought to 
be due to an inappropriate immune response at the maternal-fetal interface. Here we 
report the metabolic hormone, adiponectin, to be pro-inflammatory at the maternal-
fetal interface. Treatment of term trophoblasts with adiponectin (2µg/ml) for 5d 
increased expression of IL-1β and IL-8 mRNA, an effect that also occurred when 
syncytialized cells are exposed to adiponectin for only 24h. There exist a number of 
molecules that have been proposed to temper cellular response to pro-inflammatory 
mediators, including the cell surface proteins, CD24 and Siglec10. 
Immunohistochemistry of sections of term villi revealed abundant expression of 
CD24 in cytotrophoblasts and syncytiotrophoblasts, while Siglec10 was only 
expressed by syncytiotrophoblasts. Treatment of cytotrophoblast cells from healthy 
term placenta with globular adiponectin (2µg/ml) during the course of spontaneous 
syncytialization in vitro resulted in a significant increase in Siglec10 mRNA and 
protein levels. These data suggest the trophoblast cell is capable of upegulating 
Siglec10 expression as a means to counteract the pro-inflammatory effects of 
adiponectin. Indeed, over-expression of Siglec10 in primary trophoblast cultures 
results in a dampening of the cytokine gene expression response to adiponectin 
exposure. Our findings are novel in two respects: 1) this represents the first time the 
CD24/Siglec10 pathway has been implicated in a trophoblast response to a pro-
inflammatory mediator, and 2) these data describe a role for adiponectin in enhancing 




For mammalian pregnancy to be successful a complex interplay between 
maternal and fetal systems must take place. One crucial interaction is the maternal 
accommodation of nutrient demands placed on her both by her own rapidly changing 
body and the developing fetus. Maternal stores of adipose have been implicated in 
playing an important role in mediating this balance, both energetically as well as 
through endocrine actions. We have previously reported adiponectin, a hormone 
produced by maternal adipose stores, to cause a significant drop in hormone 
production by the placenta (McDonald and Wolfe, 2009). Although a number of 
epidemiological studies have identified adiponectin as being altered during 
metabolically stressed pregnancies (such as gestational diabetes and preeclampsia), 
much work remains in order to determine the effect(s) of adiponectin on the human 
placenta.  
 Another key aspect of a successful pregnancy is tolerance of the 
immunologically foreign fetus by the maternal immune system. The maternal-fetal 
interface has a number of systems in place which help to maintain its quiescent state 
with regards to immune activation, and this area is under intense investigation by a 
number of laboratories. A potential immunological role for adipokines, a group of 
hormones commonly associated with their potent metabolic roles, has received 
relatively little attention to date. A growing number of clinical studies have reported 
increases in term adiponectin levels in maternal serum in women diagnosed with 
preeclampsia (Avci et al., 2010, D'Anna et al., 2006, Davis et al., 2007, Fasshauer et 
al., 2008, Haugen et al., 2006, Nien et al., 2007, Ramsay et al., 2003).  Although 
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adiponectin was originally identified as being anti-inflammatory (Wolf et al., 2004, 
Wulster-Radcliffe et al., 2004, Mandal et al., 2010, Ebina et al., 2009), a number of 
studies have recently shown it to induce pro-inflammatory cytokines under specific 
conditions (Song et al., 2009, Tomizawa et al., 2009, Tomizawa et al., 2008, Kitahara 
et al., 2009, Lappas et al., 2005a, Haugen and Drevon, 2007). Additionally, 
adiponectin has now been shown to activate the NFκB signaling pathway (Haugen 
and Drevon, 2007, Tomizawa et al., 2008, Lappas et al., 2005a), one of the most 
common signaling mechanisms involved in pro-inflammatory cytokine production. 
The pro-inflammatory responses appear to be mediated primarily through globular 
adiponectin (Tomizawa et al., 2009, Tomizawa et al., 2008), the form of adiponectin 
which has shown to be highly effective in mediating a variety of biological effects, 
such as fatty acid oxidation in skeletal muscle (Fruebis et al., 2001).  
 With regards to cytokine production at the maternal-fetal interface, globular 
adiponectin has been shown to increase production of the pro-inflammatory cytokines 
IL-1β, IL-6, and TNFα in human placental explant cultures collected at term (Lappas 
et al., 2005a). Although this study suggests that adiponectin plays a pro-inflammatory 
role at the maternal-fetal interface, the use of explants leaves open the possibility that 
a cell type other than trophoblast cells is responsible for the reported cytokine 
production. Indeed, a number of studies have shown adiponectin to influence 
cytokine production by other cell types also present in placental explants, including 
macrophages (Wulster-Radcliffe et al., 2004)  and endothelial cells (Tomizawa et al., 
2009, Tomizawa et al., 2008). In order to conclusively demonstrate the effect of 
globular adiponectin on trophoblast cells of the human placenta, we examined the 
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effect of adiponectin treatment on gene expression for a variety of cytokines in 
isolated trophoblast cells.  
 Immune tolerance at the maternal-fetal interface is thought to occur through a 
variety of mechanisms, including regulation of HLA expression, regulatory T cells, 
and immunomodulatory proteins, such as members of the B7 family (Petroff, 2005, 
Clark et al., 2010). The amount of redundancy between mechanisms makes this 
system increasingly complex. In addition, a recent report has outlined a mechanism 
involving the cell membrane proteins, CD24 and Siglec10, in dampening immune 
activation initiated by damage-associated molecular patterns (DAMPs) (Chen et al., 
2009). Although no data has been reported regarding a role for the CD24/Siglec10 
pathway at the maternal-fetal interface, it remains possible this is another mechanism 
by which the human placenta regulates immune activation throughout gestation. 
In this report we demonstrate that globular adiponectin is a potent inducer of 
pro-inflammatory cytokine production by the trophoblast cells of the human placenta. 
Furthermore, we provide evidence for the CD24/Siglec10 pathway as a compensatory 
mechanism utilized by the syncytiotrophoblast in an effort to moderate the pro-
inflammatory cascade initiated by treatments such as adiponectin. These data not only 
demonstrate that adiponectin can be detrimental to the success of a pregnancy through 
its pro-inflammatory role, but also suggest a novel mechanism in trophoblast cells by 
which pro-inflammatory mediators may be brought under control, thus ensuring the 




3. Materials and Methods 
Cell Isolation and Culture 
Human placentas were obtained under protocols approved by the institutional 
review board at the University of Kansas Medical Center. Cytotrophoblasts (CTBs) 
were isolated from healthy placentas delivered via cesarean at term as previously 
described (McDonald and Wolfe, 2009). Purified cells were placed in culture media 
(Iscove’s Modified Dulbecco’s Medium with 10% fetal bovine serum, 1% L-
glutamine, 1% penicillin/streptomycin/amphotericin B) and allowed to adhere to the 
culture dish by incubation in a humidified chamber overnight prior to receiving 
treatment. All cells underwent regular media changes, with refreshment of treatment 
conditions every 48h. For all adiponectin treatments, recombinant globular 
adiponectin (2µg/ml; BioVendor, Czech Republic) was used.  
RNA Isolation and Quantitative RT-PCR (qPCR) 
RNA from trophoblasts in culture was isolated using Trizol (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. Total RNA was reverse 
transcribed using Superscript II reverse transcriptase (Invitrogen) and random 
primers. Quantitative real-time PCR (qPCR) was performed using SYBRgreen 
technology (Applied Biosystems, Foster City, CA). All gene expression data was 
normalized to 18S levels within the respective sample. All primers (Table VI-1) were 
designed using Primer Express 3.0 software (Applied Biosystems) and synthesized by 
Integrated DNA Technology (Coralville, IA). Resulting data was analyzed as outlined 
previously (McDonald and Wolfe, 2009).  
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Table VII-1. Primer Sequences for Quantitative RT-PCR. 
Gene Forward Primer Reverse Primer 
18S 5'-cgccgctagaggtgaaattct-3' 5'-cgaacctccgactttcgttct-3' 
IL-1β 5'-cttggtgatgtctggtccatatga-3' 5'-ggacatggagaacaccacttgtt-3' 
IL-8 5'-tgatttctgcagctctgtgtga-3' 5'-gggtccagacagagctctcttc-3' 






 Cytokine production was measured using media samples from cells cultured 
for 5d in the presence of adiponectin, and compared to media from corresponding 
cells from the same placenta prep that were cultured in media alone. Cytokines were 
quantified using the Milliplex MAP kit (Millipore, Billerica, MA) and the 
manufacturer’s protocol. Briefly, media samples were incubated with antibody-
labeled beads against interleukin (IL)-8 and IL-1β overnight at 4°C. After extensive 
washing, amount of bound antibodies were assayed through the use of detection 
antibodies and streptavidin-phycoerythrin. The assay plate was read on a Luminex 
200 system (Luminex, Austin, TX). Cytokine levels wer quantitated through 
application of a standard curve. 
Immunofluorescence 
Immunohistochemistry was performed on villous sections of term placentas, 
freshly isolated cytotrophoblasts, and trophoblasts cultured on chamber slides for 5d. 
Villous sections with the basal plate intact were fixed in 4% paraformaldehyde 
(Sigma Chemical, St. Louis, MO) for four hours and then infused with 18% sucrose 
solution overnight before being frozen. Frozen fixed tissue was then cut into 10µm 
sections on a cryostat. Cytospins from freshly isolated cytotrophoblasts were allowed 
to dry at room temperature overnight and stored at -20°C. Isolated cytotrophoblasts 
were also plated on chamber slides (Thermo Fisher Scientific, Rochester, NY) for 5d 
with/without adiponectin (2 µg/ml) before being fixed in 1% paraformaldehyde for 10 
minutes and permeabilized in ethanol:acetic acid at -20°C for 5 minutes, with antigen 
unmasking in 0.5M ammonium chloride for 30 minutes. 
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Slides were blocked against nonspecific antibody binding with 10% (v/v) 
donkey serum in PBS.  A primary antibody to Siglec10 (AF2130, R&D Systems, 
Minneapolis, MN), CD24 (ML5; BD Biosciences, San Jose, CA) or nonimmune 
control IgG was applied to sections and incubated overnight at 4oC in a humidified 
chamber.  Sections were washed, secondary antibody (Alexa Fluor 546 donkey anti-
goat IgG or Alexa Fluor 555 donkey anti-mouse IgG, Invitrogen) applied at the 
appropriate concentration and incubated at room temperature for 1 hr.  Sections were 
then washed and counterstained with DAPI (Invitrogen).  Immunofluorescence was 
visualized using an Olympus IX71 inverted microscope. 
Lentiviral Infection 
 Complete virus was made in 293FT cells (Invitrogen) by co-transfection with 
WPI vector harboring the complete cDNA for human Siglec10 and the packaging 
vectors, psPAX2 and pMD2.G (generous gifts from the Trono Lab). Transfections 
were completed using Lipofectamine 2000 (Invitrogen) and a standard transfection 
protocol. Briefly, vectors and lipofectamine 2000 were added to separate aliquots of 
Opti-MEM reduced media (Invitrogen) and incubated at room temperature for 5 min. 
The aliquots of Opti-MEM were then combined and allowed to form liposomes by 
incubation at room temperature for 20 min. 293FTs were trypsinized, the 
lipofectamine complexes were added to distinct 10 cm2 culture dishes, and 6 x 106 
cells added.  Mature virus was harvested by collection of the media 48 and 72h post-
transfection. Infection of term trophoblast cells was done by adding media harboring 




All experiments were performed with a minimum of three distinct placentas. 
Statistical analysis was done using SigmaStat 3.1 software (Systat Software, Inc., San 
Jose, CA). Differences in the mean relative quantity of gene expression in adiponectin 
treated compared to non-treated cells was assessed for significance through use of the 
Mann-Whitney Rank Sum Test. Cytokine production following adiponectin treatment 
was compared to levels in control cells within the sample placenta preparation using 
the Wilcoxon Signed Rank Test, in order to account for variation between placentas. 





Adiponectin elicits pro-inflammatory cytokine production in human trophoblasts 
Previous data generated in our laboratory uncovered a negative effect of long-
term (5d) adiponectin treatment on hormone production by trophoblast cells allowed 
to differentiate spontaneously in vitro (McDonald and Wolfe, 2009). Here, we 
provide evidence that within the same experimental paradigm, adiponectin also acts 
as a pro-inflammatory mediator, enhancing production of the cytokines IL-1β and IL-
8 in trophoblast cells.  
Term trophoblasts were isolated and cultured in the presence of globular 
adiponectin (2µg/ml) for 5d. We have previously shown in our laboratory that this is 
sufficient time to allow for spontaneous differentiation of the cells in culture to a 
syncytiotrophoblast phenotype (data not shown). Quantitative RT-PCR for the pro-
inflammatory cytokines IL-1β and IL-8 show an increase in gene expression for these 
two cytokines in cells collected at the end of the 5d culture period and exposed to 
adiponectin throughout the culture period, as compared to those cultured in the 
absence of adiponectin (Fig.VII-1a&b). We also analyzed the production of IL-8 and 
IL-1β in media samples collected from 5d treatment of adiponectin. The production 
of IL-1β was extremely low in some of the samples, making direct comparisons 
between treated and untreated cells difficult (data not shown). Although IL-8 
production was highly variable between placentas, the production of this cytokine 
was significantly increased following adiponectin treatment in all of the placenta 
preparations analysed (Fig. VII-1c). 
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In addition, we examined the expression of the pro-inflammatory cytokines, 
IL-1β and IL-8 in term trophoblast cells after 24h of adiponectin exposure. These 
cells were placed in culture for 4d prior to receiving adiponectin (2µg/ml) for the 
final 24h of the culture period. In this way, they were allowed to differentiate in vitro, 
and are thus comparable to the cells we have previously found to have increased 
expression of IL-1β and IL-8 with adiponectin exposure for the entire 5d culture 
period. Treatment with globular adiponectin for the final 24h of the culture period 
resulted in an up-regulation of mRNA for both IL-1β and IL-8 (Figure VII-1d&e), 
similar to what was seen with adiponectin administration for the entire 5d. These data 
suggest that the pro-inflammatory cytokine production by trophoblasts is a direct 
response to adiponectin itself, rather than the result of an intermediate effecter 
modulated by adiponectin. Taken together, these data demonstrate that adiponectin 




Figure VII-1. Adiponectin up-regulates expression of the pro-inflammatory 
cytokines, IL-1β and IL-8 in term trophoblast cells.  Quantitative RT-PCR for IL-
1β (A) and IL-8 (B) in trophoblasts collected at term and cultured in the presence of 
globular adiponectin (2µg/ml) for 5d. Gene expression for both pro-inflammatory 
cytokines is up-regulated in the adiponectin exposed cells compared to no treatment 
control cells (n=4).  Secretion of IL-8 is upregulated following 5d adiponectin 
treatment (n=5). Adiponectin also stimulates expression of IL-1β (D) and IL-8 (E) in 
term trophoblasts placed in culture for 4d prior to treatment with adiponectin for 24h 
































































































































Trophoblast cells express CD24 and Siglec10 at term 
A recent report has outlined a role for the cell membrane proteins, CD24 and 
Siglec10, as partnering to dampen a cell’s inflammatory response to danger-
associated molecular patterns (DAMPs) (Chen et al., 2009). We hypothesized this 
may represent another mechanism utilized by trophoblast cells to keep the maternal-
fetal interface in a largely inactivated immune state. Towards this end, we began by 
looking for expression of both CD24 and Siglec10 in preparations of pure trophoblast 
cells.  
Villous sections taken at term revealed robust expression of CD24 within the 
syncytiotrophoblast layer of the villous (Fig. VII-2b). Trophoblast cells collected at 
term from healthy placentas were also examined for the expression of both CD24 and 
Siglec10 proteins. Syncytiotrophoblast expressed Siglec10 protein, although at a 
much lower amount than that of CD24 (Fig. VI-2d). Interestingly, cytospins made 
from freshly isolated trophoblasts, and thus a population of >99% undifferentiated 
cytotrophoblasts, express robust levels of CD24, but remain devoid of Siglec10 (Fig. 
VI-2f&h). The dynamic expression pattern of Siglec10 is interesting, and suggests 
that it may fulfill a more specific role than CD24 in human trophoblasts. 




Figure VII-2. Both CD24 and Siglec10 are expressed by human trophoblast cells 
at term.  Villous sections of term placenta (A-D) are positive for both CD24 and 
Siglec10 protein, particularly within the syncytiotrophoblast layer. In contrast, 
cytospins of cytotrophoblasts freshly isolated from term placentas (E-H) show 
positive reactivity for CD24, but not Siglec10. Negative control for CD24 staining 
(a&e); CD24 immunohistochemistry (b&f); negative control for Siglec10 staining 
(c&g); Siglec10 immunohistochemistry (d&f). All sections were counterstained with 



















Adiponectin increases Siglec10 expression in trophoblast cells 
 We began our investigation of the effect of globular adiponectin treatment on 
term trophoblasts cells by exposing the cells to adiponectin for 5d in culture, as was 
done in our previous experiments. Quantitative RT-PCR reveals an increase in 
Siglec10 gene expression following adiponectin exposure (Fig. VII-3a). In addition, 
cells were plated on chamber slides, exposed to adiponectin for 5d, and stained for 
Siglec10. Trophoblasts cultured in the absence of adiponectin showed limited positive 
immunoreactivity for Siglec10 (Fig. VII-3c). Cells exposed to adiponectin throughout 
the culture period, however, had increased levels of Siglec10 immunoreactivity, 
compared to no treatment control cells (Fig. VII-3d). This phenomenon was not due 
to a possible effect of adiponectin on the syncytialization process, as we have 
previously shown that adiponectin does not inhibit syncytialization of term 
trophoblasts in vitro (McDonald and Wolfe, 2009). 
These data indicate that Siglec10 expression, at both the mRNA and protein 
level, is increased in trophoblast cells following long-term exposure to adiponectin. 
Based on the reported function of CD24/Siglec10 to down-regulate the pro-
inflammatory response to DAMPs (Chen et al., 2009), we hypothesized that a similar 
phenomenon may occur in human trophoblast cells. Furthermore, this may explain 
the lack of pregnancy-related phenotypes/complications following adiponectin over-
expression in mouse models (Lu et al., 2008). 
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Figure VII-3. Adiponectin treatment increases Siglec10 expression in term 
trophoblast cells.  Human trophoblasts collected at term and cultured for 5d in the 
presence of globular adiponectin (2µg/ml) show an increase in Siglec10 expression. 
A) Quantitative RT-PCR for Siglec10 shows an increase in Siglec10 mRNA after 5d 
exposure to adiponectin in vitro. B) Negative control for Siglec10 staining, 
counterstained with DAPI; C) Siglec10 staining in control term trophoblasts cultured 
for 5d. D) Siglec10 staining in term trophoblasts exposed to adiponectin while in 














































 The maternal-fetal interface is physiologically unique in its ability to 
manipulate the maternal immune system in order to ensure continued growth and 
development of the immunologically-foreign fetus. Inappropriate immune activation 
can result in a number of adverse pregnancy outcomes, including preeclampsia, fetal 
growth restriction, and preterm labor/delivery. A predominantly Th1 environment at 
the maternal-fetal interface has been implicated in mediating the onset of these 
diseases (Challis et al., 2009). Furthermore, activators of trophoblast NFκB signaling 
can result in preeclampsia-like symptoms in a mouse model (Tinsley et al., 2009). 
 The hormone adiponectin was originally identified for its role in regulating 
blood glucose levels and contributing to insulin sensitivity. Adiponectin is produced 
predominantly by adipose tissue and enhances the effects of insulin through 
decreased gluconeogenesis in the liver, and increased insulin sensitivity and glucose 
uptake in skeletal muscle (Berg et al., 2001, Combs et al., 2001, Fruebis et al., 2001, 
Yamauchi et al., 2001). Indeed, the hormone was initially suggested as a potential 
treatment option for insulin resistance and/or obesity (Shklyaev et al., 2003).  
Numerous studies have identified an anti-inflammatory role for adiponectin 
(Ebina et al., 2009, Mandal et al., 2010, Wolf et al., 2004, Wulster-Radcliffe et al., 
2004). As investigation regarding the effects of adiponectin in multiple physiological 
systems has progressed, it has been shown to also exert pro-inflammatory cytokine 
production in specific diseases, particularly autoimmune diseases such as rheumatoid 
arthritis (Kitahara et al., 2009) and lupus (Song et al., 2009). Interestingly, the pro-
inflammatory versus anti-inflammatory effects of adiponectin have been suggested to 
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be mediated through different forms of the hormone. High molecular weight (HMW) 
adiponectin has been reported to be pro- or anti-inflammatory, while the cleaved 
form, also known as globular adiponectin, has been implicated in mediating pro-
inflammatory processes (Tomizawa et al., 2008, Haugen and Drevon, 2007).  
 With regards to the placenta, adiponectin has been previously shown to 
activate NFκB signaling (Lappas et al., 2005a). These data however were collected 
with the use of placental explant cultures, meaning that the pro-inflammatory effect 
by adiponectin could be derived from a number of different cell types present in the 
culture system. In this report we have evaluated the direct effects of globular 
adiponectin on term trophoblasts collected from healthy pregnancies. Thus, these data 
support the previous data suggesting adiponectin plays a pro-inflammatory role at the 
maternal-fetal interface, and show that this effect is mediated through trophoblasts 
themselves.  
Trophoblast cells utilize a number of different mechanisms to evade and 
down-regulate the maternal immune system. Despite intense investigation, the 
redundancy and complexity of maternal immune regulation leaves much to be 
discovered. A recent paper by Chen and colleagues (Chen et al., 2009) outlined the 
cell surface molecules, CD24 and Siglec10, to potently down-regulate an organism’s 
response to self antigens classified as damage-associated molecular patterns 
(DAMPs). Microarray analysis, performed in our laboratory, of primary human 
trophoblast cells cultured in the presence of adiponectin throughout in vitro 
differentiation showed elevated expression for both CD24 and Siglec10 compared to 
the untreated control cells (McDonald and Wolfe, unpublished data). From these data 
126 
 
we hypothesized that the CD24/Siglec10 system may also be functional at the 
maternal-fetal interface. The data reported herein provides evidence that Siglec10 is 
dynamically up-regulated in trophoblasts in response to strong pro-inflammatory 
signals such as adiponectin. Further examination of the CD24/Siglec10 pathway in 
trophoblasts is warranted, as this may be another mechanism by which maternal 
immune response to the developing fetus is dampened.  
A previous report by our group identified a detrimental effect of adiponectin 
on trophoblast hormone production (McDonald and Wolfe, 2009). Using the same 
treatment paradigm as that outlined in the current report, we were able to show a 
decrease in the production of chorionic gonadotropin, placental lactogen, and 
progesterone by the cells allowed to spontaneously differentiate in the presence of 
adiponectin. If we think of pregnancy as a balance between the physiological needs 
and health of the mother versus the fetus, these data support the notion that 
adiponectin promotes the health of the mother, and thus works to keep the metabolic 
and invasive demands of the fetus and fetally-derived trophoblast cell in check.  
These data suggest that adiponectin is pro-inflammatory toward trophoblast cells, and 
thus detrimental to the ongoing success of pregnancy. Examination of the effect of 
adiponectin and the trophoblast response in malnourished or extremely lean women 
(conditions associated with elevated maternal adiponectin) is thus very important, and 
could have significant contributions to public health on a global scale. Additionally, 
these data support further investigation into the role of CD24/Siglec10 as another 
potential mechanism by which trophoblast cells successfully master maternal immune 














VIII: Chapter Four: 
 





The transfer of nutrients to the developing fetus places an enormous strain on 
the metabolic control mechanisms of the mother. This becomes increasingly true as 
gestation continues, and the fetus enters a period of high growth. Inappropriate 
regulation of glucose transfer to the fetus can result in the manifestation of diseases 
such as gestational diabetes, a condition that can have very serious implications for 
the present and future health of both mother and child. Hormones originating from 
maternal adipose tissue have recently gained interest for their potent roles in 
regulating metabolism and glucose homeostasis. We have previously shown that the 
adipocyte-derived hormone, adiponectin, can alter the hormone production of term 
syncytialized trophoblast cells, as well as initiate a pro-inflammatory response from 
these cells in vitro. In this report we identify that adiponectin can activate the ERK1/2 
and EGF signaling pathways in term trophoblasts. However, in contrast to other 
reports, including one in a choriocarcinoma cell line, we do not observe activation of 
the adenosine 5’-monophosphate-activated kinase (AMPK) pathway following 
adiponectin treatment (globular adiponectin; 2 µg/ml). Furthermore, over-expression 
of the adaptor protein, APPL2, which functions to block the actions of APPL1 at the 
adiponectin receptor, results in a loss of adiponectin signaling, implying that APPL1 
binding is necessary to transmit the adiponectin signal in trophoblast cells. Finally, 
over-expression of leptin in these cells also ablates the signal induction by 
adiponectin. These data substantiate the idea that leptin and adiponectin are two 
hormones with largely opposing functions. Thus, leptin production by the trophoblast 
may be one mechanism by which the placenta avoids some of the effects of maternal 
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adiponectin, which to this point, appear largely detrimental to the developing fetus. 
These data are novel in that they represent the first time adiponectin signaling has 
been evaluated in isolated primary trophoblast cells, and identify adiponectin 
stimulation of EGF signaling. In addition, leptin interference with adiponectin 
signaling may have important implications regarding the impact these hormones have 




Efficient and effective response to metabolic cues is crucial for life, but its 
importance is futher illuminated during pregnancy, when the placenta is responsible 
for integrating all external cues and mediating both maternal and fetal metabolism. 
The number of hormones, particularly those of pancreatic and adipocyte origin, that 
affect the metabolic and nutrient transfer responses of the placenta are great in 
number. One of these hormones, known to have a direct effect on the placenta is 
adiponectin.  
The metabolic hormone adiponectin was originally identified as possessing 
potent insulin sensitizing effects, increasing insulin responsiveness in skeletal muscle, 
decreasing hepatic glucose production and increasing β-oxidation of fatty acids in the 
liver (Berg et al., 2001, Combs et al., 2001, Yamauchi et al., 2001, Maeda et al., 
2002). Since its original characterization, adiponectin has been implicated in playing 
a role in a large variety of biological systems, many having to do with metabolic 
sensing.  
Adiponectin was originally shown to utilize both adenosine 5’-
monophosphate-activated kinase (AMPK) and peroxisome proliferator-activated 
receptor (PPAR)α signaling mechanisms, mediated through binding to two different 
receptors, adipoR1 and adipoR2, respectively (Yamauchi et al., 2003a). Since the 
original identification of the adiponectin receptors, however, adiponectin has also 
been shown to activate a diverse range of signaling pathways including the mitogen 
activated pathways, p38 and ERK1/2, PI3K, JAK/STAT and NFκB (Coope et al., 
2008, Haugen and Drevon, 2007, Yamauchi et al., 2003a). Although downstream 
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signaling may vary, adiponectin receptors appear to bind the adaptor protein, APPL1 
(adapter protein containing plekstrin homology domain, phosphotyrosine domain, and 
leucine zipper motif), which allows for downstream signaling mechanisms to be 
initiated (Mao et al., 2006). Interference of this interaction by the protein APPL2 has 
been shown to inhibit activation of downstream signaling cascades normally initiated 
by adipoR1 (Wang et al., 2009). 
At the maternal-fetal interface various reports have shown AMPK, NFκB, 
ERK1/2 and PPARγ to be activated by adiponectin (Lappas et al., 2005a, Benaitreau 
et al., 2009). To our knowledge however, these reports were based on studies using 
either placental explants, and thus harboring a multitude of cell types, or 
choriocarcinoma cell lines, which may have very unique signaling and responses 
compared to trophoblast cells in vivo. The goal of the current study was to identify the 
signaling mechanisms utilized by adiponectin in trophoblast cells of the human term 
placenta.  
We and others have previously shown that adiponectin is not produced by the 
human placenta, and therefore the syncytiotrophoblast, as the cellular layer in direct 
contact with maternal blood for most of the pregnancy, is the most likely region of the 
placenta to be exposed to maternal adiponectin (Ichida et al., 2007, McDonald and 
Wolfe, 2009, Haugen et al., 2006, Desoye and Hauguel-de Mouzon, 2007). We and 
others have shown that adiponectin can exert dramatic effects on the hormone 
production and proliferation of trophoblast cells (Benaitreau et al., 2009, McDonald 
and Wolfe, 2009).  
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Adiponectin is not the only metabolic hormone that can affect trophoblasts. 
Leptin, produced by the human placenta, is a known mediator of proliferation and 
invasion by trophoblasts (Magarinos et al., 2007, Schulz and Widmaier, 2004, Senaris 
et al., 1997). In general, many of the effects of leptin appear to directly oppose that of 
adiponectin. Additionally, leptin has been reported to cause increased production of 
hCG by trophoblast cells (Cameo et al., 2003), the opposite effect as what we have 
reported to occur following trophoblast exposure to adiponectin (McDonald and 
Wolfe, 2009). We expect the oppostion of leptin and adiponectin to continue at the 
maternal-fetal interface. Consequently, in addition to identifying the signaling 
mechanisms activated by adiponectin in syncytialized trophoblast cells, we also 
determined if leptin could modify these reponses. A lentiviral construct was used to 
produce high levels of leptin within these cells prior to examination of the signaling 
cascades initiated by adiponectin treatment. In this report we are able to identify 
activation of the ERK1/2, JNK, and EGF signaling cascades following treatment with 
adiponectin. In addition, we have found that overexpression of leptin within these 
cells interferes with the ability of adiponectin to initiate downstream signaling 
cascades.   
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3. Materials and Methods 
Materials 
 The AMPK agonist, AICAR was purchased from Calbiochem (EMD 
Chemicals, Gibbstown, NJ). The pAMPKα, pERK1/2, pJNK antibodies were 
purchased from Cell Signaling Technology (Danvers, MA). The pEGFR and ERK1/2 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Secondary antibodies were purchased from Invitrogen (Carlsbad, CA) and LiCor 
Biosciences (Lincoln, NE). Lentiviral vectors, WPI, psPAX2 and pMD2.G were a 
generous gift from the Trono lab (Lausanne, Switzerland). The APPL2 mammalian 
expression vector was purchased from Open Biosystems (Thermo Fisher Scientific, 
Waltham, MA). All quantitative RT-PCR primers were purchased from Integrated 
DNA Technology (Coralville, IA).  
Cell Isolation and Culture 
Human placentas were obtained under protocols approved by the institutional 
review board at the University of Kansas Medical Center. Cytotrophoblasts (CTBs) 
were isolated from healthy placentas delivered via cesarean at term as previously 
described (McDonald and Wolfe, 2009). Purified cells were placed in culture media 
(Iscove’s Modified Dulbecco’s Medium with 10% fetal bovine serum, 1% L-
glutamine, 1% penicillin/streptomycin/ amphotericin B) and allowed to adhere to the 
culture dish and syncytialize in vitro by incubation in a humidified chamber for 5d 
prior to receiving treatment. All cells underwent regular media changes every 48h and 
were placed in culture media in the absence of serum for the last 24h prior to 
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receiving adiponectin treatment. In lentiviral infection experiments, cells were 
allowed to adhere to the culture dish by overnight incubation prior to infection.  
Immunoblots 
Proteins (10 µg) were fractionated by 10% SDS-PAGE and transferred to 
nitrocellulose membranes (Whatman Inc., Florham Park, NJ).  Membranes were then 
subjected to western blot analysis for the protein of interest. Primary antibodies for 
pAMPKα (Thr172; 40H9), pERK (Thr202/Tyr204; E10), pJNK (Thr183/Tyr185; 
G9), ERK (C-14), pEGFR (Tyr 1173), and actin were detected using secondary 
antibodies conjugated to near-infrared fluorophores (Alexa Fluor 680 goat anti-mouse 
IgG, Alexa Fluor 680 donkey anti-goat IgG, Invitrogen; IRDye 800 goat anti-rabbit 
IgG, LiCor Biosciences).  Western blots were then imaged with the use of the 
Odyssey Infrared Imaging System (LiCor Biosciences). 
Lentiviral Production and Infection 
 Complete virus was made in 293FT cells (Invitrogen) by co-transfection with 
WPI vector harboring either the complete cDNA for human APPL2, leptin or the 
empty vector control, WPI and the packaging vectors, psPAX2 and pMD2.G. 
Transfections were completed using Lipofectamine 2000 (Invitrogen) and a standard 
transfection protocol. Briefly, vectors and lipofectamine 2000 were added to separate 
aliquots of Opti-MEM reduced media (Invitrogen) and incubated at room temperature 
for 5 min. The aliquots of Opti-MEM were then combined and allowed to form 
liposomes by incubation at room temperature for 20 min. 293FTs were trypsinized, 
the lipofectamine complexes were added to distinct 10 cm2 culture dishes, and 6 x 106 
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cells added.  Mature virus was harvested by collection of the media 48 and 72h post-
transfection. Infection of term trophoblast cells was done by adding media harboring 
mature APPL2-WPI, leptin-WPI, or WPI (empty vector control) virus in the presence 
of 8µg/ml Sequabrene (Sigma Chemical).  
RNA Isolation and Quantitative RT-PCR (qPCR) 
RNA from trophoblasts in culture was isolated using Trizol (Invitrogen) 
according to the manufacturer’s instructions. Total RNA was reverse transcribed 
using Superscript II reverse transcriptase (Invitrogen) and random primers. 
Quantitative real-time PCR (qPCR) was performed using SYBRgreen technology 
(Applied Biosystems). All gene expression data was normalized to 18S levels within 
the respective sample. All primers (Table VIII-1) were designed using Primer Express 
3.0 software (Applied Biosystems). Resulting data was analyzed using the ΔΔCt 




Table VIII-1. Primer Sequences for Quantitative RT-PCR 
Gene Forward Primer Reverse Primer 
18S 5'-cgccgctagaggtgaaattct-3' 5'-cgaacctccgactttcgttct-3' 
APPL2 5'-ctccatagacgcgctgcat-3' 5'-cccccagactcgctctttact-3' 






Adiponectin does not activate AMPK in the human trophoblast 
 The AMP-activated protein kinase (AMPK) signaling pathway has been 
implicated as one of the primary means by which adiponectin elicits intracellular 
responses on target cells. Therefore, we initiated our investigations into the signaling 
mechanisms utilized by adiponectin in human trophoblast cells by examining the 
AMPK pathway. Despite treatment with adiponectin over a broad range of time 
points, we were unable to observe activation of AMPK by adiponectin (Fig. VIII-1a). 
We also treated the cells with aminoimidazole carboxamide ribonuclotide (AICAR), 
an AMPK agonist, as a positive control. As expected, AICAR activates AMPK within 
10-15 minutes of treatment (Fig. VIII-1b). From these data we conclude that the 
effects of adiponectin must be mediated through alternate mechanisms in 
syncytialized human trophoblast cells.   
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Figure VIII-1. Adiponectin does not stimulate AMPK in human term 
trophoblast cells. Despite its well characterized activation of AMPK in liver and 
skeletal muscle, adiponectin does not appear to initiate activation of the AMPK signal 
cascade in human trophoblast cells collected at term. Western blot for AMPK 
following treatment with globular adiponectin (2µg/ml) for 5, 10, 15, 30, or 45 min 
(A). In contrast, the AMPK agonist, AICAR, stimulated AMPK activation within 10 


















Adiponectin activates the ERK1/2 and JNK signaling cascades in human trophoblast 
cells 
 Despite a lack of activation of either AMPK or its downstream signaling 
molecule, ACC (data not shown), globular adiponectin did appear to cause an 
increase in the activated forms of two members of the MAPK family of signaling 
molecules, ERK1/2 and JNK (Fig. VIII-2). Activation in JNK can be seen by an 
increase in the phosphorylated form of JNK within 15 minutes of adiponectin 
treatment. In contrast, the activation of ERK1/2 appeared to occur in a biphasic 
pattern, with an increase in phosphorylated ERK1/2 with 5 minutes of adiponectin 
treatment, and then again at 15 minutes. The second activation appeared to be more 
sustained, as ERK1/2 was still phosphorylated following 30 minutes of adiponectin 
treatment. These data suggest that adiponectin is activating ERK1/2 through two 
different mechanisms, 1) directly through the rapid activation of its own receptor 
followed by 2) a secondary delayed activation of phosphorylated ERK1/2 through 
different pathway 15 minutes after adiponectin treatment. To investigate this further 
we examined activation of candidate signaling mechanisms known to activate 
ERK1/2 in trophoblast cells.    
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Figure VIII-2. Adiponectin activates ERK1/2 and JNK signaling cascades 
in term trophoblast cells. Treatment with globular adiponectin (2µg/ml) results in 
activation of members of the MAPK family of signaling pathways, including ERK1/2 
and JNK. An increase in the activated form of JNK is apparent within 10 minutes 
following adiponectin treatment (A). ERK1/2 is activated both at 5 minutes and again 
at 15 minutes in trophoblasts collected at term (B). Total ERK1/2 levels were 


















Adiponectin activates EGF receptor signaling in human trophoblast cells 
 Epidermal growth factor (EGF) is known to exert dramatic effects on human 
trophoblast cells, mediated in part through activation of the ERK1/2 signaling 
pathway (Takeuchi and Ito, 2010). Based on the biphasic activation pattern we 
observed following adiponectin exposure, we hypothesized that adiponectin may also 
be working through the EGF signaling pathway, resulting in a more robust ERK1/2 
activation. Treatment of trophoblast cells with adiponectin revealed an increase in 
levels of phosphorylated EGF receptor (EGFR) after 5 minutes (Fig. VIII-3). This is 
in keeping with the idea that EGF signaling may be responsible for the secondary 
activation of ERK1/2 we see following 15 minutes of adiponectin exposure. These 
data are novel, in that to our knowledge adiponectin working in this manner through 





Figure VIII-3. Adiponectin activates EGFR in syncytialized trophoblast 
cells. Treatment of primary trophoblast cells allowed to syncytialize in vitro display 
activation of the EGF receptor following 5 minutes of exposure to adiponectin. Cells 
were cultured for 5d prior to receiving adiponectin. Whole cell lysates show an 
increase in phosphorylated EGFR, the active form of the receptor, after adiponectin 
treatment for 5 minutes. This activation is transient, as the levels of phosphorylated 
EGFR go back down to control levels by 10 minutes of adiponectin treatment. Actin 

















Adiponectin signaling in trophoblast cells requires the adaptor protein, APPL1 
 Previous reports have demonstrated the importance of APPL1 binding to the 
adiponectin receptor in order to perpetuate downstream signaling. Binding of the 
sister protein, APPL2, to the adiponectin receptor prevents adiponectin receptor 
activation, and thus quenches any intracellular signaling mediated by adiponectin 
(Wang et al., 2009). In order to investigate whether this phenomenon holds true in the 
trophoblast, we interfered with the binding of APPL1 to its receptor by using a 
lentiviral construct to over-express APPL2 in primary cultures of term trophoblasts. 
Over-expression of the APPL2 protein in these cells caused a loss of activation of the 
signaling molecules previously seen with adiponectin (i.e. EGFR, Fig. VIII-4). These 
data indicate that the APPL1 protein is indeed necessary to bind to the adiponectin 
receptor in order to elicit downstream signaling events in the human trophoblast. This 




Figure VIII-4. Adiponectin signaling in trophoblast cells requires APPL1. 
Over-expression of the complimentary protein to APPL1, APPL2, in primary 
trophoblast cells results in a loss of downstream signaling events following treatment 
with adiponectin. Western blot for the activated form of EGFR, phosphorylated 
EGFR, in primary trophoblast cells over-expressing APPL2 reveals no increase in 
pEGFR protein following a 5, 10, or 15 minute treatment with adiponectin. This is in 
contrast to the increase in activation seen within 5 minutes of adiponectin treatment in 
cells infected with empty vector control. Actin levels were assessed as a loading 
control (C&D). Overexpression of APPL2 was measured through qPCR (E). Blot is a 






















































Leptin production can inhibit adiponectin signaling in trophoblast cells 
 Leptin and adiponectin are known to have opposing actions in a variety of 
systems. We hypothesized that leptin and adiponectin may function in a similar 
manner at the trophoblast cell. Although the human placenta is known to produce 
leptin (Cameo et al., 2003), in our hands primary human cytotrophoblasts collected at 
term produce very low levels of leptin (data not shown). In order to investigate the 
effects of leptin on adiponectin signaling we employed a lentiviral-mediated over-
expression system to induce large amounts of leptin production by the trophoblasts 
themselves. Interestingly, induction of leptin by these cells severely attenuated the 
activation of the signaling cascades we have identified adiponectin to utilize in 
syncytialized human trophoblast cells (Fig VIII-5). These data indicate that leptin 




Figure VIII-5. Adiponectin-induced activation of EGFR is blocked by 
leptin production in trophoblast cells.  Over-expression of leptin blocks 
adiponectin-induced signaling in primary cytotrophoblasts syncytialized in culture. 
Western blots for pEGFR revealed activation following a 5 minute exposure to 
adiponectin in both non-infected cells (data not shown) and cells infected with the 
empty vector control (A). In contrast, cells over-expressing leptin were refractory to 
activation by adiponectin at 5, 10, and 15 minutes (B). Actin levels were assessed as a 
loading control (C&D). Overexpression of leptin was measured through qPCR (E). 


















































Investigation into the role adiponectin may play at the maternal-fetal interface 
is still in its infancy. Although data to support the idea that adiponectin exerts 
important effects during pregnancy are being reported with increasing frequency, 
only a couple of studies have investigated the mechanism(s) by which adiponectin 
may be performing these actions. These studies have been performed in placental 
explants, which contain many different cell types found at the maternal-fetal 
interface, and in choriocarcinoma cell lines, cells that do not always display the same 
characteristics as cultured primary trophoblast cells. Indeed, we have been unable to 
observe effects of adiponectin on Jeg-3, JAR, or BeWo choriocarcinoma cell models 
using the same doses and treatment paradigms as we have reported in our findings 
with primary trophoblast cell cultures (data not shown). Nevertheless, these published 
reports represent a good basis from which to hypothesize which signaling 
mechanisms may mediate the effects of adiponectin in human trophoblast cells, and 
have demonstrated that adiponectin can signal through AMPK, ERK1/2 and PI3K, as 
well as the transcription factors, NFκB and PPARγ (Lappas et al., 2005a, Benaitreau 
et al., 2009).  
Adiponectin has been thought to signal primarily through the AMPK pathway 
(Yamauchi et al., 2003a). Amplification of the adiponectin signal by means of AMPK 
has been proposed to increase glucose transport in skeletal muscle, both through 
enhancing sensitivity to insulin signaling, and translocation of the glucose transporter, 
GLUT4, to the plasma membrane in a manner independent of insulin (Fujii et al., 
2006). In addition, AMPK has been implicated in a variety of other cellular processes, 
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including tight junction formation in BeWo cells, decreased apoptosis in blastocysts, 
and inhibition of adipocyte differentiation (Hwang et al., 2005, Egawa et al., 2008, 
Eng et al., 2007, Giri et al., 2006, Habinowski and Witters, 2001, Yamaguchi et al., 
2008). Despite the many reports linking adiponectin to the AMPK signaling pathway, 
as well as one in choriocarcinoma cells, we have been unable to observe AMPK 
activation following adiponectin treatment in primary term trophoblast cells.  
The MAPK pathways, ERK1/2 and p38 have been linked to adiponectin 
signaling in other biological systems (Benaitreau et al., 2009, Haugen and Drevon, 
2007, Lee et al., 2008). Indeed, there is data to suggest that adiponectin does not 
always activate the AMPK pathway, and in such instances ERK1/2 signaling may be 
the primary conductor of adiponectin signaling (Maillard et al., 2010). Other reports 
have shown the JAK/STAT and PI3K pathways to be activated via adiponectin 
(Coope et al., 2008). Our data are in agreement with the previous reports of 
adiponectin signaling through ERK1/2 in the placenta, however, we also observe an 
induction of another MAPK, c-Jun N-terminal kinase (JNK), in response to 
adiponection exposure. In addition, we identified activation of the epidermal growth 
factor (EGF) receptor following adiponectin treatment. To our knowledge, this 
phenomenon has not been reported previously. Indeed, an opposite phenomenon, 
where adiponectin binds to heparin-binding EGF (HB-EGF) and precludes it from 
activating its receptor has been reported (Wang et al., 2005). 
The adiponectin receptor has been shown to require binding of the adaptor 
protein APPL1 in order to perpetuate adiponectin’s signal (Mao et al., 2006). 
Interaction of APPL1 with the GTPase Rab5 has been shown to mediate signaling 
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events downstream of the adiponectin receptor (Mao et al., 2006). Indeed, 
experimental downregulation of APPL1 can impair downstream activation of 
signaling pathways, specifically activation of ERK1/2 (Lee et al., 2008). Furthermore, 
APPL1 is known to form a dimer with its isoform, APPL2. Over-expression of 
APPL2 in myotubes leads to a downregulation of adiponectin signaling by interfering 
with APPL1 binding to the adiponectin receptor (Wang et al., 2009). Our data suggest 
this is also the case in human trophoblast cells, as over-expression of APPL2 in these 
cells also resulted in a loss of signaling by adiponectin. Thus, although the 
downstream signaling mediators for adiponectin may not include the common AMPK 
pathway, the requirement for APPL1 binding to the adiponectin receptor appears to 
be conserved, suggesting this portion of the signaling mechanism is required, and not 
unique to a specific cell type(s).  
Another adipokine whose role at the maternal-fetal interface has been studied 
in much more depth than that of adiponectin is the hormone leptin. Interestingly, 
increased amounts of maternal leptin have been shown to result in the maintenance of 
an increased number of pups to term in hamsters (French et al., 2009). From these 
data the authors conclude that leptin acts as signal to the mother, telling her that 
sufficient energy stores are met and she might support more offspring (French et al., 
2009). Indeed, in an artificial system such as performed in this study, leptin appears 
capable of pushing the mother into releasing more energy stores to the fetoplacental 
unit, to the point of it being detrimental to her own health (French et al., 2009). This 
seems to be in keeping with our own data and associated hypothesis, suggesting 
adiponectin functions largely to promote the mother’s interests during pregnancy, and 
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therefore, in the words of French and colleagues, could be said to decrease maternal 
investment in gestation. Our data showing the attenuation of adiponectin signaling by 
leptin represents a possible mechanism by which the trophoblast may temper some of 
the actions of adiponectin, which we have previously reported to not necessarily be 
beneficial to continued growth of the fetus (see Chapters 2 and 3). Physiologically, as 
leptin levels increase in a fed state, adiponectin levels decrease, setting the stage for 
these two hormones to exert opposing actions. Indeed, Fang and coworkers have 
reported that leptin can have direct effects on adiponectin-mediated signaling, 
resulting in a blockade of adiponectin-stimulated glucose uptake in myotubes (Fang 
et al., 2009). These data are in accordance with our findings that over-expression of 
leptin in trophoblast cells (a cell type that makes leptin in vivo) can attenuate 
adiponectin-stimulated intracellular signaling. 
The data reported herein provide evidence for the first time that adiponectin 
signaling in trophoblast requires the adaptor protein APPL1 in order to activate 
signaling cascades that include ERK1/2, JNK, and EGFR (Fig. VIII-6). In addition, 
production of leptin by these cells interferes with the ability of the trophoblast to 
respond to adiponectin. This may prove useful to the syncytiotrophoblast given the 
largely detrimental effects adiponectin has on this cell type (McDonald and Wolfe, 
2009).    
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Figure VIII-6. Model of adiponectin signaling in the syncytiotrophoblast 
at term. Adiponectin, binding to its receptor on the surface of syncytiotrophoblast, 
can initiate signaling through ERK1/2 and JNK. In addition, treatment with 
adiponectin can activate the EGF receptor. These actions are mediated through the 
binding of APPL1 to the adiponectin receptor, as interference by APPL2 causes a loss 
of downstream signal activation. Additionally, leptin can work through its receptor, 































IX: Chapter 5: 
 





In the relatively short period since its discovery, the hormone adiponectin has 
been implicated in the regulation of a number of cellular functions including glucose 
metabolism, lipid oxidation, hormone production, differentiation, proliferation, and 
inflammation. The range of functions serves to underscore adiponectin’s biological 
importance. In addition, the role of adiponectin has broadened to include a range of 
tissue types. As the developed world continues to become increasingly obese, 
instances in which adiponectin production is low are becoming more and more 
frequent. It is thus vital to understand the role of this hormone on many different 
physiological systems, so that we may be better able to anticipate and treat conditions 
that arise as a consequence of an obese state. In order to identify functions altered by 
adiponectin in human trophoblast cells on a global scale, we performed microarrays 
on isolated cytotrophoblasts exposed to adiponectin for 5d as they syncytialized in 
vitro. The data show that the expression of a number of different genes was 
significantly affected by adiponectin treatment. The majority of these genes were 
repressed following adiponectin exposure, however, a smaller but sizable group were 
up-regulated in trophoblasts by adiponectin. These data not only support our previous 
findings regarding the effects of adiponectin on isolated trophoblast cells, but also 
allow for identification of new mechanisms that are regulated by adiponectin. These 
include processes such as insulin-like growth factor (IGF) bioavailability, cortisol 
production and metabolism, chemotaxis, and cholesterol metabolism. Completion of 
this study has significantly advanced our understanding of the range of effects 
adiponectin may have on the human placenta. These data may be of particular interest 
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in cases of altered adiponectin levels, such as during maternal metabolic syndrome. 
Our findings in conjunction with the large number of studies outlining alterations in 
circulating levels of adiponectin during diseases of pregnancy (i.e. gestational 
diabetes and preeclampsia) support the hypothesis that adiponectin may be mediating 




With continued investigation, adiponectin is being found to have a broad 
range of effects on many different tissues throughout the body. No longer is 
adiponectin limited to the maintenance of insulin sensitivity and metabolic 
homeostasis, but it has also been shown in recent years to affect cell proliferation and 
differentiation, inflammatory responses, and hormone production. Additionally, the 
response to adiponectin appears to be highly dependent on the tissue under 
investigation. Adiponectin also appears to interact with many other growth factors 
and hormones (e.g. insulin, IGF-I and –II, EGF, GnRH, LH) to “fine-tune” the 
responses of a target cell.  
Despite the multifaceted nature of the hormone, the metabolic function for 
which it was initially identified remains of great importance, and has broad 
implications on numerous biological systems. It follows therefore that adiponectin 
may profoundly influence metabolism within the placenta. Despite this, extremely 
little has been reported regarding the role of adiponectin on placental metabolism. We 
hypothesized that adiponectin would alter the expression of transporters and enzymes 
involved in metabolism that are expressed by the syncytiotrophoblast. In order to 
investigate this in an unbiased manner, we performed microarray analysis of isolated 
trophoblasts after they had been exposed to adiponectin in a long-term culture system. 
We did indeed find many alterations in gene expression following adiponectin 
treatment, including some of which we have already reported (see Chapters 2, 3, and 
4). While expression of some transporters was altered, we also observed changes in 
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various hormones and growth factor-related pathways. The results of these 
microarrays will be discussed herein.   
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3. Materials and Methods 
Cell Isolation and Culture 
Human placentas were obtained under protocols approved by the institutional 
review board at the University of Kansas Medical Center. Cytotrophoblasts were 
isolated from healthy placentas delivered via cesarean at term as previously described 
(23). Villous tissue was dissected away from the basal plate of the placenta and 
subjected to treatment with deoxyribonuclease I (type IV; Sigma Chemical, St. Louis, 
MO) and trypsin (Invitrogen Corp., Carlsbad, CA). The resulting single-cell 
suspension was size fractionated by application to a Percoll (Sigma) density gradient. 
To ensure a homogeneous population of cytotrophoblasts, the cells underwent 
negative selection using an antibody recognizing human leukocyte antigen-A, -B, and 
-C (W6/32; Bio-Express, West Lebanon, NH) with a magnetically labeled secondary 
antibody (Miltenyi Biotec GmBH, Bergisch Gladbach, Germany). Cytospins of 
trophoblasts from each preparation were stained for cytokeratin 7 expression (N-TL 
12/30; Dako, Glostrup, Denmark) to assess purity. Purified cells were placed in 
culture medium (Iscove’s modified Dulbecco’s medium with 10% fetal bovine serum, 
1% L-glutamine, 1% penicillin/streptomycin/ amphotericin B) and allowed to adhere 
to the culture dish by incubation in a humidified chamber for 4 h before receiving 
treatment. All cells underwent regular medium changes, with refreshment of 
treatment conditions every 48 h. After addition of recombinant globular adiponectin 
(2 µg/ml; Phoenix Pharmaceuticals, Burlingame, CA) to the culture medium, cells 




Isolated trophoblasts from three distinct placentas were placed in culture for 
5d. Cells from each preparation were cultured with media alone (control) or with the 
addition of 2 µg/ml globular adiponectin beginning on d1 of the culture period 
(adpn). RNA quality and quantity were assessed using the 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA) prior to use on the microarrays. Preparation of the 
biotin-labeled targets for the 3’ expression analysis was performed using the 
GeneChip 3’ IVT Express Kit (Affymetrix). Microarrays were performed using 
Affymetrix HG U133 Plus 2.0 gene chips (Affymetrix, Santa Clara, CA) and the 
GeneChip system (Affymetrix). Results from the microarrays were analyzed using 
GeneSpring GX 7.3.1 software (Agilent Technologies). Only genes that were flagged 
“present” in at least one of the treatment conditions (treatment versus control) were 
analyzed. Expression data was normalized to the 50th percentile of gene expression 
for each individual sample to control for chip-to-chip variation before being 
normalized to the median of the control samples for each cytotrophoblast isolation. 
Statistical analysis was performed using one-way ANOVA, with a Benjamini and 
Hochberg False Discovery Rate of 0.05. Changes in gene expression between adpn 
and control samples ≥2-fold and with P< 0.05 were considered significant.  
RNA Isolation and Quantitative RT-PCR 
RNA was isolated from placentas unique from those used in the microarray 
and quantitative RT-PCR done on specific transcripts which showed a significant 
difference in gene expression on the microarray, in order to validate the findings of 
the microarray. RNA from trophoblasts in culture was isolated using Trizol 
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(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Total RNA 
was reverse transcribed using Superscript II reverse transcriptase (Invitrogen) and 
random primers. Quantitative real-time PCR (qPCR) was performed using 
SYBRgreen technology (Applied Biosystems, Foster City, CA). All gene expression 
data was normalized to 18S levels within the respective sample. All primers (Table 
VIII-1) were designed using Primer Express 3.0 software (Applied Biosystems) and 
synthesized by Integrated DNA Technology (Coralville, IA). Resulting data was 
analyzed using the ΔΔCt method, as has been previously described (McDonald and 
Wolfe, 2009). All experiments were performed with four distinct placentas. Statistical 
analysis was done using SigmaStat 3.1 software (Systat Software, Inc., San Jose, 
CA). Means for untreated control cells versus adiponectin treated cells were 
compared using the Mann-Whitney Rank Sum Test. For all experiments, P < 0.05 




Table IX-1. Primer Sequences for Quantitative RT-PCR 
Gene Forward Primer Reverse Primer 
18S 5'-cgccgctagaggtgaaattct-3' 5'-cgaacctccgactttcgttct-3' 
ADAM12 5'-gggcaagaaggcataaaagaga-3' 5'-ctcggttgtctgccacgat-3' 
ALPP 5'-gtgcccggtatgtgtggaa-3' 5'-ggctcaaagagacccatgagat-3' 
CD24 5’-ggtgccctgcagtcaacag-3’ 5’-cttgccacattggacttcca-3’ 
CGB 5'-acaaccccgaggtataaagcc-3' 5'-ccttggatgcccatgtcc-3' 
CSH1 5'-tccttctgcttctcagactctattcc-3' 5'-ctagattggatttctgttgcgtttc-3' 
CYP11A1 5'-caccttcaccatgtccagaattt-3' 5'-ctccacgttgccgagctt-3' 
CYP19A1 5'-catatgatctgtctgtggcaaaagt-3' 5'-aagtggctgaggcataaatcga-3' 
FURIN 5’-cggaaagtgagccactcatatg-3’ 5’-gaggatgtcgatgatgcacttc-3’ 
GH2 5’-gaaaacgcagcagaaatctaaccta-3’ 5’-acgggctccagccatga-3’ 
HSD11B2 5’-gcgctactcatggacacattca-3’ 5’-ccacgtttctcactgactctgtct-3’ 
IGFBP3 5’-cgccagctccaggaaatg-3’ 5’-tgccctttcttgatgatgattatc-3’ 
INSL4 5’-tggacgtcccaaagaaatgg-3’ 5’-gctctggtgacaaattaggaatga-3’ 
LDLR 5’-ggctgcgttaatgtgacactct-3’ 5’-gcactctttgatgggttcatctg-3’ 
PAPPA 5’-accaaaaaggtcaccccattc-3’ 5’-ccggttgggtgctaaggat-3’ 
PAPPA2 5’-gattgaggtcctacgggtgttt-3’ 5’-gagtcttgtgggttccaagtgtt-3’ 
PGF 5’-gttcagcccatcctgtgtct-3’ 5’-ttaggagctgcatggtgaca-3’ 









 A total of 195 transcripts were significantly down-regulated and 62 were up-
regulated by a factor of ≥2.0 following adiponectin treatment (Tables VIII-2 and 
VIII-3). One of the most prominent groupings of genes that were down-regulated 
with adiponectin treatment are related to the endocrine function of the cells. These 
findings are in keeping with our previous findings (see Chapter 2). Although there are 
many more genes significantly down-regulated than vice versa, many interesting 
genes relating to immune response are higher following adiponectin treatment. These 
include Siglec10 and CD24 (see Chapter 3), as well as B7-DC, B7-H4, and 
chemokines CCL5 and CCL18.  We have validated the results of the microarray 
through quantitative RT-PCR for a number of genes (Table VIII-4). These genes were 
chosen to include a variety of functions, as well as genes that were both up- and 
down-regulated with adiponectin.  Additionally, the genes CGB, CSH1, CYP11A1, 





Table IX-2. Genes down-regulated following adiponectin treatment. 
Affymetrix 









ankyrin repeat and SOCS 
box-containing 2 ASB2 
AK00204
9 -17.64 0.001 
201785_at 
ribonuclease, RNase A 








beta polypeptide CGB 
NM_0007
37 -8.936 0.000 
231454_at Placenta-specific 4 PLAC4 R31094 -8.078 0.015 
206886_x_
at growth hormone 1 GH1 
NM_0225
60 -7.884 0.021 
210997_at 
hepatocyte growth factor 
(hepapoietin A; scatter 
factor) HGF M77227 -7.529 0.001 
206605_at 26 serine protease P11 
NM_0060
25 -7.422 0.004 
208069_x_
at growth hormone 1 GH1 
NM_0225
61 -7.286 0.019 
205840_x_
at growth hormone 1 GH1 
NM_0005
15 -6.967 0.045 
230550_at 
membrane-spanning 4-





5 -6.877 0.000 
205158_at 





37 -6.557 0.000 
211508_s_
at growth hormone 2 GH2 AF006060 -6.372 0.017 
206885_x_
at growth hormone 1 GH1 
NM_0225






7 -6.364 0.001 
1555880_at 
HERV-FRD provirus 




2 -6.196 0.001 
227915_at 
ankyrin repeat and SOCS 





hormone 2 CSH2 
NM_0226
44 -5.845 0.021 
219666_at 
membrane-spanning 4-




















hormone 2 CSH2 
NM_0226
46 -5.475 0.022 
208068_x_
at growth hormone 1 GH1 
NM_0225
62 -5.471 0.020 
211151_x_





hormone 1 (placental 
lactogen) CSH1 
NM_0226





hormone 1 (placental 
lactogen) CSH1 
NM_0226





hormone 2 CSH2 
NM_0226





hormone-like 1 CSHL1 
NM_0225
81 -5.077 0.019 
210503_at 
melanoma antigen family 
A, 11 
MAGE





hormone-like 1 CSHL1 
NM_0225





hormone 2 CSH2 
NM_0209





hormone 1 (placental 
lactogen) CSH1 
NM_0226





hormone 1 (placental 
lactogen) CSH1 
NM_0013





hormone 1 (placental 


















Transcribed locus, weakly similar to 
NP_061913.2 elongation protein 4 
homolog; PAX6 neighbor gene; 
chromosome 11 open reading frame 





hormone-like 1 CSHL1 
NM_0013
18 -4.469 0.026 
235336_at 




5 -4.437 0.009 
242629_at 
Transcribed locus, moderately similar 
to XP_508230.1 PREDICTED: zinc 
finger protein 195 [Pan troglodytes] BF056092 -4.219 0.004 
244750_at Transcribed locus 
 
R63757 -4.184 0.048 
227519_at placenta-specific 4 PLAC4 R53820 -4.18 0.016 
209993_at 
ATP-binding cassette, sub-
family B (MDR/TAP), 
member 1 ABCB1 AF016535 -4.121 0.003 
227123_at 
RAB3B, member RAS 
oncogene family RAB3B 
AU15671





hormone-like 1 CSHL1 
NM_0225
79 -4.051 0.020 
210353_s_
at 





2 M65105 -3.989 0.000 
232268_at 
ADAM metallopeptidase 








glycoprotein 7 PSG7 
NM_0027




family B (MDR/TAP), 
member 1 ABCB1 AF016535 -3.951 0.006 
204753_s_
at hepatic leukemia factor HLF AI810712 -3.901 0.000 
209220_at glypican 3 GPC3 L47125 -3.839 0.006 
206549_at insulin-like 4 (placenta) INSL4 
NM_0021
95 -3.837 0.005 
239202_at 
RAB3B, member RAS 
oncogene family RAB3B BE552383 -3.819 0.008 
213790_at 
ADAM metallopeptidase 
domain 12 (meltrin alpha) 
ADAM












chromosome 3 open 




plasma protein A, 
pappalysin 1 PAPPA 
BG62095




expressed on myeloid 
cells-like 3 
TREM
L3 H53073 -3.675 0.001 
201540_at 
four and a half LIM 
domains 1 FHL1 
NM_0014
49 -3.625 0.009 
219702_at placenta-specific 1 PLAC1 
NM_0217





hormone-like 1 CSHL1 
NM_0225




5 -3.565 0.041 
227503_at 
CDNA FLJ43100 fis, clone 
CTONG2003100 
 
















96 -3.494 0.007 
205924_at 
RAB3B, member RAS 





6 -3.459 0.009 




2 -3.413 0.018 
235735_at 




8 AI936516 -3.37 0.000 
206195_x_
at growth hormone 2 GH2 
NM_0225




(Ig), short basic domain, 





















low density lipoprotein 
receptor (familial 




coupled receptor, 3 EDG3 
AA53481
7 -3.241 0.034 
224942_at 
pregnancy-associated 
plasma protein A, 
pappalysin 1 PAPPA 
BG43427




factor 15 GDF15 AF003934 -3.235 0.023 
204755_x_
at hepatic leukemia factor HLF M95585 -3.234 0.043 
219748_at 
triggering receptor 









glycoprotein 4 PSG4 
NM_0027
80 -3.146 0.020 
223137_at 
zinc finger, DHHC-type 
containing 4 
ZDHH
C4 AF201931 -3.142 0.000 
203918_at 
protocadherin 1 (cadherin-
like 1) PCDH1 
NM_0025
87 -3.1 0.007 
201981_at 
pregnancy-associated 
plasma protein A, 
pappalysin 1 PAPPA 
AA14853
4 -3.085 0.012 
232035_at histone 1, H4h 
HIST1





1 AL133609 -3.067 0.007 
214750_at placenta-specific 4 PLAC4 L13197 -3.056 0.015 
213577_at squalene epoxidase SQLE 
AA63970
5 -3.056 0.005 
220769_s_




63 -3.038 0.001 
204644_at 
cytosolic ovarian 
carcinoma antigen 1 
COVA












78 -2.97 0.003 
209582_s_












G protein-coupled receptor 
126 
GPR12
6 AL033377 -2.908 0.011 
213685_at 
Transcription elongation 
factor B (SIII), polypeptide 
3 (110kDa, elongin A) TCEB3 
AA83014








74 -2.904 0.012 
236875_at Transcribed locus 
 




glycoprotein 1 PSG1 
NM_0069
















3 -2.9 0.009 
204943_at 
ADAM metallopeptidase 




41 -2.9 0.013 
210299_s_
at 
four and a half LIM 
domains 1 FHL1 AF063002 -2.895 0.020 
218918_at 
mannosidase, alpha, class 




79 -2.884 0.006 
239394_at 










6 -2.867 0.017 
204309_at 
cytochrome P450, family 





81 -2.856 0.011 
208180_s_




43 -2.853 0.028 
237313_at 
Homo sapiens, clone 
IMAGE:5225774, mRNA 
 
BE856800 -2.853 0.004 
209652_s_
at 
placental growth factor, 
vascular endothelial 
growth factor-related 






75 -2.844 0.020 
216611_s_
at 



















furin (paired basic amino 
acid cleaving enzyme) FURIN 
NM_0025




homolog F (avian) MAFF 
NM_0123
23 -2.815 0.000 
230614_at 
Cytochrome P450, family 
19, subfamily A, 
polypeptide 1 
CYP19
A1 AI740573 -2.8 0.041 
215715_at 










BC035117 -2.782 0.004 
230360_at gliomedin GLDN 
AW00664
8 -2.779 0.009 
239583_x_
at placenta-specific 7 PLAC7 
BG35457
3 -2.762 0.019 
227706_at 
spire homolog 2 
(Drosophila) SPIRE2 AI215798 -2.738 0.001 
228838_at 
Full length insert cDNA 
clone YA77F06 
 
BF431870 -2.718 0.027 
218717_s_




92 -2.709 0.032 
213332_at Pappalysin 2 
PAPPA
2 AL031290 -2.698 0.001 





0084 AI824021 -2.651 0.027 
202068_s_
at 




27 -2.638 0.004 
240705_at 
cytochrome P450, family 
19, subfamily A, 
polypeptide 1 
CYP19
A1 AI472257 -2.632 0.016 
221582_at histone 3, H2a 
HIST3
H2A BC001193 -2.632 0.009 
232167_at 
solute carrier family 2 
(facilitated glucose 
transporter), member 11 
SLC2A


















at syndecan 1 SDC1 
NM_0029
97 -2.613 0.024 
205319_at prostate stem cell antigen PSCA 
NM_0056
72 -2.609 0.034 
209735_at 
ATP-binding cassette, sub-
family G (WHITE), 
member 2 
ABCG
2 AF098951 -2.603 0.004 
231353_at 
  
R77414 -2.595 0.006 
209283_at crystallin, alpha B 
CRYA
B AF007162 -2.583 0.005 
214247_s_
at 
dickkopf homolog 3 
(Xenopus laevis) DKK3 
AU14805
7 -2.55 0.016 
209442_x_
at 
ankyrin 3, node of Ranvier 




protein 2 TACC2 AI458065 -2.545 0.001 
226777_at 
ADAM metallopeptidase 








glycoprotein 6 PSG6 
NM_0027




plasma protein A, 
pappalysin 1 PAPPA AI110886 -2.528 0.029 
209278_s_
at 
tissue factor pathway 
inhibitor 2 TFPI2 L27624 -2.527 0.013 
224941_at 
pregnancy-associated 
plasma protein A, 
pappalysin 1 PAPPA BF107618 -2.521 0.012 
203911_at 





85 -2.519 0.033 
215613_at 
ADAM metallopeptidase 








7 -2.51 0.046 
213216_at OTU domain containing 3 
OTUD
3 AL537463 -2.508 0.001 
202708_s_




28 -2.507 0.011 
227113_at 
alcohol dehydrogenase, 
iron containing, 1 
ADHF























18 -2.496 0.017 
1566739_at Phospholipase C, epsilon 1 PLCE1 
AK02536













glycoprotein 9 PSG9 
NM_0027
84 -2.465 0.030 
229576_s_
at 
T-box 3 (ulnar mammary 
syndrome) TBX3 N29712 -2.463 0.011 




3 -2.462 0.016 
239460_at 
  




plasma protein A, 
pappalysin 1 PAPPA 
NM_0025
81 -2.442 0.014 
203697_at frizzled-related protein FRZB U91903 -2.441 0.036 
230854_at hypothetical LOC400500 
LOC40














7407 AF086098 -2.428 0.014 
225369_at 
endothelial cell adhesion 




acetylmannosamine kinase GNE 
NM_0054






PL AI829726 -2.406 0.019 
236593_at 




BF109310 -2.403 0.001 
240450_at Transcribed locus 
 
BF061543 -2.403 0.007 
235100_at 




5 -2.402 0.038 
219682_s_
at 
T-box 3 (ulnar mammary 
syndrome) TBX3 
NM_0165













specific phospholipase C, 




5 -2.394 0.018 
209218_at squalene epoxidase SQLE AF098865 -2.391 0.006 
210358_x_
at GATA binding protein 2 
GATA
2 BC002557 -2.378 0.020 
241929_at 
CD36 antigen (collagen 
type I receptor, 
thrombospondin receptor) CD36 
AV76030




family W, env(C7), 
member 1 (syncytin) 
ERVW
E1 AF072506 -2.374 0.017 
237006_at 
AF4/FMR2 family, 
member 1 MLLT2 
AA70352
3 -2.361 0.017 
219181_at lipase, endothelial LIPG 
NM_0060






1 -2.355 0.004 
237411_at 
ADAM metallopeptidase 
with thrombospondin type 
1 motif, 6 
ADAM
TS6 N71063 -2.354 0.018 
230978_at hypothetical LOC401464 
LOC40























7 -2.328 0.005 
225373_at 
chromosome 10 open 
reading frame 54 
C10orf
54 BE271644 -2.325 0.002 
206385_s_
at 
ankyrin 3, node of Ranvier 
(ankyrin G) ANK3 
NM_0209




glycoprotein 1 PSG1 M34715 -2.322 0.012 
218660_at 
dysferlin, limb girdle 
muscular dystrophy 2B 
(autosomal recessive) DYSF 
NM_0034




















plasma protein A, 
pappalysin 1 PAPPA BF107618 -2.298 0.018 
209583_s_
at CD200 antigen CD200 AF063591 -2.296 0.044 
214397_at 
methyl-CpG binding 
domain protein 2 MBD2 AI827820 -2.296 0.000 
230084_at 
solute carrier family 30 
(zinc transporter), member 
2 
SLC30
A2 BF510698 -2.29 0.005 
243423_at Transcribed locus 
 
AF150368 -2.289 0.017 
220289_s_
at absent in melanoma 1-like AIM1L 
NM_0179
77 -2.284 0.022 
236829_at 
TATA element modulatory 














64 -2.27 0.009 
225372_at 
chromosome 10 open 




9 -2.258 0.022 
1558540_s
_at 
solute carrier family 2 
(facilitated glucose 




3 -2.252 0.016 
210141_s_
at inhibin, alpha INHA M13981 -2.239 0.007 
201261_x_
at biglycan BGN BC002416 -2.238 0.008 
205931_s_
at 
cAMP responsive element 
binding protein 5 CREB5 
NM_0049
04 -2.235 0.034 
1552481_s
_at 
mannosidase, alpha, class 




99 -2.227 0.042 
227752_at 
serine palmitoyltransferase, 
long chain base subunit 2-








glycoprotein 9 PSG9 M34421 -2.221 0.020 
243871_at 
CDNA FLJ42179 fis, clone 
THYMU2030796 
 





















specific phospholipase C, 












60 -2.205 0.036 
238466_at 
CDNA FLJ33443 fis, clone 
BRALZ1000103 
 
R43486 -2.201 0.001 












gamma ESRRG AF094518 -2.2 0.019 
228918_at 
CDNA FLJ32207 fis, clone 
PLACE6003204 
 
AI457453 -2.199 0.000 
219866_at 
chloride intracellular 
channel 5 CLIC5 
NM_0169
29 -2.194 0.017 
205549_at Purkinje cell protein 4 PCP4 
NM_0061
98 -2.188 0.000 
244523_at 
monocyte to macrophage 
differentiation-associated MMD 
AW10445




Weber syndrome 1) ENG 
NM_0001
18 -2.179 0.016 
219710_at 
SH3 domain and 




77 -2.178 0.009 
204388_s_
at monoamine oxidase A MAOA 
NM_0002
40 -2.176 0.017 
205581_s_
at 
nitric oxide synthase 3 
(endothelial cell) NOS3 
NM_0006
03 -2.175 0.027 
205026_at 
signal transducer and 





48 -2.161 0.006 
232748_at 
pregnancy-associated 
plasma protein A, 
pappalysin 1 PAPPA 
AU15672
1 -2.155 0.017 
209454_s_
at 
TEA domain family 
member 3 TEAD3 AF142482 -2.155 0.000 
217920_at 
mannosidase, alpha, class 
1A, member 2 
MAN1
A2 H97940 -2.151 0.000 
239167_at 
AF4/FMR2 family, 












at nucleoredoxin NXN 
NM_0178
21 -2.15 0.001 
210387_at histone 1, H2bg 
HIST1
H2BG BC001131 -2.148 0.016 
220703_at 
chromosome 10 open 




70 -2.139 0.007 
200982_s_








(SDR family) member 9 DHRS9 
NM_0057
71 -2.127 0.013 
209277_at 
Tissue factor pathway 
inhibitor 2 TFPI2 AL574096 -2.125 0.047 
210879_s_
at 
RAB11 family interacting 
protein 5 (class I) 
RAB11






09 -2.122 0.001 
237372_at 
Pregnancy specific beta-1-
glycoprotein 5 PSG5 N30169 -2.116 0.003 
241970_at 
Poliovirus receptor-related 
3 PVRL3 C14898 -2.114 0.029 
230908_at Transcribed locus 
 
AA46149
0 -2.112 0.001 







1 -2.109 0.023 
209228_x_
at 
tumor suppressor candidate 





sialoprotein II) IBSP BE466675 -2.106 0.019 
206346_at prolactin receptor PRLR 
NM_0009
49 -2.106 0.019 
237263_at 
Full length insert cDNA 
clone YI54D04 
 
BF590253 -2.101 0.033 
1558460_at 
ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 5 ABCC5 AL707614 -2.099 0.009 
206374_at 
dual specificity 
phosphatase 8 DUSP8 
NM_0044




related protein 1 (alpha-2-
macroglobulin receptor) LRP1 
NM_0023












Sushi, von Willebrand 






00 -2.098 0.009 
203417_at 
microfibrillar-associated 
protein 2 MFAP2 
NM_0174
59 -2.096 0.003 




4 -2.095 0.000 
220440_at 
lectin, galactoside-binding, 




68 -2.093 0.006 
201787_at fibulin 1 FBLN1 
NM_0019
96 -2.091 0.041 
222513_s_
at 
sorbin and SH3 domain 
containing 1 
SORBS
1 N21458 -2.089 0.029 
215240_at 
integrin, beta 3 (platelet 
glycoprotein IIIa, antigen 
CD61) ITGB3 AI189839 -2.085 0.001 
209453_at 
solute carrier family 9 
(sodium/hydrogen 








(SDR family) member 9 DHRS9 AF240697 -2.078 0.034 
240873_x_
at 
disabled homolog 2, 
mitogen-responsive 
phosphoprotein 
(Drosophila) DAB2 R62907 -2.077 0.034 
213562_s_
at squalene epoxidase SQLE BF979497 -2.076 0.013 
204121_at 





05 -2.071 0.036 
204664_at 
alkaline phosphatase, 
placental (Regan isozyme) ALPP 
NM_0016
32 -2.069 0.017 
202052_s_
at retinoic acid induced 14 RAI14 
NM_0155
77 -2.068 0.008 
202178_at protein kinase C, zeta PRKCZ 
NM_0027
44 -2.052 0.009 
240303_at 








glycoprotein 3 PSG3 
NM_0210


















9 -2.037 0.006 




09 -2.034 0.002 
201924_at 
AF4/FMR2 family, 
member 1 AFF1 
NM_0059
35 -2.033 0.011 
202995_s_
at fibulin 1 FBLN1 
NM_0064
86 -2.029 0.003 
240620_at Transcribed locus 
 
AI733442 -2.028 0.001 
221766_s_
at 
family with sequence 




3 -2.026 0.021 
205100_at 
glutamine-fructose-6-
phosphate transaminase 2 GFPT2 
NM_0051
10 -2.025 0.033 
1562997_a
_at 
Homo sapiens, clone 
IMAGE:5418716, mRNA 
 




delta isomerase 1 IDI1 BC005247 -2.014 0.016 
205925_s_
at 
RAB3B, member RAS 
oncogene family RAB3B 
NM_0028
67 -2.013 0.011 
209710_at GATA binding protein 2 
GATA











glycoprotein 5 PSG5 
NM_0027
81 -2.012 0.005 
201625_s_










Table IX-3. Genes up-regulated following adiponectin treatment. 
Affymetrix 








chromosome 6 open 




9 5.952 0.005 
205844_at vanin 1 VNN1 
NM_0046
66 5.435 0.025 
202917_s_
at 
S100 calcium binding 




64 5.076 0.000 
219768_at 
V-set domain containing T 
cell activation inhibitor 1 VTCN1 
NM_0246
26 4.425 0.031 
209924_at 
chemokine (C-C motif) 
ligand 18 (pulmonary and 
activation-regulated) CCL18 
AB00022
1 4.149 0.031 
227697_at 
suppressor of cytokine 
signaling 3 SOCS3 AI244908 3.788 0.007 
218541_s_
at 
chromosome 8 open 
reading frame 4 C8orf4 
NM_0201
30 3.472 0.025 
32128_at 
chemokine (C-C motif) 
ligand 18 (pulmonary and 





5628 AL389942 3.311 0.042 
207528_s_
at 
solute carrier family 7, 
(cationic amino acid 





31 3.049 0.025 
1552807_a
_at 
sialic acid binding Ig-like 
lectin 10 
SIGLE




dehydrogenase 15-(NAD) HPGD AL574184 2.950 0.002 
214084_x_
at 
neutrophil cytosolic factor 
1 (47kDa, chronic 
granulomatous disease, 
autosomal 1) NCF1 
AW07238
8 2.915 0.042 
208747_s_
at 
complement component 1, 
s subcomponent C1S M18767 2.899 0.048 
205220_at 





18 2.890 0.005 
209921_at 
solute carrier family 7, 
(cationic amino acid 
















1554098_at spindlin family, member 3 SPIN3 BC032490 2.841 0.042 
202998_s_
at lysyl oxidase-like 2 LOXL2 
NM_0023

















93 2.611 0.042 
208084_at integrin, beta 6 ITGB6 
NM_0008
88 2.591 0.042 
1569003_at transmembrane protein 49 
TMEM




dehydrogenase 15-(NAD) HPGD J05594 2.558 0.000 
220049_s_
at 





39 2.494 0.041 
237415_at Transcribed locus 
 
BF508849 2.469 0.042 
1405_i_at 
chemokine (C-C motif) 











11 AI376997 2.445 0.010 
203535_at 
S100 calcium binding 








dehydrogenase 15-(NAD) HPGD 
NM_0008






27 2.392 0.042 
223767_at 
G protein-coupled receptor 
84 GPR84 AF237762 2.364 0.031 
234306_s_
at SLAM family member 7 
SLAM
F7 AJ271869 2.364 0.029 
203543_s_
at Kruppel-like factor 9 KLF9 
NM_0012
06 2.331 0.042 
206420_at 
immunoglobulin 
superfamily, member 6 IGSF6 
NM_0058
49 2.299 0.006 
215977_x_
at glycerol kinase GK X68285 2.294 0.042 
203922_s_
at 
cytochrome b-245, beta 
polypeptide (chronic 












at glycerol kinase GK AJ252550 2.283 0.042 
241068_at 
DORA reverse strand 






4 AF260335 2.273 0.025 
231972_at 




1 2.252 0.042 
217678_at 
solute carrier family 7, 
(cationic amino acid 













4 2.212 0.042 
210095_s_
at 
insulin-like growth factor 
binding protein 3 
IGFBP
3 M31159 2.208 0.025 
1553151_at 
ATPase, H+ transporting, 
lysosomal 38kDa, V0 








protein 1 SFRP1 AI332407 2.193 0.042 
217107_at 
  
AL035603 2.188 0.042 
208792_s_
at clusterin CLU M25915 2.183 0.004 
224325_at 
frizzled homolog 8 
(Drosophila) FZD8 
AB04370
3 2.174 0.042 
219159_s_




81 2.165 0.027 
203873_at 
SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
subfamily a, member 1 
SMAR









5513 AI819722 2.132 0.006 
209772_s_
at 
CD24 antigen (small cell 
lung carcinoma cluster 4 
antigen) CD24 X69397 2.123 0.007 
210904_s_
at 
interleukin 13 receptor, 
alpha 1 
IL13R












chemokine (C-C motif) 
ligand 5 CCL5 
NM_0029









6 2.079 0.036 
1561430_s
_at 
chromosome 3 open 
reading frame 15 
C3orf1
5 BC035248 2.075 0.001 
230230_at 
CDNA: FLJ21893 fis, 
clone HEP03412 
 
AI379691 2.070 0.042 
208864_s_
at thioredoxin TXN AF313911 2.070 0.042 
203355_s_
at 
pleckstrin and Sec7 domain 
containing 3 PSD3 
NM_0153
10 2.066 0.000 
214702_at fibronectin 1 FN1 AJ276395 2.062 0.042 
216191_s_
at 
T cell receptor alpha locus 
; T cell receptor delta locus 
TRA@ 
; 
TRD@ X72501 2.062 0.042 
231697_s_
at Transmembrane protein 49 VMP1 
AV66082
5 2.053 0.033 
1569054_at 
solute carrier family 1 




3 BC022285 2.041 0.001 
1568609_s
_at 
family with sequence 





39 AL118843 2.020 0.008 
240137_at Tudor domain containing 6 TDRD6 AI915629 2.020 0.027 
227236_at tetraspanin 2 
TSPAN
2 AI743596 2.016 0.042 
228718_at 
zinc finger protein 44 
(KOX 7) ZNF44 AI379070 2.016 0.010 
212382_at Transcription factor 4 TCF4 BF433429 2.000 0.002 
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Table IX-4. Adiponectin-regulated genes identified by microarray and 
validated by quantitative RT-PCR. 
Gene 
Symbol 
Function GenBank Fold Change 
Adpn/Control 
Microarray qPCR 
ADAM12 protease NM_003474 -2.904 -2.717a 
ALPP phosphatase NM_001632 -2.069 -1.887 
CD24 sialoglycoprotein X69397 2.123 1.480 
CGB hormone NM_000737 -8.936 -4.952a 
CSH1 hormone NM_022641 -4.899 -3.864a 
CYP11A1 steroid synthesis NM_000781 -2.856 -2.654a 
CYP19A1 steroid synthesis AI740573 -2.800 -3.699a 
ERVWE1 cell fusion AF072506 -2.374 -1.366 
FURIN proprotein convertase NM_002569 -2.835 -2.389a 
GH2 hormone AF006060 -6.372 -4.248a 
HSD11B2 steroid metabolism NM_000196 -3.494 -2.655a 
INSL4 insulin superfamily NM_002195 -3.837 -3.109a 
IGFBP3 
insulin-like growth factor 
availability M31159 2.208 1.659 
LDLR cholesterol metabolism NM_000527 -2.638 -2.499a 
PAPPA2 IGFBP protease AL031290 -2.698 -1.747a 
PGF growth factor BC001422 -2.852 -2.781a 
PAPPA IGFBP protease NM_002581 -2.442 -3.254a 
SIGLEC10 immunoglobulin superfamily AF301007 3.012 2.938a 
SOCS3 immune regulation AI244908 3.788 2.403 




 In addition to the endocrine changes and induction of an inflammatory 
response (see Chapters 2 and 3), adiponectin has many diverse effects on 
syncytialized trophoblast cells. One of the interesting mechanisms identified from 
these data is the IGF processing pathway. Amino acid and glucose transfer as well as 
the health and development of the placenta are all influenced by IGFs (Forbes and 
Westwood, 2008). The bioavailability of IGF is regulated by binding proteins, which 
sequester IGF in the serum, not allowing it to bind to its receptor on the surface of the 
target cell. The interaction between IGF and IGF binding proteins (IGFBPs) is 
disrupted through the actions of proteases which degrade specific IGFBPs and release 
IGF, allowing it to bind its receptor. Treatment with adiponectin in long-term culture 
resulted in a decrease in expression for a number of proteases and a phosphatase 
involved in this process including furin, disintegrin and metallopeptidase domain-
containing protein 12 (ADAM12), pregnancy associated plasma protein 1 and 2 
(PAPPA and PAPPA2), and placental alkaline phophatase (ALPP). Conversely, 
although not reaching statistical significance, there was a trend for increased 
expression of IGFBP3 after these cells had been exposed to adiponectin for 5d.  
Increased expression of the protease PAPPA2 has been reported in cases of 
preeclampsia (Winn et al., 2009, Nishizawa et al., 2008), perhaps in an effort by the 
placenta to increase the amount of available IGF and, thus, stimulate nutrient uptake 
to what is often a metabolically deprived fetus. These data are in keeping with the 
overall hypothesis of our laboratory, that adiponectin functions to keep the demands 
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of the fetus in check, and in that manner may be regarded as serving the interests of 
the mother’s metabolic system(s) over that of the fetoplacental unit.  
Two steroidogenic enzymes, 11-β hydroxysteroid dehydrogenase B1 
(HSD11B1) and HSD11B2, were also changed with adiponectin treatment. An 
increase in HSD11B1 was accompanied by a concomitant decrease in HSD11B2. 
These data raise an interesting phenomenon regarding potential cortisol levels in the 
placenta. Cortisol, one of the major stress-induced hormones, is converted from its 
inactive metabolite, cortisone by HSD11B1. Conversely, active cortisol is 
metabolized to inactive cortisone by HSD11B2. Thus, a reduction in HSD11B2 and 
an increase in HSD11B1 may lead to a net increase in cortisol in the 
syncytiotrophoblast exposed to adiponectin. Maternal levels of cortisol are 
approximately 10x higher than that of the fetus, thus a decrease in placental 
HSD11B2 may allow for increased levels of maternal cortisol to cross to the fetus (Ni 
et al., 2009). Increased glucocorticoids during gestation have been shown to result in 
a number of negative impacts on the fetus, including intrauterine growth restriction 
(IUGR) (Ain et al., 2005). In addition, studies in humans suggest that maternal stress 
and cortisol levels can alter postnatal cognitive development in the child (Davis and 
Sandman, 2010). 
It is remarkable how many of the changes we observe with adiponectin 
treatment are opposite to what have been associated with preeclampsia. Genes such as 
PAPPA2, chorionic gonadotropin β, endoglin, and α-mannosidase, all of which drop 
following adiponectin treatment (Table IX-2), have been reported to be increased in 
placenta samples from preeclamptic patients (Winn et al., 2009). Still others are up-
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regulated in both preeclampsia and with adiponectin exposure, including ankyrin 
repeat and SOCS box-containing 2 (ASB2) and 17βHSD (Winn et al., 2009). These 
data are difficult to interpret given multiple reports showing a positive correlation 
between circulating adiponectin levels and preeclampsia (Avci et al., 2010, D'Anna et 
al., 2006, Fasshauer et al., 2008, Nien et al., 2007). However, an increase in 
adiponectin in preeclampsia has been challenged (Mazaki-Tovi et al., 2009c). It is 
also important to consider the large variation in diagnostic criteria for a complex, 
multifactorial disease such as preeclampsia. Alternatively, the largely opposing 
effects of preeclampsia versus adiponectin on global gene expression may be 
explained by suggesting that adiponectin has the capacity to counteract many of the 
effects at the maternal-fetal interface initiated by preeclampsia. One must also be 
careful to draw too many parallels between our data and that reported with 
preeclampsia, as the two studies used whole placental tissue (Winn and colleagues) 
versus isolated trophoblasts (this report). Furthermore, it is currently unclear as to the 
responsiveness of placental trophoblasts to adiponectin during preeclampsia. Cells 
from healthy placentas may respond to adiponectin in culture in a very different 
manner than preeclamptic trophoblasts would in vivo. 
Adiponectin has long been associated with inhibiting endothelial cell and 
macrophage activation, and as a consequence is widely considered a 
vasculoprotective factor (Zhu et al., 2008). It follows that adiponectin would 
counteract diseases such as preeclampsia, which is characterized by endothelial 
dysfunction. Thus, it is important to understand the effects adiponectin has, not only 
on endothelial cells, but also on the trophoblast. As the functional unit of the placenta, 
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their response to adiponectin will have important implications for the potential of 
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X. Chapter Six: 
 
Concluding Remarks  
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Only relatively recently has adipose tissue been appreciated for the profound 
impact it has on whole-body physiology. Its function as a storage depot for energy 
reserves has been expanded to include a potent endocrine role. Indeed, the number of 
hormones, cytokines, and growth factors, collectively termed adipokines, produced 
by adipose tissue is amended to include novel members on an almost weekly basis. 
One of these hormones is adiponectin. Adiponectin has been shown to influence 
metabolic homeostasis and promote insulin sensitivity in a number of different tissue 
types. As one of the most abundant hormones in circulation, adiponectin also has the 
potential to regulate many biological systems other than those traditionally 
appreciated for their metabolic role. The proportion of the population in the United 
States that are now considered overweight or obese has reached epidemic proportions. 
It is therefore critical that we make understanding the role of adipose tissue, and 
hormones such as adiponectin, a priority in this country. In addition, a woman’s risk 
of developing specific diseases of pregnancy, such as gestational diabetes and 
preeclampsia, is positively correlated with her BMI. Normal pregnancy represents a 
state of altered maternal energy metabolism and glucose utilization. Given the 
importance of adiponectin in these processes, it follows that adiponectin expression 
and actions may play an important role in mediating the effects of metabolic stress 
during gestation. This is particularly true in instances of exaggerated reductions in 
adiponectin production, such as gestational diabetes, making adiponectin a prime 
candidate for an important mediator of trophoblast cells during pregnancy. The 
available literature regarding adiponectin and the placenta are correlative studies and 
thus succeeds primarily in substantiating, while not directly testing, the hypothesis 
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that the adipokine plays an important role at the maternal-fetal interface. Precisely 
what this role involves needs to be elucidated. Thus, an understanding of 
adiponectin’s role, if any, on human trophoblast cells was the aim of these studies. 
 
1. Adiponectin is not expressed by the human placenta. 
We have utilized RT-PCR and quantitative RT-PCR in an effort to amplify a 
transcript for adiponectin in the human placenta. Despite the design of multiple 
primer sets, including those that have been published for placental adiponectin 
(Caminos et al., 2005), and the use of TaqMan primer/probe sets (Applied 
Biosystems), we have been unable to detect adiponectin gene expression. This is true 
in the choriocarcinoma cell lines, Jeg-3, Jar, and BeWo, as well as freshly isolated 
cytotrophoblasts from term, term cytotrophoblasts syncytialized in vitro with 
administration of epidermal growth factor (EGF), and RNA collected from whole 
placenta collected at term. Thus, we conclude that adiponectin is not produced by the 
human term placenta. 
 
2. The human placenta has the capacity to respond to adiponectin.  
Using RT-PCR and quantitative RT-PCR, we have been able to identify 
transcripts for the adiponectin receptors, adipoR1 and adipoR2. This is the case in 
both freshly isolated cytotrophoblasts as well as syncytialized trophoblasts. From 
these data we conclude that the human placenta may be able to respond to adiponectin 




3. Adiponectin inhibits hormone production by syncytialized human 
trophoblasts. 
We exposed term trophoblasts to physiological levels of adiponectin for a 
culture period of 5d. As hormone production is one of the primary functions of the 
syncytiotrophoblast, we began by assessing the production of a number of hormones 
following adiponectin exposure. Using qRT-PCR, we determined that adiponectin 
treatment resulted in a significant drop in gene expression for human chorionic 
gonadotropin (hCG) β, the common glycoprotein α subunit, and placental lactogen. In 
addition, expression of CYP11A1 and CYP19A1, the genes that encode the 
steroidogenic enzymes p450 side chain cleavage and aromatase, respectively, were 
also decreased. All of these changes were also observed at the protein level through 
the use of western blots. Furthermore, we identified a decrease in progesterone 
secretion from cells that had been exposed to adiponectin for the entire culture period. 
These data demonstrate that adiponectin exerts a potent effect on trophoblast cells. 
Many of these hormones, such as placental lactogen, will promote a shuttling of 
nutrients and glucose to the fetoplacental unit. It is therefore possible that adiponectin 
works to keep these demands in check by decreasing the production of these 
hormones. 
 
4. Adiponectin induces a pro-inflammatory response by syncytialized 
trophoblast cells. 
Exposure to adiponectin also elicits an up-regulation in gene expression for 
the pro-inflammatory cytokines, interleukin (IL)-1β and IL-8. We observed these 
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changes after the cells were placed in culture with adiponectin treatment for a total of 
5d. Induction of the pro-inflammatory response also occurs when the cells are 
allowed to syncytialize spontaneously in vitro for 4d prior to 24h adiponectin 
treatment. Thus, the pro-inflammatory response to adiponectin is more likely to be a 
direct effect of adiponectin on the trophoblast cells. In addition, we have noted an 
increase in the gene expression and protein levels of the sialic acid-binding receptor, 
Siglec10. Siglec10 contains an immune receptor tyrosine-based inhibitory motif 
(ITIM), and has been proposed to function as an inhibitory receptor in the innate 
immune system (Munday et al., 2001). We have also shown that the 
syncytiotrophoblast expresses Siglec10 as well as the glycoprotein CD24, which has 
been suggested to function with Siglec10 to dampen the innate immune response to 
components released by injured cells (Chen et al., 2009). From these data we 
hypothesize that the trophoblast may be increasing Siglec10 expression, normally 
expressed at relatively low levels, in an effort to reduce the pro-inflammatory 
response initiated by adiponectin.  
 
5. Adiponectin activates the MAPK pathways, ERK1/2 and JNK as well as 
EGFR through the actions of APPL1. 
We have shown that adiponectin activates both of the mitogen-activated 
protein kinases (MAPKs), extracellular signal-related kinase (ERK)1/2 and c-Jun N-
terminal kinase (JNK). In addition, treatment with adiponectin elicits an increase in 
the levels of activated EGFR. Through lentiviral-mediated over-expression of the 
inhibitory binding partner, APPL2, we have also shown that the signaling capacity of 
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adiponectin is dependent on the adaptor protein APPL1, which will bind to the 
adiponectin receptor and mediate downstream signaling events.  
 
6. Leptin attenuates the signaling actions induced by adiponectin. 
By over-expressing the hormone leptin in isolated trophoblasts collected at 
term we are able to abolish the ability of adiponectin to signal in these cells. Leptin 
and adiponectin are known to initiate opposing actions in a variety of metabolic 
systems, and the adipose expression patterns of the two hormones mirror one another 
(i.e. leptin production increases with increased lipid stores, adiponectin decreases). It 
is thus not surprising that leptin attenuates the actions of adiponectin at the maternal-
fetal interface, however this is the first time such a phenomenon has been reported. 
 
7. Adiponectin can also elicit changes in a variety of metabolism-related 
genes in trophoblasts, including those involved in IGF bioavailability. 
To assess the changes initiated by adiponectin treatment on syncytialized 
trophoblast cells, we used a global microarray approach. These data allowed us to 
identify a number of genes that were down-regulated following adiponectin 
treatment, including many of the genes already identified by our previous 
investigations. In addition, many genes were up-regulated by adiponectin, although 
only about 1/3 as many as those we determined to be reduced. One of the interesting 
pathways that arose from this study was the identification of a reduction in the 
expression of the proteases, ADAM12, PAPPA1 and 2, and the phosphatase, ALPP. 
All of these proteins are involved in the degradation of IGF binding proteins and the 
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liberation of IGF for cell signaling. In addition, from these data we have observed a 
trend toward an increase in the expression of IGFBP3. Taken together, these data 
suggest that adiponectin may be decreasing the amount of available IGF at the 
maternal-fetal interface, by keeping more of it sequestered by IGFBPs. 
 
Completion of these studies has elucidated alterations in a number of 
important functions of the syncytiotrophoblast following adiponectin exposure. 
Clinical studies continue to be published highlighting the changes in circulating 
adiponectin levels during gestational diseases, and relating those to not only the 
disease state during pregnancy, but also the long-term health of both mother and 
child. It has now been suggested that low levels of adiponectin during pregnancy can 
predict pancreatic β-cell dysfunction and consequent insulin resistance postpartum 
(Retnakaran et al., 2010). Despite these potentially serious implications for 
adiponectin, we remain one of the few groups that are examining its effects on 
trophoblast cells specifically. Thus, the data reported herein have substantially 
enhanced our understanding of the role for adiponectin in trophoblast function.  
In addition, these data have resulted in the generation of a number of 
hypotheses that may be tested in the future. Examination of the effects of adiponectin 
during pregnancy in vivo is the next logical progression from these data, and will 
significantly advance our understanding of the effects of too little or too much 
adiponectin on the placenta. Careful examination of pregnancy in adiponectin null 
mice, as well as utilization of the adenovirus-mediated over-expression rodent model 
during pregnancy may allow us to ascertain if the effects we have observed in human 
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primary cell cultures remains true when examined in a physiologically relevant model 
system with many different hormonal and environmental cues also at work.  
There is an increased appreciation for the two adiponectin receptors, adipoR1 
and adipoR2, in mediating distinct biological functions within the same or different 
cell types. It would therefore significantly enhance our understanding of adiponectin 
biology at the maternal-fetal interface, if we were to begin to examine the individual 
effects of the two receptors in trophoblast cells. This may be done through the use of 
lentiviral shRNA constructs, as we have utilized for some of the studies described 
above. It is possible that each receptor serves a unique function within the trophoblast 
cell, stimulating distinct signaling pathways, and thus some of the effects we have 
attributed to adiponectin may be specifically due to the hormone’s actions through a 
specific receptor.  
Finally, all of our data has been generated using term trophoblast cells. It 
would be extremely interesting to investigate the effect of adiponectin on the placenta 
earlier in gestation. To do this, we may be able to utilize first trimester human cell 
lines, or possibly even primary tissue collected from first trimester placentas. The 
developing placenta is a very different organ than the mature form, and therefore we 
expect that adiponectin may have very different effects on trophoblast cells from the 



















Ain R, Canham LN, Soares MJ (2005) Dexamethasone-induced intrauterine growth 
restriction impacts the placental prolactin family, insulin-like growth factor-II 
and the Akt signaling pathway. J Endocrinol, 185, 253-63. 
Altinova AE, Toruner F, Bozkurt N, et al. (2007) Circulating concentrations of 
adiponectin and tumor necrosis factor-α in gestational diabetes mellitus. 
Gynecol Endocrinol, 23, 161 - 165. 
Aluvihare V, Kallikourdis M, Betz A (2004) Regulatory T cells mediate maternal 
tolerance to the fetus. Nat Immunol, 5, 266-71. 
Aris A, Leblanc S, Ouellet A, Moutquin J-M (2008) Detrimental effects of high levels 
of antioxidant vitamins C and E on placental function: Considerations for the 
Vitamins in Preeclampsia (VIP) trial. J Obstet Gynaecol Res, 34, 504-511. 
Arita Y, Kihara S, Ouchi N, et al. (1999) Paradoxical Decrease of an Adipose-
Specific Protein, Adiponectin, in Obesity. Biochem Biophys Res Comm, 257, 
79-83. 
Asimakopoulos B, Milousis A, Gioka T, et al. (2009) Serum Pattern of Circulating 
Adipokines throughout the Physiological Menstrual Cycle. Endocrine J, 56, 
425-433. 
Avci I, Özerkan K, Uncu G (2010) Serum adiponectin levels increase in lean 
preeclamptic women. Prenat Diag, 30, 91-92. 
Baeten JM, Bukusi EA, Lambe M (2001) Pregnancy complications and outcomes 
among overweight and obese nulliparous women. Am J Public Health, 91, 
436-440. 
Bai X, Williams JLR, Greenwood SL, Baker PN, Aplin JD, Crocker IP (2009) A 
Placental Protective Role for Trophoblast-Derived TNF-Related Apoptosis-
Inducing Ligand (TRAIL). Placenta, 30, 855-860. 
Barbour LA, Shao J, Qiao L, et al. (2002) Human placental growth hormone causes 
severe insulin resistance in transgenic mice. Am J Obstet Gynecol, 186, 512-
517. 
Baschat A, Galan H, Ross M, Gabbe S (2007) Intrauterine Growth Restriction. In 
Obstetrics: Normal and Problem Pregnancies (eds Gabbe S, Niebyl J, 
Simpson J). Philadelphia: Churchill Livingstone Elsevier. 
Baviera G, Corrado F, Dugo C, Cannata ML, Russo S, Rosario DA (2007) 
Midtrimester Amniotic Fluid Adiponectin in Normal Pregnancy. Clin Chem, 
53, 1723-1724. 
Benaitreau D, Dieudonne M-N, Dos Santos E, Leneveu M-C, de Mazancourt P, 
Pecquery R (2009) Antiproliferative Effects of Adiponectin on Human 
Trophoblastic Cell Lines JEG-3 and BEWO. Biol Reprod, 80, 1107-14. 
Benirschke K, Kaufmann P (1990) Pathology of the Human Placenta, Springer-
Verlag, New York. 
Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted 
protein Acrp30 enhances hepatic insulin action. Nat Med, 7, 947-953. 
Bienertová-Va J, Dostálová Z, Ka ková K, Bienert P, Va k F. Vít Unzeitig A (2008) 
Is there any link between severe pre-eclampsia and defined polymorphisms in 
leptin and adiponectin genes? J Obstet Gynaecol Res, 34, 858-864. 
Bjursell M, Ahnmark A, Bohlooly-Y M, et al. (2007) Opposing Effects of 
Adiponectin Receptors 1 and 2 on Energy Metabolism. Diabetes, 56, 583-593. 
203 
 
Bluher M (2009) Adipose Tissue Dysfunction in Obesity. Exp Clin Endocrinol 
Diabetes, 117, 241-250. 
Bluher M (2010) The distinction of metabolically 'healthy' from 'unhealthy' obese 
individuals. Curr Opin Lipidol, 21, 38-43. 
Boyd J, Hamilton W (1970) The Human Placenta, W. Heffer & Sons, Cambridge. 
Briana DD, Malamitsi-Puchner A (2009) Reviews: Adipocytokines in Normal and 
Complicated Pregnancies. Reprod Sci, 16, 921-937. 
Cameo P, Bischof P, Calvo JC (2003) Effect of Leptin on Progesterone, Human 
Chorionic Gonadotropin, and Interleukin-6 Secretion by Human Term 
Trophoblast Cells in Culture. Biol Reprod, 68, 472-7. 
Caminos JE, Nogueiras R, Gallego R, et al. (2005) Expression and Regulation of 
Adiponectin and Receptor in Human and Rat Placenta. J Clin Endocrinol 
Metab, 90, 4276-4286. 
Caminos JE, Nogueiras R, Gaytan F, et al. (2008) Novel Expression and Direct 
Effects of Adiponectin in the Rat Testis. Endocrinology, 149, 3390-3402. 
Catalano PM, Hoegh M, Minium J, et al. (2006) Adiponectin in human pregnancy: 
implications for regulation of glucose and lipid metabolism. Diabetologia, 49, 
1677-1685. 
Cetin I, de Santis MSN, Taricco E, et al. (2005) Maternal and fetal amino acid 
concentrations in normal pregnancies and in pregnancies with gestational 
diabetes mellitus. Am J Obstet Gynecol, 192, 610-617. 
Chabrolle C, Tosca L, Ramé C, Lecomte P, Royère D, Dupont J (2009) Adiponectin 
increases insulin-like growth factor I-induced progesterone and estradiol 
secretion in human granulosa cells. Fertil Steril, 92, 1988-96. 
Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF, III, Petraglia F (2009) 
Inflammation and Pregnancy. Reprod Sci, 16, 206-215. 
Chappell LC, Seed PT, Briley AL, et al. (1999) Effect of antioxidants on the 
occurrence of pre-eclampsia in women at increased risk: a randomised trial. 
Lancet, 354, 810-6. 
Chen D, Dong M, Fang Q, He J, Wang Z, Yang X (2005) Alterations of serum 
resistin in normal pregnancy and pre-eclampsia. Clin Sci (Lond), 108, 81-84. 
Chen G-Y, Tang J, Zheng P, Liu Y (2009) CD24 and Siglec-10 Selectively Repress 
Tissue Damage-Induced Immune Responses. Science, 323, 1722-1725. 
Chen J, Tan B, Karteris E, et al. (2006) Secretion of adiponectin by human placenta: 
differential modulation of adiponectin and its receptors by cytokines. 
Diabetologia, 49, 1292-1302. 
Chudek J, Wiecek A (2006) Adipose tissue, inflammation and endothelial 
dysfunction. Pharmacol Rep, 58 Suppl, 81-88. 
Clark D, Chaouat G, Wong K, Gorczynski R, Kinsky R (2010) Tolerance 
Mechanisms in Pregnancy: A Reappraisal of the Role of Class I Paternal 
MHC Antigens*. Am J Reprod Immunol, 63, 93-103. 
Cleal JK, Lewis RM (2008) The Mechanisms and Regulation of Placental Amino 
Acid Transport to the Human Foetus. J Neuroendocrinol, 20, 419-426. 
Combs T, Berg A, Obici S, Scherer P, Rossetti L (2001) Endogenous glucose 




Combs TP, Pajvani UB, Berg AH, et al. (2004) A Transgenic Mouse with a Deletion 
in the Collagenous Domain of Adiponectin Displays Elevated Circulating 
Adiponectin and Improved Insulin Sensitivity. Endocrinology, 145, 367-383. 
Coope A, Milanski M, Araújo EP, et al. (2008) AdipoR1 mediates the anorexigenic 
and insulin/leptin-like actions of adiponectin in the hypothalamus. FEBS Lett, 
582, 1471-6. 
Cortelazzi D, Corbetta S, Ronzoni S, et al. (2007) Maternal and foetal resistin and 
adiponectin concentrations in normal and complicated pregnancies. Clin 
Endocrinol, 66, 447-453. 
Cronier L, Defamie N, Dupays L, et al. (2002) Connexin expression and gap 
junctional intercellular communication in human first trimester trophoblast. 
Mol Hum Reprod, 8, 1005-1013. 
Cseh K, Baranyi E, Melczer Z, Kaszas E, Palik E, Winkler G (2004) Plasma 
Adiponectin and Pregnancy-Induced Insulin Resistance. Diabetes Care, 27, 
274-275. 
D'Anna R, Baviera G, Corrado F, et al. (2006) Adiponectin and insulin resistance in 
early- and late-onset pre-eclampsia. BJOG, 113, 1264-1269. 
D'Anna R, Baviera G, Corrado F, Giordano D, Di Benedetto A, Jasonni VM (2005) 
Plasma Adiponectin Concentration in Early Pregnancy and Subsequent Risk 
of Hypertensive Disorders. Obstet Gynecol, 106, 340-344. 
Dancis J, Schneider H (1975) Physiology: Transfer and Barrier Function. In The 
Placenta and its Maternal Supply Line (ed Gruenwald P). Baltimore: 
University Park Press. 
Davis E, Sandman C (2010) The Timing of Prenatal Exposure to Maternal Cortisol 
and Psychosocial Stress Is Associated With Human Infant Cognitive 
Development. Child Dev, 81, 131-48. 
Davis G, Mackenzie C, Brown M, et al. (2007) Predicting transformation from 
gestational hypertension to preeclampsia in clinical practice: a possible role 
for 24 hour ambulatory blood pressure monitoring. Hypertens Pregnancy, 26, 
77-87. 
Delporte ML, Brichard SM, Hermans MP, Beguin C, Lambert M (2003) 
Hyperadiponectinaemia in anorexia nervosa. Clin Endocrinol, 58, 22-29. 
Desoye G, Hartmann M, Jones C, et al. (1997) Location of insulin receptors in the 
placenta and its progenitor tissues. Microsc Res Tech, 38, 63-75. 
Desoye G, Hauguel-de Mouzon S (2007) The Human Placenta in Gestational 
Diabetes Mellitus: The insulin and cytokine network. Diabetes Care, 30, 
S120-126. 
Di Simone N, Di Nicuolo F, Sanguinetti M, et al. (2006) Resistin regulates human 
choriocarcinoma cell invasive behaviour and endothelial cell angiogenic 
processes. J Endocrinol, 189, 691-699. 
Duckitt K, Harrington D (2005) Risk factors for pre-eclampsia at antenatal booking: 
systematic review of controlled studies. BMJ, 330, 565. 
Duffield JA, Vuocolo T, Tellam R, et al. (2009) Intrauterine Growth Restriction and 
the Sex Specific Programming of Leptin and Peroxisome Proliferator-
Activated Receptor γ (PPARγ) mRNA Expression in Visceral Fat in the 
Lamb. Pediatr Res, 66, 59-65. 
205 
 
Ebina K, Oshima K, Matsuda M, et al. (2009) Adenovirus-mediated gene transfer of 
adiponectin reduces the severity of collagen-induced arthritis in mice. 
Biochem Biophys Res Comm, 378, 186-191. 
Egawa M, Kamata H, Kushiyama A, et al. (2008) Long-term Forskolin Stimulation 
Induces AMPK Activation and Thereby Enhances Tight Junction Formation 
in Human Placental Trophoblast BeWo Cells. Placenta, 29, 1003-1008. 
Enders A (1965a) A Comparative Study of the Fine Structure of the Trophoblast in 
Several Hemochorial Placentas. Am J Anat, 116, 29-68. 
Enders A (1965b) Formation of Syncytium from Cytotrophoblast in the Human 
Placenta. Obstet Gynecol, 25, 378-86. 
Eng GS, Sheridan RA, Wyman A, et al. (2007) AMP Kinase Activation Increases 
Glucose Uptake, Decreases Apoptosis, and Improves Pregnancy Outcome in 
Embryos Exposed to High IGF-I Concentrations. Diabetes, 56, 2228-2234. 
Ericsson A, Hamark B, Powell TL, Jansson T (2005) Glucose transporter isoform 4 is 
expressed in the syncytiotrophoblast of first trimester human placenta. Hum 
Reprod, 20, 521-530. 
Fang X, Fetros J, Dadson K, Xu A, Sweeney G (2009) Leptin prevents the metabolic 
effects of adiponectin in L6 myotubes. Diabetologia, 52, 2190-2200. 
Farina A, Morano D, Arcelli D, et al. (2009) Gene expression in chorionic villous 
samples at 11 weeks of gestation in women who develop preeclampsia later in 
pregnancy: implications for screening. Prenat Diagn, 29, 1038-44. 
Fasshauer M, Bluher M, Stumvoll M, Tonessen P, Faber R, Stepan H (2007) 
Differential regulation of visfatin and adiponectin in pregnancies with normal 
and abnormal placental function. Clin Endocrinol, 66, 434-439. 
Fasshauer M, Kralisch S, Klier M, et al. (2003) Adiponectin gene expression and 
secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys 
Res Comm, 301, 1045-1050. 
Fasshauer M, Waldeyer T, Seeger J, et al. (2008) Circulating high-molecular-weight 
adiponectin is upregulated in preeclampsia and is related to insulin sensitivity 
and renal function. Eur J Endocrinol, 158, 197-201. 
Fiaschi T, Cirelli D, Comito G, et al. (2009) Globular adiponectin induces 
differentiation and fusion of skeletal muscle cells. Cell Res, 19, 584-597. 
Forbes K, Westwood M (2008) The IGF Axis and Placental Function. Horm Res, 69, 
129-137. 
Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Allen Hogge W, Conrad KP 
(2009) Altered Global Gene Expression in First Trimester Placentas of 
Women Destined to Develop Preeclampsia. Placenta, 30, 15-24. 
French SS, Greives TJ, Zysling DA, Chester EM, Demas GE (2009) Leptin increases 
maternal investment. Proceedings of the Royal Society B: Biological Sciences, 
276, 4003-4011. 
Fruebis J, Tsao T-S, Javorschi S, et al. (2001) Proteolytic cleavage product of 30-kDa 
adipocyte complement-related protein increases fatty acid oxidation in muscle 
and causes weight loss in mice. Proc Nat Acad Sci, 98, 2005-2010. 
Fuglsang J, Skjaerbaek C, Frystyk J, Flyvbjerg A, Ovesen P (2006) A longitudinal 
study of serum adiponectin during normal pregnancy. BJOG, 113, 110-113. 
206 
 
Fujii N, Jessen N, Goodyear LJ (2006) AMP-activated protein kinase and the 
regulation of glucose transport. Am J Physiol Endocrinol Metab, 291, E867-
877. 
Fulco M, Cen Y, Zhao P, et al. (2008) Glucose Restriction Inhibits Skeletal Myoblast 
Differentiation by Activating SIRT1 through AMPK-Mediated Regulation of 
Nampt. Dev Cell, 14, 661-673. 
Gaither K, Quraishi AN, Illsley NP (1999) Diabetes Alters the Expression and 
Activity of the Human Placental GLUT1 Glucose Transporter. J Clin 
Endocrinol Metab, 84, 695-701. 
Gao X, Yang H, Zhao Y (2008) Variations of tumor necrosis factor-α, leptin and 
adiponectin in mid-trimester of gestational diabetes mellitus. Chin Med J, 121, 
701-705. 
Gauster M, Hiden U, Blaschitz A, et al. (2007) Dysregulation of Placental Endothelial 
Lipase and Lipoprotein Lipase in Intrauterine Growth-Restricted Pregnancies. 
J Clin Endocrinol Metab, 92, 2256-2263. 
Gauster M, Moser G, Orendi K, Huppertz B (2009) Factors Involved in Regulating 
Trophoblast Fusion: Potential Role in the Development of Preeclampsia. 
Placenta, 30, 49-54. 
Georgiou H, Lappas M, Georgiou G, et al. (2008) Screening for biomarkers 
predictive of gestational diabetes mellitus. Acta Diabetologica, 45, 157-65. 
Gilbert J (1949) The association of maternal obesity, large babies, and diabetes. Br 
Med J, 1, 702-704. 
Giri S, Rattan R, Haq E, et al. (2006) AICAR inhibits adipocyte differentiation in 
3T3L1 and restores metabolic alterations in diet-induced obesity mice model. 
Nutr Metab, 3, 31. 
Gu Y, Lewis DF, Wang Y (2008) Placental Productions and Expressions of Soluble 
Endoglin, Soluble fms-Like Tyrosine Kinase Receptor-1, and Placental 
Growth Factor in Normal and Preeclamptic Pregnancies. J Clin Endocrinol 
Metab, 93, 260-266. 
Guilherme A, Virbasius JV, Puri V, Czech MP (2008) Adipocyte dysfunctions 
linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell 
Biol, 9, 367-377. 
Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E (2008) Recombinant 
luteinizing hormone induces increased production of ovarian follicular 
adiponectin in vivo: implications for enhanced insulin sensitivity. Fertil Steril, 
91, 1837-41. 
Habinowski SA, Witters LA (2001) The Effects of AICAR on Adipocyte 
Differentiation of 3T3-L1 Cells. Biochem Biophys Res Comm, 286, 852-856. 
Handwerger S, Freemark M (2000) The roles of placental growth hormone and 
placental lactogen in the regulation of human fetal growth and development. J 
Pediatr Endocrinol Metab, 13, 343-56. 
Haugen F, Drevon CA (2007) Activation of Nuclear Factor-κB by High Molecular 
Weight and Globular Adiponectin. Endocrinology, 148, 5478-86. 
Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA (2006) Increased 
plasma levels of adipokines in preeclampsia: relationship to placenta and 
207 
 
adipose tissue gene expression. Am J Physiol Endocrinol Metab, 290, E326-
333. 
Hauguel-de Mouzon S, Challier JC, Kacemi A, Cauzac M, Malek A, Girard J (1997) 
The GLUT3 Glucose Transporter Isoform Is Differentially Expressed within 
Human Placental Cell Types. J Clin Endocrinol Metab, 82, 2689-2694. 
Hedge G, Colby H, Goodman R (1987) Clinical Endocrine Physiology, W.B. 
Saunders Company, Philadelphia. 
Heron M, Hoyert D, Murphy S, Xu J, Kochanek K, Tejada-Vera B (2009) Deaths: 
Final data for 2006.  (ed Statistics NCfH). Hyattsville, MD. 
Herse F, Bai Y, Staff AC, Yong-Meid J, Dechend R, Zhou R (2009) Circulating and 
Uteroplacental Adipocytokine Concentrations in Preeclampsia. Reprod Sci, 
16, 584-590. 
Hiby SE, Walker JJ, O'Shaughnessy KM, et al. (2004) Combinations of Maternal 
KIR and Fetal HLA-C Genes Influence the Risk of Preeclampsia and 
Reproductive Success. J Exp Med, 200, 957-965. 
Hiden U, Glitzner E, Hartmann M, Desoye G (2009) Insulin and the IGF system in 
the human placenta of normal and diabetic pregnancies. J Anat, 215, 60-68. 
Hiden U, Maier A, Bilban M, et al. (2006) Insulin control of placental gene 
expression shifts from mother to foetus over the course of pregnancy. 
Diabetologia, 49, 123-31. 
Hosch SE, Olefsky JM, Kim JJ (2006) APPLied mechanics: Uncovering how 
adiponectin modulates insulin action. Cell Metab, 4, 5-6. 
Hu E, Liang P, Spiegelman BM (1996) AdipoQ Is a Novel Adipose-specific Gene 
Dysregulated in Obesity. J Biol Chem, 271, 10697-10703. 
Hug C, Wang J, Ahmad NS, Bogan JS, Tsao T-S, Lodish HF (2004) T-cadherin is a 
receptor for hexameric and high-molecular-weight forms of 
Acrp30/adiponectin. Proc Nat Acad Sci, 101, 10308-10313. 
Hunt J (2006) Stranger in a strange land. Immunol Rev, 213, 36-47. 
Huppertz B (2008) The anatomy of the normal placenta. J Clin Pathol, 61, 1296-
1302. 
Huppertz B, Frank HG, Reister F, Kingdom J, Korr H, Kaufmann P (1999) Apoptosis 
Cascade Progresses during Turnover of Human Cytotrophoblast: Analysis of 
Villous Cytotrophoblast and Syncytial Fragments In Vitro. Lab Invest, 79, 
1687-1702. 
Hwang J-T, Park I-J, Shin J-I, et al. (2005) Genistein, EGCG, and capsaicin inhibit 
adipocyte differentiation process via activating AMP-activated protein kinase. 
Biochem Biophys Res Comm, 338, 694-699. 
Ichida K, Moriyama T, Morita H, et al. (2007) Plasma adiponectin concentrations and 
placental adiponectin expression in pre-eclamptic women. Gynecol 
Endocrinol, 23, 238 - 243. 
Illsley N (2000) Placental glucose transport in diabetic pregnancy. Clin Obstet 
Gynecol, 43, 116-26. 
Irgens HU, Reisater L, Irgens LM, Lie RT, Roberts JM (2001) Long term mortality of 
mothers and fathers after pre-eclampsia: population based cohort study Pre-




Jansson N, Nilsfelt A, Gellerstedt M, et al. (2008) Maternal hormones linking 
maternal body mass index and dietary intake to birth weight. Am J Clin Nutr, 
87, 1743-1749. 
Jansson T, Wennergren M, Illsley NP (1993) Glucose Transporter Protein Expression 
in Human Placenta throughout Gestation and in Intrauterine Growth 
Retardation. J Clin Endocrinol Metab, 77, 1554-62. 
Jarvenpaa J, Vuoristo JT, Santaniemi M, et al. (2009) Adiponectin induced placental 
cell apoptosis could be mediated via the ADIPOR1-receptor in pre-eclampsia 
with IUGR. J Perinat Med, 37, 257-262. 
Jauniaux E, Hempstock J, Greenwold N, Burton GJ (2003) Trophoblastic Oxidative 
Stress in Relation to Temporal and Regional Differences in Maternal Placental 
Blood Flow in Normal and Abnormal Early Pregnancies. Am J Pathol, 162, 
115-125. 
Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A (2008) Circulating 
and Placental Endoglin Concentrations in Pregnancies Complicated by 
Intrauterine Growth Restriction and Preeclampsia. Placenta, 29, 555-563. 
Johansson M, Karlsson L, Wennergren M, Jansson T, Powell TL (2003) Activity and 
Protein Expression of Na+/K+ ATPase Are Reduced in Microvillous 
Syncytiotrophoblast Plasma Membranes Isolated from Pregnancies 
Complicated by Intrauterine Growth Restriction. J Clin Endocrinol Metab, 88, 
2831-2837. 
Jones HN, Jansson T, Powell TL (2010) Full-Length Adiponectin Attenuates Insulin 
Signaling and Inhibits Insulin-Stimulated Amino Acid Transport in Human 
Primary Trophoblast Cells. Diabetes, 59, 1161-70. 
Kadowaki T, Yamauchi T (2005) Adiponectin and Adiponectin Receptors. Endocr 
Rev, 26, 439-451. 
Kane N, Kelly R, Saunders PTK, Critchley HOD (2009) Proliferation of Uterine 
Natural Killer Cells Is Induced by Human Chorionic Gonadotropin and 
Mediated via the Mannose Receptor. Endocrinology, 150, 2882-2888. 
Kaufmann P, Sen D, Schweikhart G (1979) Classification of Human Placental Villi I. 
Histology. Cell Tissue Res, 200, 409-23. 
Kim J-Y, van de Wall E, Laplante M, et al. (2007) Obesity-associated improvements 
in metabolic profile through expansion of adipose tissue. J Clin Invest, 117, 
2621-37. 
King A (2000) Uterine leukocytes and decidualization. Hum Reprod Update, 6, 28-
36. 
King A, Burrows T, Verma S, Hiby S, Loke YW (1998) Human uterine lymphocytes. 
Hum Reprod Update, 4, 480-5. 
Kitahara K, Kusunoki N, Kakiuchi T, Suguro T, Kawai S (2009) Adiponectin 
stimulates IL-8 production by rheumatoid synovial fibroblasts. Biochem 
Biophys Res Comm, 378, 218-223. 
Kliman H, Nestler J, Sermasi E, Sanger J, Strauss J (1986) Purification, 
characterization, and in vitro differentiation of cytotrophoblasts from human 
term placentae. Endocrinology, 118, 1567-1582. 
209 
 
Kralisch S, Stepan H, Kratzsch J, et al. (2009) Serum levels of adipocyte fatty acid 
binding protein are increased in gestational diabetes mellitus. Eur J 
Endocrinol, 160, 33-38. 
Kubota N, Terauchi Y, Yamauchi T, et al. (2002) Disruption of Adiponectin Causes 
Insulin Resistance and Neointimal Formation. J Biol Chem, 277, 25863-
25866. 
Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ (2008) Role of 
adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell 
Endocrinol, 284, 38-45. 
Lain K, Catalano PM (2007) Metabolic changes in pregnancy. Clin Obstet Gynecol, 
50, 938-48. 
Lain K, Daftary A, Ness R, Roberts JM (2008) First trimester adipocytokine 
concentrations and risk of developing gestational diabetes later in pregnancy. 
Clin Endocrinol, 69, 407-411. 
Langbein M, Strick R, Strissel P, et al. (2008) Impaired cytotrophoblast cell-cell 
fusion is associated with reduced Syncytin and increased apoptosis in patients 
with placental dysfunction. Mol Reprod Dev, 75, 175-183. 
Lanman J (1975) Immunological Functions of the Placenta. In The Placenta and its 
Maternal Supply Line (ed Gruenwald P). Baltimore: University Park Press. 
Lappas M, Permezel M, Rice GE (2005a) Leptin and Adiponectin Stimulate the 
Release of Proinflammatory Cytokines and Prostaglandins from Human 
Placenta and Maternal Adipose Tissue via Nuclear Factor-κB, Peroxisomal 
Proliferator-Activated Receptor-γ and Extracellularly Regulated Kinase 1/2. 
Endocrinology, 146, 3334-3342. 
Lappas M, Yee K, Permezel M, Rice GE (2005b) Release and regulation of leptin, 
resistin and adiponectin from human placenta, fetal membranes, and maternal 
adipose tissue and skeletal muscle from normal and gestational diabetes 
mellitus-complicated pregnancies. J Endocrinol, 186, 457-465. 
Leber A, Teles A, Zenclussen A (2010) Regulatory T Cells and Their Role in 
Pregnancy. Am J Reprod Immunol, 63, 445-459. 
Ledoux S, Campos DB, Lopes FL, Dobias-Goff M, Palin M-F, Murphy BD (2006) 
Adiponectin Induces Periovulatory Changes in Ovarian Follicular Cells. 
Endocrinology, 147, 5178-5186. 
Lee M-H, Klein RL, El-Shewy HM, Luttrell DK, Luttrell LM (2008) The 
Adiponectin Receptors AdipoR1 and AdipoR2 Activate ERK1/2 through a 
Src/Ras-Dependent Pathway and Stimulate Cell Growth. Biochemistry, 47, 
11682-11692. 
Levine RJ, Lam C, Qian C, et al. (2006) Soluble Endoglin and Other Circulating 
Antiangiogenic Factors in Preeclampsia. N Engl J Med, 355, 992-1005. 
Levine RJ, Maynard SE, Qian C, et al. (2004) Circulating Angiogenic Factors and the 
Risk of Preeclampsia. N Engl J Med, 350, 672-83. 
Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM (1998) 
Fetal and maternal contributions to risk of pre-eclampsia: population based 
study. BMJ, 316, 1343-7. 
Lindsay RS, Funahashi T, Hanson RL, et al. (2002) Adiponectin and development of 
type 2 diabetes in the Pima Indian population. Lancet, 360, 57-58. 
210 
 
Lindsay RS, Walker JD, Havel PJ, Hamilton BA, Calder AA, Johnstone FD (2003) 
Adiponectin Is Present in Cord Blood but Is Unrelated to Birth Weight. 
Diabetes Care, 26, 2244-2249. 
Lockwood CJ, Yen C-F, Basar M, et al. (2008) Preeclampsia-Related Inflammatory 
Cytokines Regulate Interleukin-6 Expression in Human Decidual Cells. Am J 
Pathol, 172, 1571-1579. 
Lu M, Tang Q, Olefsky JM, Mellon PL, Webster NJG (2008) Adiponectin Activates 
Adenosine Monophosphate-Activated Protein Kinase and Decreases 
Luteinizing Hormone Secretion in LβT2 Gonadotropes. Mol Endocrinol, 22, 
760-771. 
Ma K, Cabrero A, Saha PK, et al. (2002) Increased β-Oxidation but No Insulin 
Resistance or Glucose Intolerance in Mice Lacking Adiponectin. J Biol Chem, 
277, 34658-34661. 
Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (1996) 
cDNA Cloning and Expression of a Novel Adipose Specific Collagen-like 
Factor, apM1 (dioseost Abundant Gene Transcript 1). Biochem Biophys Res 
Comm, 221, 286-289. 
Maeda N, Shimomura I, Kishida K, et al. (2002) Diet-induced insulin resistance in 
mice lacking adiponectin/ACRP30. Nat Med, 8, 731-737. 
Maeda N, Takahashi M, Funahashi T, et al. (2001) PPARγ Ligands Increase 
Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived 
Protein. Diabetes, 50, 2094-2099. 
Magarinos MP, Sanchez-Margalet V, Kotler M, Calvo JC, Varone CL (2007) Leptin 
Promotes Cell Proliferation and Survival of Trophoblastic Cells. Biol Reprod, 
76, 203-210. 
Maghbooli Z, Hossein-nezhad A, Mirzaei K, et al. (2010) Association Between 
Retinol-Binding Protein 4 Concentrations and Gestational Diabetes Mellitus 
and Risk of Developing Metabolic Syndrome After Pregnancy. Reprod Sci, 
17, 196-201. 
Maillard V, Uzbekova S, Guignot F, et al. (2010) Effect of adiponectin on bovine 
granulosa cell steroidogenesis, oocyte maturation and embryo development. 
Reprod Biol Endocrinol, 8, 23. 
Majuri A, Santaniemi M, Rautio K, et al. (2007) Rosiglitazone treatment increases 
plasma levels of adiponectin and decreases levels of resistin in overweight 
women with PCOS: a randomized placebo-controlled study. Eur J 
Endocrinol, 156, 263-269. 
Makimura H, Wei J, Dolan-Looby SE, Ricchiuti V, Grinspoon S (2009) Retinol-
binding protein levels are increased in association with gonadotropin levels in 
healthy women. Metabolism, 58, 479-487. 
Mandal P, Pritchard M, Nagy L (2010) Anti-inflammatory pathways and alcoholic 
liver disease: role of an adiponectin/interleukin-10/heme oxygenase-1 
pathway. World J Gastroenterol, 16, 1330-6. 
Manten GTR, Sikkema MJ, Voorbij HAM, Visser GHA, Bruinse HW, Franx A 
(2007) Risk Factors for Cardiovascular Disease in Women with a History of 
Pregnancy Complicated by Preeclampsia or Intrauterine Growth Restriction. 
Hypertens Pregnancy, 26, 39 - 50. 
211 
 
Mao X, Kikani CK, Riojas RA, et al. (2006) APPL1 binds to adiponectin receptors 
and mediates adiponectin signalling and function. Nat Cell Biol, 8, 516-523. 
Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y (2007) Correlation between 
soluble endoglin, vascular endothelial growth factor receptor -1 and 
adipocytokines in preeclampsia. J Clin Endocrinol Metab, jc.2006-2349. 
Mazaki-Tovi S, Kanety H, Pariente C, et al. (2007) Maternal serum adiponectin levels 
during human pregnancy. J Perinatol, 27, 77-81. 
Mazaki-Tovi S, Kanety H, Pariente C, et al. (2009a) Adiponectin and Leptin 
Concentrations in Dichorionic Twins with Discordant and Concordant 
Growth. J Clin Endocrinol Metab, 94, 892-898. 
Mazaki-Tovi S, Romero R, Vaisbuch E, et al. (2009b) Maternal serum adiponectin 
multimers in gestational diabetes. J Perinat Med, 37, 637-650. 
Mazaki-Tovi S, Romero R, Vaisbuch E, et al. (2010) Retinol-binding protein 4: a 
novel adipokine implicated in the genesis of LGA in the absence of 
gestational diabetes mellitus. J Perinat Med, 38, 147-55. 
Mazaki-Tovi S, Romero R, Vaisbuch E, et al. (2009c) Maternal serum adiponectin 
multimers in preeclampsia. J Perinat Med, 37, 349-363. 
McDonald EA, Wolfe MW (2009) Adiponectin Attenuation of Endocrine Function 
within Human Term Trophoblast Cells. Endocrinology, 150, 4358-4365. 
Metzger B (2007) Long-term outcomes in mothers diagnosed with gestational 
diabetes mellitus and their offspring. Clin Obstet Gynecol, 50, 972-979. 
Mitchell M, Armstrong DT, Robker RL, Norman RJ (2005) Adipokines: implications 
for female fertility and obesity. Reproduction, 130, 583-597. 
Miwa N, Hayakawa S, Miyazaki S, et al. (2005) IDO expression on decidual and 
peripheral blood dendritic cells and monocytes/macrophages after treatment 
with CTLA-4 or interferon-γ increase in normal pregnancy but decrease in 
spontaneous abortion. Mol Hum Reprod, 11, 865-70. 
Mjösberg J, Berg G, Ernerudh J, Ekerfelt C (2007) CD4+CD25+ regulatory T cells in 
human pregnancy: development of a Treg-MLC-ELISPOT suppression assay 
and indications of paternal specific Tregs. Immunology, 120, 456-66. 
Moffett-King A (2002) Natural killer cells and pregnancy. Nat Rev Immunol, 2, 656-
663. 
Munday J, Kerr S, Ni J, et al. (2001) Identification, characterization and leucocyte 
expression of Siglec-10, a novel human sialic acid-binding receptor. Biochem 
J, 355, 489-97. 
Nakano Y, Tobe T, Choi-Miura N-H, Mazda T, Tomita M (1996) Isolation and 
Characterization of GBP28, a Novel Gelatin-Binding Protein Purified from 
Human Plasma. J Biochem, 120, 803-812. 
Ness RB, Roberts JM (1996) Heterogeneous causes constituting the single syndrome 
of preeclampsia: A hypothesis and its implications. Am J Obstet Gynecol, 175, 
1365-70. 
Ness RB, Sibai BM (2006) Shared and disparate components of the 
pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet 
Gynecol, 195, 40-49. 
Newhouse SM, Davidge ST, Winkler-Lowen B, Demianczuk N, Guilbert LJ (2007) 
In Vitro Differentiation of Villous Trophoblasts from Pregnancies 
212 
 
Complicated by Intrauterine Growth Restriction With and Without Pre-
Eclampsia. Placenta, 28, 999-1003. 
Ni XT, Duan T, Yang Z, Guo CM, Li JN, Sun K (2009) Role of Human Chorionic 
Gonadotropin in Maintaining 11[beta]-hydroxysteroid Dehydrogenase Type 2 
Expression in Human Placental Syncytiotrophoblasts. Placenta, 30, 1023-8. 
Nien J, Mazaki-Tovi S, Romero R, et al. (2007) Adiponectin in severe preeclampsia. 
J Perinat Med, 35, 503-12. 
Nishizawa H, Pryor-Koishi K, Suzuki M, et al. (2008) Increased levels of pregnancy-
associated plasma protein-A2 in the serum of pre-eclamptic patients. Mol 
Hum Reprod, 14, 595-602. 
O'Sullivan A, Kriketos A, Martin A, Brown M (2006) Serum Adiponectin Levels in 
Normal and Hypertensive Pregnancy. Hypertens Pregnancy, 25, 193-203. 
Okazaki S, Sekizawa A, Purwosunu Y, Farina A, Wibowo N, Okai T (2007) 
Placenta-Derived, Cellular Messenger RNA Expression in the Maternal Blood 
of Preeclamptic Women. Obstet Gynecol, 110, 1130-1136. 
Oshima K, Nampei A, Matsuda M, et al. (2005) Adiponectin increases bone mass by 
suppressing osteoclast and activating osteoblast. Biochem Biophys Res Comm, 
331, 520-526. 
Østerdal M, Strøm M, Klemmensen Å, et al. (2009) Does leisure time physical 
activity in early pregnancy protect against pre-eclampsia? Prospective cohort 
in Danish women. BJOG, 116, 98-107. 
Pajvani UB, Du X, Combs TP, et al. (2003) Structure-Function Studies of the 
Adipocyte-secreted Hormone Acrp30/Adiponectin. Implications for Metabolic 
Regulation and Bioactivity. J Biol Chem, 278, 9073-9085. 
Petroff M, Perchellet A (2010) B7 Family Molecules as Regulators of the Maternal 
Immune System in Pregnancy. Am J Reprod Immunol, 63, 506-19. 
Petroff MG (2005) Immune interactions at the maternal-fetal interface. J Reprod 
Immunol, 68, 1-13. 
Petroff MG, Chen L, Phillips TA, Azzola D, Sedlmayr P, Hunt JS (2003) B7 Family 
Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface. 
Biol Reprod, 68, 1496-1504. 
Petroff MG, Kharatyan E, Torry DS, Holets L (2005) The Immunomodulatory 
Proteins B7-DC, B7-H2, and B7-H3 Are Differentially Expressed across 
Gestation in the Human Placenta. Am J Pathol, 167, 465-473. 
Phillips TA, Ni J, Hunt JS (2001) Death-Inducing Tumour Necrosis Factor (TNF) 
Superfamily Ligands and Receptors are Transcribed in Human Placentae, 
Cytotrophoblasts, Placental Macrophages and Placental Cell Lines. Placenta, 
22, 663-72. 
Phillips TA, Ni J, Pan G, et al. (1999) TRAIL (Apo-2L) and TRAIL Receptors in 
Human Placentas: Implications for Immune Privilege. J Immunol, 162, 6053-
9. 
Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH (2006) Vitamin C and vitamin 
E in pregnant women at risk for pre-eclampsia (VIP trial): randomised 
placebo-controlled trial. Lancet, 367, 1145-54. 
213 
 
Radaelli T, Varastehpour A, Catalano P, Hauguel-de Mouzon S (2003) Gestational 
Diabetes Induces Placental Genes for Chronic Stress and Inflammatory 
Pathways. Diabetes, 52, 2951-2958. 
Ramathal CY, Bagchi IC, Taylor RN, Bagchi MK (2010) Endometrial 
Decidualization: Of Mice and Men. Semin Reprod Med, 28, 17-26. 
Ramsay JE, Jamieson N, Greer IA, Sattar N (2003) Paradoxical Elevation in 
Adiponectin Concentrations in Women With Preeclampsia. Hypertension, 42, 
891-894. 
Ranheim T, Haugen F, Staff AC, Braekke K, Harsem NK, Drevon CA (2004) 
Adiponectin is reduced in gestational diabetes mellitus in normal weight 
women. Acta Obstet Gynecol Scand, 83, 341-347. 
Redman CW, Sargent IL (2005) Latest Advances in Understanding Preeclampsia. 
Science, 308, 1592-1594. 
Reece EA (2008) Perspectives on obesity, pregnancy and birth outcomes in the 
United States: The scope of the problem. Am J Obstet Gynecol, 198, 23-27. 
Retnakaran R, Connelly PW, Maguire G, Sermer M, Zinman B, Hanley AJG (2007) 
Decreased high-molecular-weight adiponectin in gestational diabetes: 
implications for the pathophysiology of Type 2 diabetes. Diabet Med, 24, 245-
252. 
Retnakaran R, Qi Y, Connelly P, Sermer M, Hanley A, Zinman B (2010) Low 
adiponectin concentration during pregnancy predicts postpartum insulin 
resistance, beta cell dysfunction and fasting glycaemia. Diabetologia, 53, 268-
276. 
Rodriguez-Pacheco F, Martinez-Fuentes AJ, Tovar S, et al. (2007) Regulation of 
Pituitary Cell Function by Adiponectin. Endocrinology, 148, 401-410. 
Saito S, Shima T, Nakashima A, Shiozaki A, Ito M, Sasaki Y (2007) What is the role 
of regulatory T cells in the success of implantation and early pregnancy? J 
Assist Reprod Genet, 24, 379-86. 
Sasaki H, Roberts J, Lykins D, Fujii Y, Auclair D, Chen LB (2002) Novel 
chemiluminescence assay for serum periostin levels in women with 
preeclampsia and in normotensive pregnant women. Am J Obstet Gynecol, 
186, 103-108. 
Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S (2004) Decidual and 
peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects 
and spontaneous abortion cases. Mol Hum Reprod, 10, 347-53. 
Satoh H, Nguyen MTA, Trujillo M, et al. (2005) Adenovirus-Mediated Adiponectin 
Expression Augments Skeletal Muscle Insulin Sensitivity in Male Wistar 
Rats. Diabetes, 54, 1304-1313. 
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A Novel Serum 
Protein Similar to C1q, Produced Exclusively in Adipocytes. J Biol Chem, 
270, 26746-26749. 
Schmidt T, Fischer S, Tsikolia N, et al. (2008) Expression of adipokines in 
preimplantation rabbit and mice embryos. Histochem Cell Biol, 129, 817-25. 
Schulz LC, Widmaier EP (2004) The Effect of Leptin on Mouse Trophoblast Cell 
Invasion. Biol Reprod, 71, 1963-1967. 
214 
 
Schumacher A, Brachwitz N, Sohr S, et al. (2009) Human Chorionic Gonadotropin 
Attracts Regulatory T Cells into the Fetal-Maternal Interface during Early 
Human Pregnancy. J Immunol, 182, 5488-97. 
Seiji I, Norio T, Yoichiro A, et al. (2009) Elevated level of serum retinol-binding 
protein 4 in pregnancy-induced hypertension. J Obstet Gynaecol Res, 35, 293-
300. 
Senaris R, Garcia-Caballero T, Casabiell X, et al. (1997) Synthesis of Leptin in 
Human Placenta. Endocrinology, 138, 4501-4504. 
Shklyaev S, Aslanidi G, Tennant M, et al. (2003) Sustained peripheral expression of 
transgene adiponectin offsets the development of diet-induced obesity in rats. 
Proc Nat Acad Sci, 100, 14217-14222. 
Sibai B (2003) Diagnosis and management of gestational hypertension and 
preeclampsia. Obstet Gynecol, 102, 181-192. 
Solomon CG, Seely EW (2001) Brief Review: Hypertension in Pregnancy: A 
Manifestation of the Insulin Resistance Syndrome? Hypertension, 37, 232-
239. 
Song H, Chan J, Rovin BH (2009) Induction of chemokine expression by adiponectin 
in vitro is isoform dependent. Transl Res, 154, 18-26. 
Spalding KL, Arner E, Westermark PO, et al. (2008) Dynamics of fat cell turnover in 
humans. Nature, 453, 783-787. 
Stepan H, Ebert T, Schrey S, et al. (2009) Preliminary report: serum levels of retinol-
binding protein 4 in preeclampsia. Metabolism, 58, 275-277. 
Street M, Volta C, Ziveri M, Viani I, Bernasconi S (2009) Markers of insulin 
sensitivity in placentas and cord serum of intrauterine growth-restricted 
newborns. Clin Endocrinol, 71, 394-399. 
Suwaki N, Masuyama H, Nakatsukasa H, et al. (2006) Hypoadiponectinemia and 
circulating angiogenic factors in overweight patients complicated with pre-
eclampsia. Am J Obstet Gynecol, 195, 1687-1692. 
Taglauer ES, Trikhacheva AS, Slusser JG, Petroff MG (2008) Expression and 
Function of PDCD1 at the Human Maternal-Fetal Interface. Biol Reprod, 79, 
562-9. 
Tai P, Wang J, Jin H, et al. (2008) Induction of regulatory T cells by physiological 
level estrogen. J Cell Physiol, 214, 456-64. 
Takata K, Kasahara T, Kasahara M, Ezaki O, Hirano H (1992) Localization of 
erythrocyte/HepG2-type glucose transporter (GLUT1) in human placental 
villi. Cell Tissue Res, 267, 407-12. 
Takeuchi K, Ito F (2010) EGF receptor in relation to tumor development: molecular 
basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase 
inhibitors. FEBS J, 277, 316-26. 
Tang C, Lu M (2009) Adiponectin increases motility of human prostate cancer cells 
via adipoR, p38, AMPK, and NF-κB pathways. Prostate, 69, 1781-9. 
Tang Y, Hu T, Arterburn M, et al. (2005) PAQR Proteins: A Novel Membrane 
Receptor Family Defined by an Ancient7-Transmembrane Pass Motif. J Mol 
Evol, 61, 372-380. 
Tayade C, Hilchie D, He H, et al. (2007) Genetic Deletion of Placenta Growth Factor 
in Mice Alters Uterine NK Cells. J Immunol, 178, 4267-4275. 
215 
 
Tepper BJ, Kim Y-K, Shete V, Shabrova E, Quadro L (2010) Serum Retinol-Binding 
Protein 4 (RBP4) and retinol in a cohort of borderline obese women with and 
without gestational diabetes. Clin Biochem, 43, 320-3. 
Thaxton J, Sharma S (2010) Interleukin-10: A Multi-Faceted Agent of Pregnancy. Am 
J Reprod Immunol, 63, 482-91. 
The Hapo Study Cooperative Research Group (2008) Hyperglycemia and Adverse 
Pregnancy Outcomes. N Engl J Med, 358, 1991-2002. 
Tie W, Yu H, Chen J, Wang X, Chen W, Zhou R (2009) Expressions of Adiponectin 
Receptors in Placenta and Their Correlation With Preeclampsia. Reprod Sci, 
16, 676-84. 
Tilburgs T, Roelen DL, van der Mast BJ, et al. (2008) Evidence for a Selective 
Migration of Fetus-Specific CD4+CD25bright Regulatory T Cells from the 
Peripheral Blood to the Decidua in Human Pregnancy. J Immunol, 180, 5737-
45. 
Tilburgs T, Roelen DL, van der Mast BJ, et al. (2006) Differential Distribution of 
CD4+CD25bright and CD8+CD28- T-cells in Decidua and Maternal Blood 
During Human Pregnancy. Placenta, 27, 47-53. 
Tinsley JH, Chiasson VL, Mahajan A, Young KJ, Mitchell BM (2009) Toll-Like 
Receptor 3 Activation During Pregnancy Elicits Preeclampsia-Like Symptoms 
in Rats. Am J Hypertens, 22, 1314-1319. 
Tomizawa A, Hattori Y, Kasai K (2009) Induction of gene expression in response to 
globular adiponectin in vascular endothelial cells. Life Sci, 85, 457-461. 
Tomizawa A, Hattori Y, Kasai K, Nakano Y (2008) Adiponectin induces NF-κB 
activation that leads to suppression of cytokine-induced NF-κB activation in 
vascular endothelial cells: globular adiponectin vs. high molecular weight 
adiponectin. Diab Vasc Dis Res, 5, 123-127. 
Trayhurn P, Bing C, Wood IS (2006) Adipose Tissue and Adipokines--Energy 
Regulation from the Human Perspective. J Nutr, 136, 1935S-1939. 
Trayhurn P, Wang B, Wood IS (2008) Hypoxia in adipose tissue: a basis for the 
dysregulation of tissue function in obesity? Br J Nutr, 100, 227-35. 
Trupin LS, Simon LP, Eskenazi B (1996) Change in Paternity: A Risk Factor for 
Preeclampsia in Multiparas. Epidemiology, 7, 240-4. 
Tsai P-J, Yu C-H, Hsu S-P, et al. (2005) Maternal plasma adiponectin concentrations 
at 24 to 31 weeks of gestation: negative association with gestational diabetes 
mellitus. Nutrition, 21, 1095-1099. 
Ueland T, Dalsoren T, Voldner N, Godang K, Henriksen T, Bollerslev J (2008) 
Retinol-binding protein-4 is not strongly associated with insulin sensitivity in 
normal pregnancies. Eur J Endocrinol, 159, 49-54. 
Ursell W, Brudenell M, Chard T (1973) Placental lactogen levels in diabetic 
pregnancy. Br Med J, 2, 80-2. 
Vaisbuch E, Romero R, Mazaki-Tovi S, et al. (2009) Retinol binding protein 4 - a 
novel association with early-onset preeclampsia. J Perinat Med, 38, 129-39. 
Valsamakis G, Kanaka-Gantenbein C, Malamitsi-Puchner A, Mastorakos G (2006) 
Causes of Intrauterine Growth Restriction and the Postnatal Development of 
the Metabolic Syndrome. Ann NY Acad Sci, 1092, 138-147. 
216 
 
Villee D (1969) Development of Endocrine Function in the Human Placenta and 
Fetus. N Engl J Med, 281, 533-41. 
Visser N, van Rijn B, Rijkers G, Franx A, Bruinse H (2007) Inflammatory changes in 
preeclampsia: current understanding of the maternal innate and adaptive 
immune response. Obstet Gynecol Surv, 62, 191-201. 
Waller DK, Shaw GM, Rasmussen SA, et al. (2007) Prepregnancy Obesity as a Risk 
Factor for Structural Birth Defects. Arch Pediatr Adolesc Med, 161, 745-50. 
Wang C-N, Chang S-D, Peng H-H, et al. (2010) Change in Amniotic Fluid Levels of 
Multiple Anti-Angiogenic Proteins before Development of Preeclampsia and 
Intrauterine Growth Restriction. J Clin Endocrinol Metab, 95, 1431-1441. 
Wang C, Xin X, Xiang R, et al. (2009) Yin-Yang Regulation of Adiponectin 
Signaling by APPL Isoforms in Muscle Cells. J Biol Chem, 284, 31608-15. 
Wang Y, Lam KSL, Xu JY, et al. (2005) Adiponectin Inhibits Cell Proliferation by 
Interacting with Several Growth Factors in an Oligomerization-dependent 
Manner. J Biol Chem, 280, 18341-18347. 
Wen J-P, Lv W-S, Yang J, et al. (2008) Globular adiponectin inhibits GnRH secretion 
from GT1-7 hypothalamic GnRH neurons by induction of hyperpolarization 
of membrane potential. Biochem Biophys Res Comm, 371, 756-61. 
Williams MA, Qiu C, Muy-Rivera M, Vadachkoria S, Song T, Luthy DA (2004) 
Plasma Adiponectin Concentrations in Early Pregnancy and Subsequent Risk 
of Gestational Diabetes Mellitus. J Clin Endocrinol Metab, 89, 2306-2311. 
Winn VD, Gormley M, Paquet AC, et al. (2009) Severe Preeclampsia-Related 
Changes in Gene Expression at the Maternal-Fetal Interface Include Sialic 
Acid-Binding Immunoglobulin-Like Lectin-6 and Pappalysin-2. 
Endocrinology, 150, 452-462. 
Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H (2004) Adiponectin induces the 
anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. 
Biochem Biophys Res Comm, 323, 630-635. 
Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME (2004) 
Adiponectin differentially regulates cytokines in porcine macrophages. 
Biochem Biophys Res Comm, 316, 924-929. 
Yamaguchi N, Kukita T, Li Y-J, et al. (2008) Adiponectin inhibits induction of TNF-
α/RANKL-stimulated NFATc1 via the AMPK signaling. FEBS Lett, 582, 
451-456. 
Yamaguchi N, Kukita T, Li Y-J, et al. (2007) Adiponectin inhibits osteoclast 
formation stimulated by lipopolysaccharide from Actinobacillus 
actinomycetemcomitans. FEMS Immunol Med Microbiol, 49, 28-34. 
Yamauchi T, Kamon J, Ito Y, et al. (2003a) Cloning of adiponectin receptors that 
mediate antidiabetic metabolic effects. Nature, 423, 762-769. 
Yamauchi T, Kamon J, Waki H, et al. (2003b) Globular Adiponectin Protected ob/ob 
Mice from Diabetes and ApoE-deficient Mice from Atherosclerosis. J Biol 
Chem, 278, 2461-2468. 
Yamauchi T, Kamon J, Waki H, et al. (2001) The fat-derived hormone adiponectin 
reverses insulin resistance associated with both lipoatrophy and obesity. Nat 
Med, 7, 941-946. 
217 
 
Yamauchi T, Nio Y, Maki T, et al. (2007) Targeted disruption of AdipoR1 and 
AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat 
Med, 13, 332-9. 
Yang H, Qiu L, Di W, et al. (2009) Proportional change of CD4+CD25+ regulatory T 
cells after lymphocyte therapy in unexplained recurrent spontaneous abortion 
patients. Fertil Steril, 92, 301-5. 
Yano W, Kubota N, Itoh S, et al. (2008) Molecular Mechanism of Moderate Insulin 
Resistance in Adiponectin-Knockout Mice. Endocrine Journal, 55, 515-522. 
Yura S, Sagawa N, Itoh H, et al. (2003) Resistin Is Expressed in the Human Placenta. 
J Clin Endocrinol Metab, 88, 1394-1397. 
Zenclussen AC, Gerlof K, Zenclussen ML, et al. (2005) Abnormal T-Cell Reactivity 
against Paternal Antigens in Spontaneous Abortion: Adoptive Transfer of 
Pregnancy-Induced CD4+CD25+ T Regulatory Cells Prevents Fetal Rejection 
in a Murine Abortion Model. Am J Pathol, 166, 811-22. 
Zhao J-x, Zeng Y-y, Liu Y (2007) Fetal alloantigen is responsible for the expansion 
of the CD4+CD25+ regulatory T cell pool during pregnancy. J Reprod 
Immunol, 75, 71-81. 
Zhou CC, Ahmad S, Mi T, et al. (2008) Autoantibody From Women With 
Preeclampsia Induces Soluble Fms-Like Tyrosine Kinase-1 Production via 
Angiotensin Type 1 Receptor and Calcineurin/Nuclear Factor of Activated T-
Cells Signaling. Hypertension, 51, 1010-1019. 
Zhu W, Cheng KKY, Vanhoutte PM, Lam KSL, Xu A (2008) Vascular effects of 
adiponectin: molecular mechanisms and potential therapeutic intervention. 
Clin Sci (Lond), 114, 361-374. 
Zoccali C, Mallamaci F, Tripepi G, et al. (2002) Adiponectin, Metabolic Risk 
Factors, and Cardiovascular Events among Patients with End-Stage Renal 
Disease. Am J Soc Nephrol, 13, 134-141. 
 
 
